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Penfigóide bolhoso e pênfigo pertencem a um grupo de doenças bolhosas 
auto-imunes que afectam tecidos saudáveis do corpo, causando formação de 
bolhas e lesões na pele. Penfigóide bolhoso é caracterizado pelo ataque aos 
queratinócitos basais, fazendo com que estes percam a capacidade de 
aderência à zona da membrana basal, enquanto no pênfigo os queratinócitos 
na epiderme e membranas mucosas perdem adesão celular.  
Um único click no tópico “pemphigus” na PubMed revela mais de 9 000 artigos 
que providenciam informação acerca deste grupo de doenças bolhosas auto-
imunes. Isto demonstra o enorme interesse clínico e científico em desvendar 
os mistérios que ainda cercam estas doenças, que começou há mais de 60 
anos com a diferenciação de penfigóide bolhoso de pênfigo.  
Penfigóide bolhoso é a doença bolhosa auto-imune mais comum e afecta 
maioritariamente os idosos. Tem uma taxa de mortalidade elevada sobretudo 
devido a terapia associada e outras complicações que surgem associadas à 
doença. As lesões são causadas por autoanticorpos que fixam o complemento, 
mediando um processo inflamatório. Pênfigo tem uma incidência superior nas 
mulheres. A idade média de início de pênfigo vulgar é entre os 60 e os 70 anos 
nos países Europeus e entre 30 e 50 nos restantes zonas do globo. Pênfigo 
foliáceo tem uma idade média de iniciação entre 30 a 45 anos. Além disso, as 
taxas de mortalidade de penfigóide bolhoso são cerca de duas vezes superior 
e de pênfigo cerca de três vezes superior, comparando com a população geral. 
Muita informação aponta para uma clara predisposição genética da doença, 
combinada com factores que podem desencadear a doença. No que respeita o 
diagnóstico, a avaliação física é um marco importante, onde a pele é 
examinada, tal como as membranas mucosas e as unhas. Os pacientes 
também são submetidos a questões meticulosas sobre os sintomas, onde o 
historial médico não é deixado de fora. Examinação histológica quantitativa e 
qualitativa é sempre feita, por exemplo ELISA.  
Hoje em dia os corticosteróides continuam a ser a terapia principal, contudo, 
novas estratégias terapêuticas têm vindo a ser desenvolvidas. A gestão 
terapêutica compreende uma serie de medicação, como os corticosteróides, 
micofenolato, rituximab ou abordagens inovadoras associadas a biotecnologia. 
O uso de compostos associados melhora o prognóstico do doente. Contudo, 
estas medicações podem levar ao aparecimento de complicações devido a 
alterações no sistema imunitário, tais como complicações respiratórias. 
Quando este tipo de complicações aparecem em ambiente hospitalar são, 
normalmente, devido a uma ou varias estirpes, o que dificulta o tratamento. 
Infecções com origem bacteriana, vírus, etc., são elas próprias associadas a 
penfigóide bolhoso e pênfigo. Tem vindo a ser documentados casos de ambas 
doenças associadas a outras complicações, como cancros, outras doenças do 
foro imunitário, neurológicas, etc.  
Esta breve revisão aborda as três doenças bolhosas auto-imunes – penfigóide 
bolhoso, pênfigo vulgar e pênfigo foliáceo. 
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abstract 
 
 
Bullous pemphigoid and pemphigus belong to a group of autoimmune blistering 
diseases that attacks the body healthy tissue, causing blisters and erosions on 
the skin. Bullous pemphigoid is characterized by an attack to the basal 
keratinocytes, making them to lose adhesion to the basement membrane zone, 
whereas in pemphigus happens that keratinocytes in epidermis and mucous 
membranes lose cell-to-cell adhesion. 
A single mouse click on the topic pemphigus in PubMed reveals more than 9 
000 articles providing one or the other information about this group of 
autoimmune blistering disease. This could only demonstrate the enormous 
scientific and clinical interest in unraveling the mysteries that still surrounds 
these diseases, which began over 60 years ago with the differentiation of 
bullous pemphigoid from pemphigus. 
BP is the most common ABD affecting mainly the elderly. It has a high mortality 
rate, mainly due to therapy and some other complications disease-associated. 
Lesions are caused by autoantibodies that fix the complement and thus 
mediate an inflammatory process. Pemphigus has an increased incidence in 
women. PV has a mean age of onset between 60 and 70 years old in European 
countries and between the ages of 30 and 50 in the remaining countries of the 
world. PF has it between 30 to 45 years old. Moreover, the mortality rates of BP 
patients are two times higher and of pemphigus patients three times higher, 
than general population. 
Much information points out a clear genetic predisposition for disease, 
combined with triggering factors. Regarding the diagnosis, the physical 
evaluation is a milestone, where the skin, mucous membranes and the nails 
are examined. Also, patients are submitted to meticulous questions about 
symptoms where the medical history is not left out. Some quantitative and 
qualitative histologic examination is always performed, like ELISA.  
Nowadays, corticosteroids are still the main therapy; however, novel 
therapeutic targets have been developed. 
The therapeutic management comprised a series of drugs, like corticosteroids, 
mycophenolate mofetil, rituximab or innovative approaches associated to 
biotechnology. Using two associated drugs really improved patients’ prognosis. 
However, these medications could lead to the arising of other disorders, 
namely respiratory ones, as they debilitate the immune system. The contraction 
of such disease in a hospital environment often occurs due to one or more 
strains, which makes it difficult to choose a suitable therapy. Infections with 
bacterial origin, viruses, etc., also associate themselves to the diseases, 
sometimes. There have been documented cases of patients with pemphigus or 
BP associated with other disorders, such as neoplasia, neurologic disorders, 
other immune disorders. 
This brief review will focus on three autoimmune diseases – BP, PV and PF. 
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This dissertation emerged not only due to my master degree but also from the necessity 
to gather information about the scourge that these autoimmune blistering diseases (ABD) 
are in our society. In this document it will be possible to analyse the lack of information 
that still haunts this theme, which is the main disadvantage for those who suffer from 
these conditions. 
This document was structured in an intuitive way, easy to read, taking into account the 
large amount of information that it is gathered. So, it was divided in ten chapters that were 
selected in a conscious way. The first three chapters, excluding this one, intend to 
elucidate on the molecular mecanisms underlying the three diseases: bullous pemphigoid 
(BP), pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The fifth chapter guides us 
through diagnosis lay-outs, where it’s possible to read about assays and come outs. I 
found important that this chapter came after the molecular basis because the assays also 
had a molecular basis. The following chapter, the sixth, describes the diseases that are 
associated to the three ABD. Then, I found it pertinent to talk about the triggers that could 
initiate the pathomechanisms underlying the three diseases. The genetic susceptibilities 
are described in chapter eight, where it is possible to read about gene alleles that may 
cause susceptibility to these diseases. Next I approached the treatment used in these 
diseases and its many side effects. And, lastely, the epidemiology data is described in the 
tenth chapter. 
This review stands out from the others already published for the simple reason that this 
one covers all the most important topics, while the other reviews only covers few topics at 
a time. They are reliable and consistent, but in order to gather a comprehensive 
understanding of the big picture, you’d need to read many.  
The ABD addressed in this document, as the name suggests, is characterized by an 
attack to the skin, more specifically to the epidermis. The epidermis is composed by the 
five layers (Proksch et al., 2008) demonstrated in the figure below (Figure 1): stratum 
corneum, stratum lucidum, stratum granulosum, stratum spinosum, stratum basale.  
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Figure 1 – Layers of epidermis (https://opentextbc.ca/anatomyandphysiology/chapter/5-1-layers-of-the-
skin/) 
 
While in pemphigus cases the attack occurs throughout the epidermis (DiMarco, 2016), in 
bullous pemphigoid (BP) cases the attack occurs exclusively in the basement membrane 
zone (Beutner and Jordon, 1964), between the stratum basale and the dermis.  
1.1. Characterization 
The ABD are characterized by a heterogeneous group of disorders that attacks the body 
healthy tissue, which will cause blisters and erosions that primarily affect the skin and 
mucous membranes. This group of diseases is chronic and it’s important to distinguish 
from others non-autoimmune blistering diseases that have short duration and have typical 
clinical features, like herpes simplex, poison ivy, or bullous erythema mulfiforme. Mortality 
and significant morbidity are factors that have direct association with these diseases 
(Cotell et al., 2000; Schmidt and Zillikens, 2011). Despite being relatively uncommon, they 
are potentially fatal associated with deposits of autoantibodies and complement against 
distinct molecules of the epidermis and dermal/epidermal basement membrane zone 
(BMZ) (Velez et al., 2013). 
1.2. Bullous Pemphigoid 
The most common ABD is bullous pemphigoid, which mainly affects older people. The 
reported incidence of BP in Europe has more than doubled, in the past decade (Schmidt 
and Zillikens, 2013) and, despite the fact that a higher incidence occurs in the elderly, 
there are a few cases occorring in childhood (Reis-Filho et al., 2013), with a mean age of 
onset of 4.5 months old and being often severe with blisters in hands and feet. In terms of 
pathogenicity and diagnostic criteria, BP behaves similarly between adults and children 
(Schwieger-Briel et al., 2014). For instance, in Israel the incidence of BP in such young 
age as an incidence of 2.36 cases per 100 000 per year but in most world countries there 
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are no registry and the disease can easily be under-recognized (Waisbourd-Zinman et al., 
2008). 
Being a subepidermal autoimmune blistering disease, BP has autoantibodies that attack 
the hemidesmosomal structural proteins; wich will cause the cleavage between the 
epidermis and the dermis, as seen in Figure 2 (Schmidt and Zillikens, 2011). 
The clinical spectrum of BP includes tense blisters, urticarial plaques and prurigo-like 
eczematous lesions (Velez et al., 2013). When a patient suspecting BP searchs for some 
medical evaluation, the procedures must include histopathology that shows subepidermal 
blisters with a perivascular and an infiltrate made of eosinophils (Samhaber et al., 2016). 
 
 
Figure 2 – Tense blisters in a BP patient (adapted from Hammers and Stanley, 2016). 
 
1.3. Pemphigus Vulgaris 
Another well know ABD is pemphigus. Here the two basic forms are covered: pemphigus 
vulgaris (PV) and pemphigus folieaceus (PF). The major incidence of PV is localized in 
Europe and USA, whereas the incidence of PF is mostly frequent in some areas in Brazil, 
along with other underdeveloped areas of the world (Aboobaker et al., 2001), like, Tunisia 
and Colombia (Tron et al., 2005).  
Pemphigus vulgaris is an uncommon and chronic vesiculobullous disease that represent 
the majority of all pemphigus cases, with an average incidence of 0.1 – 1.0 cases per 100 
000 per year. Moreover, prevalence of PV is predominant in regions with Jewish 
population. It is a potentially letal disease affecting mainly mucous membranes and skin. 
Females are the most affected gender, and have a mean age of onset of 50 to 60 years 
old. This disease usually has a Nikolsky sign positive (Velez et al., 2013). 
The first thing to do when there is suspect of PV in a patient is observe if there are any 
mucocutaneous erosions or blisters, like in Figure 3. Then the oral mucosa should be 
carefully observed because is most affected in this disease (Kumar et al., 2016). Usually, 
PV mantains confined to mucosal surfaces. In cases that it is not confined, it extends to 
the skin, with a latency period of about 4 months. PV, usually, has a peak of incidence in 
the third to sixth decades of life (Harman et al., 2003). It causes extensive and painful 
erosions in mouth which could result in a decrease in food or drinks intake, although, 
esophagus, conjunctiva, nasal mucosa, vagina, penis, anus and labia may be affected too 
(Velez et al., 2013).  
Before cortisteroid therapy become avalible in the 50s, PV held a high mortality rate, due 
to adverse effects of therapy (Bystryn and Steinman, 1996; Meurer, 2012). 
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Figure 3 – Patient with erosions from PV (adapted from Hammers and Stanley, 2016). 
 
1.4. Pemphigus Foliaceus 
Clinically, PF was first described by Dr. Pierre Louis Alphée Cazanave, in 1844. It was 
characterized as a disease that produces superficial cutaneous blisters and erosions. Dr. 
Pierre Cazanave described the non-endemic form occurring world wide and with a low 
incidence (Cazanave, 1844). The phenotype of this disease includes flaccid bullae which 
then ruptures and results in inflamed and excoriated skin, as seen in Figure 4, and it also 
affects the mucosae (Velez et al., 2013). 
Diagnose is based on clinical manifestations like flaccid blisters and erosions of skin, on 
histologic findings, such as epidermal acantholysis, and on immunological abnormalties 
(Castro and Proença, 1982; James et al., 2011). 
Usually PF affects both sexes and commonly manifests in the fourth and fifth decades. 
Desmoglein 1 (Dsg1) is the main disease antigen; however, others should also be taken 
into account, such as desmoplakin, periplakin and envoplakin (Velez et al., 2013).  The 
endemic pemphigus foliaceus (EPF) is historically also called fogo selvagem (FS), in 
Brazil (Velez et al., 2013). Brazilian studies reported that serum concentrations of specific 
antibodies directly correlated with disease extent and activity; however, FS’ healthy 
relatives may also have similar non-pathogenic autoantibodies. EPF was also described in 
Tunisia and Colombia (Velez et al., 2013). This disease can be triggered by some 
environmental factors, such as sunlight; parasites, such as Trypanosoma cruzi; and 
insects, like bed bugs and sand flies (Hans-Filho et al., 1999; Kano et al., 2000). When 
compared with PV, EPF is less aggressive and the therapy applied is also soft, but the 
generalized cases are more difficult to treat and eventually lead to high morbidity and 
mortality. While PV is more common in the age group of 61 to 75 years old, PF is more 
common between 30 and 45 years old (Khondker et al., 2014). 
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Figure 4 – Patient with lesions from PF (from Hammers and Stanley, 2016). 
 
A study was made to evaluate the perception that general population have of pemphigus 
vulgaris (PV) and pemphigus foliaceus (PF), with a group of 115 subjects. About 14% in 
the case of PV and 6% in the case of PF, consider having those conditions worse than 
death. However, none in the cohort have the disease or was ever diagnosed with any 
form of pemphigus (Rencz et al., 2016). 
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2.1. BP230 and BP180 BP’s autoantigens 
In 1953, Lever first distinguished BP from pemphigus, through clinical and histological 
characteristics of both diseases (Lever, 1953). Later, in 1964, Beutner and Jordon proved 
that patients with BP produce circulating autoantibodies directed against the BMZ of the 
skin, using immunofluorescence (Beutner and Jordon, 1964). 
BP is the most common of the pemphigoid diseases group, and is the most frequent 
autoimmune blistering disease in general. Within the group of the autoimmune disorders, 
pemphigoid diseases are a group characterized by autoantibodies against structural 
proteins of the dermal epidermal junction (DEJ) (Kasperkiewicz and Zillikens, 2007).  
BP patients have IgG autoantibodies circulating against two hemidesmosomal antigens 
with 230 kDa – BP230 or BPAG1 – and with 180 kDa – BP180 or BPAG2 or type XVII 
collagen (COL17) – and these two proteins are components of hemidesmosomes, 
responsible for the connection of cytoskeleton of basal keratinocytes to structures of the 
papillary dermis (Mutasim et al., 1985; Stanley et al., 1981). The hemidesmosomes 
compose the epithelia multiprotein complexes, and are responsible for promoting the 
adhesion of epithelial cells to the underlying basement membrane. The major component 
of hemidesmosomes is α6β4 integrin, mainly responsible for transducing signals from the 
extracellular matrix to the inner cell. This communication modulates the cytoskeletons’ 
organization, proliferation, apoptosis, and differentiation. A contact to anchoring fibrils is 
achieved via filamentous proteins, such as laminin 5. This contact has origin in the lamina 
densa of the basement membrane and extends into the subjacent connective tissue, and 
will terminate at structures known as anchoring plaques, which the major component is 
COL17, represented in Figure 5 (Borradori and Sonnenberg, 1999). 
 
 
Figure 5 – Molecular composition of hemidesmosomes (adapted from Nishie et al., 2014). 
 
Both BP180 (COL17) and BP230 have already been cloned and well characterized. This 
cloning has shown that corresponding epidermal cDNAs are products of distinct and 
unrelated genes (Diaz et al., 1990; Giudice et al., 1992; Hopkinson et al., 1992; Li et al., 
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1992, 1993; Stanley et al., 1988). BPAG2 gene – BP180 – was mapped by chromosomal 
in situ hybridization to the long arm of human chromosome 10, at locus 10q24.3 (Li et al., 
1991), whereas BP230 is a cytoplasmic component of hemidesmosomes that belongs to 
the plakin family of cytolinkers, promoting the association between hemidesmosomes and 
keratin intermediate filaments (Sawamura et al., 1991). BP230 also has a relevant 
homology with plectin and desmoplakins I and II (Green et al., 1992).  
On the other hand, COL17 is a transmembrane protein with type II orientation, its amino-
terminal region is localized in the intracellular hemidesmosomal plaque and its carboxyl-
terminal region projects itself through extracellular milieu of the basal membrane zone 
(Giudice et al., 1991), as seen in Figure 5. It is molecule with a globular head (intracellular 
domain), a central rod and a flexible tail (Hirako et al., 1996). The extracellular region has 
fifteen collagen domains that alternate with noncollagen sequences, and its ectodomain 
contains numerous peptide segments in which every third position encapsules a glycine 
residue and the proline content is elevated. This pattern suggests that this proteins 
domain assembles to a collagen triple helix (Li et al., 1993). Both BP180 and BP230 are 
diagrammed in Figure 6. 
 
 
Figure 6 – Diagram depicting BP180 (COL17) (A) and BP230 (B) (from Lee et al., 2012). 
 
Studies with immunoelectron microscopy indicate that the largest noncollagenous NC16A 
domain of COL17 is located inside the upper lamina lucida immediately subjacent to the 
hemidesmosome. This C-terminal region of BP180 co-localizes with the anchoring 
filaments at the interface between the lamina lucida and the lamina densa, as represented 
in Figures 5 and 6 (Bédane et al., 1997; Masunaga et al., 1997). Also, is an easy target to 
pathogenic autoantibodies (Kasperkiewicz and Zillikens, 2007; Ujiie et al., 2010). It was 
demonstrated that a great number of BP patients with active disease recognized COL17 
and others reacted with the ectodomain, a 120kDa protein that is shed from the 
keratinocyte surface (Schumann et al., 2000).  
The importance of COL17 was also demonstrated by a truncating mutation in COL17A1 
gene. This mutation compromised the assembly of hemidesmosomes, impairing both 
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mechanical stability of basal keratinocytes and dermo-epidermal adhesion. This 
information also reinforces that without the cytoplasmic domain of BP180, BP230, plectin 
and α6β4 are not quite effective in intermediate filaments conection to hemidesmosomes, 
so to extracellular matrix proteins (Fontao et al., 2004). 
An enzyme-linked immunosorbent assay, utilizing baculovirus-expressed recombinant 
forms of NH2 and COOH-terminal region of the BP180 ectodomain, screening sera from 
116 patients with active BP was analysed. This test demonstrated that 80% and 47% of 
the BP patients recognized NH2 and COOH-terminal, respectively. Also, patients with 
acute BP also had IgG1 antibodies against the NH2-terminal region of the BP180 
ectodomain, and patients in remission revealed higher levels of IgG4 autoantibodies. The 
IgG autoantibodies titers against the NH2-terminal, and not against the COOH-terminus, 
could reflect the skin involvement. This event also demonstrates that the autoantibodies 
against NC16A BP’subdomains could critical in BP pathogenesis (Hofmann et al., 2002). 
This 16th noncollagenous domain of BP180 – NC16A, represented in Figure 6 – have four 
main antigenic sites clusters - MCW-0, MCW-1, MCW-2, MCW-3 (Zillikens et al., 1997). 
However, and despite the importance if this subdomain, BP autoantibodies are capable to 
recognize antigenic sites over the entire BP180 molecule (Di Zenzo et al., 2007; Perriard 
et al, 1999). 
It is also important not to forget that BP patients also respond to BP230, the 
transmembrane component (Skaria et al., 2000; Tanaka et al., 1991). In fact, in the sera 
of BP patients, autoantibodies against BP180 are less detected than those against 
BP230, despite BP180 having autoantibodies epitopes in the extracellular domain. This 
data suggests that BP180 could be a target of BP autoantibodies, which could initiate the 
primary response, and then, BP230 autoantibodies will accelerate lesions (Ishiko et al., 
1993).  
Regarding BP230 recognition, it seems that some antibodies bound with the N-terminal 
half of the BP230 but in the majority of cases, the epitopes recognized by antibodies are 
mapped in the C-terminal region, represented in Figure 6 (Skaria et al., 2000). Moreover, 
BP230 has more important functions besides composing the hemidesmosomes that are 
targeted BP autoantibodies. It also plays important functions in various organs, such as 
central nervous system and skeletal muscle, so the DST gene, encoding BP230, gives 
rise to three major isoforms: epithelial, neuronal and muscular (Künzli et al., 2015).  
Since the correlation between epitopes of BP autoantibodies and the clinical features are 
not clearly elucidated, a recent study found a clear difference in autoantibodies profile, 
which divides BP in inflammatory and noninflammatory. In other words, it was concluded 
that the inflammatory phenotype, the more common, includes erythema and 
autoantibodies against the NC16A domain and the noninflammatory phenotype the 
autoantibodies seem to specificallty target the midportion of COL17 and not the NC16A 
subdomain. Also, the noninflammatory pattern reveals patients with a reduced erythema 
and short lesional infiltration of eosinophils (Izumi et al., 2016). 
 
2.2. Immunity in Bullous Pemphigoid 
Since human and murine BP180 antigens are not cross-reactive, Liu et al., in 2008, 
humanized a mouse strain expressing the BP immunodominat epitopes – BP180 NC16A 
– to study the humoral immune response in BP disease immunopathologhy. The 
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humanized NC16A mice injected with anti-BP180 NC16A autoantibodies developed BP-
like subepidermal blisters and the mice pretreated with mast cell activation blocker or 
depleting of complement or neutrophils, become BP resistant (Liu et al., 2008). It was also 
demonstrated that BP patients recognize at least another antigenic reactive site other than 
NC16A, suggesting that in the course of the disease patients exhibit a distinct epitope 
pattern and that reactivity against various intracellular epitopes, besides NC16A, can be 
observed even in the early stages of the disease (Di Zenzo et al., 2004). This information 
can be validated by studies with animal models that have been suggesting that 
autoimmune diseases are characterized by an “early” phase, in which the immune 
response is restricted to one or two epitopes among the antigen (dominant epitopes) and 
a “late” phase, where specificity spreads to additional subdominant epitopes – epitope 
spreading (Chan et al., 1998; Vanderlugt and Miller, 2002). The evidence of epitope 
spreading phenomenon has been reported in humans too (Bonifacio et al., 2000; Tuohy et 
al., 1999). As mentioned above, NC16A domain is the leading pathogenic target in BP, 
and antibodies (Abs) that react against a small portion of NC16A are essential for inducing 
depletion of COL17. Along with this, Natsuga et al. proposed that, besides the 
complement-dependent pathway leading to inflammation, direct effects of pathogenic 
antibodies, which deplete COL17 in epidermal keratinocytes, might contribute to skin 
fragility in a complement-independent pathway (Natsuga el al., 2012). These pathogenic 
antibodies belong to the subclasses of the immunoglobulins IgG1 and IgG4 (Bernard et 
al., 1990; Sitaru et al., 2007; Zhou et al., 2016) and IgE isotype (Döpp et al., 2000). It also 
has been proven that IgE and IgG4 react against two different epitopes within the BP180 
NC16A – MCW-1 and MCW-2. The major IgG subclass targeting BP180 NC16A before 
treatment are IgG4 and IgG1 and the IgE levels in sera and blister fluid are usually high, 
correlating the levels of these autoantibodies with disease activity (Döpp et al., 2000; van 
Beek et al., 2016). Usually, IgG4 is present in relatively low amounts in the sera of healthy 
individuals, its level increase upon repeated antigen exposure, which can be used as a 
marker of successful immunotherapy. Zuo et al., showed that IgG4 can function in an 
inhibitory capacity in autoantibody mediated autoimmune disease, by passive transfer. It 
was imperative to solve the mystery of why IgG4 anti-NC16A antibodies bind the 
pathogenic NC16A domain, but do not induce disease. Their results suggest that anti-
NC16A IgG4 binds to NC16A domain and blocks or reduces pathogenic anti-NC16A IgG1 
and IgG3, binding to the same sites, which cause the reduction of anti-NC16A IgG1 and 
IgG3 mediated complement activation and subsequent neutrophil infiltration and BP 
blistering. Administration of IgG4 anti-NC16A antibodies could represent a new therapy 
strategy (Zuo et al., 2016). Moreover, Mihai et al. reported that BP IgG4 autoantibodies 
have the ability to induce leukocyte-dependent tissue damage. After binding to the 
epidermal basement membrane, IgG4 autoantibodies recruit and activate leukocytes and 
induce dermal-epidermal separation in the cryosections of human skin. Nevertheless, 
comparatively to IgG1, IgG4 autoantibodies show a lower pathogenic capacity (Mihai et 
al., 2007).  
A recent study reported results claiming that levels of anti-BP180 NC16A IgE generally 
reflect disease severity over its course but not early on. This conclusion emerged from 
previous results, that indicating levels of IgE were higher in the sera than blister fluids 
(Bing et al., 2015). It is also reaffirmed that IgE anti-BP180 antibodies have correlation 
with disease activity, but not with disease phenotype (Hashimoto et al., 2016). Hofmann et 
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al., in 2002, reported that in a sample with 116 patients with active BP, about 78% were 
IgE-reactive and had generalized skin involvement (Hofmann et al., 2002). IgE and IgG 
seem to target the same or similar epitopes of BP230 and BP180, which indicates a good 
relation correlation of IgE and IgG auto reactivity in classic BP (Fania et al., 2012). It 
remains a challenge to evaluate the vital roles of IgE in the BP development due to the 
low levels in circulation and the lack of easy tools for assays (Ujiie, 2015), giving rise to 
some inconsistencies concerning the IgE role. So, how do IgE autoantibodies to COL17 
act in the development of BP? It is hypothesized that IgE autoantibodies bind to FcɛRI that 
are expressed by eosinophils (Messingham et al., 2014b; Delaporte et al., 1996), mast 
cells (Dimson et al., 2003) and basophils in blood (Messingham et al., 2014b) or it binds to 
target antigen COL17 at the DEJ in the skin (Parodi and Rebora, 1992; Provost and 
Tomasi Jr., 1974; Yayli et al., 2011). The IgE and COL17 bound mast cells have been 
demonstrated in lesion of patients with BP (Dimson et al., 2003).  All combined, the 
COL17 ectodomains seem to bind to IgE autoantibodies, which in turn will bind to mast 
cells or eosinophils, promoting degranulation, as previously proposed by Messingham et 
al. (Messingham et al., 2014a), and as demonstrated in Figure 7 (Ujiie, 2015). The mast 
cell granulate released, such as histamine, induce vasodilation and increase vascular 
permeability, and cytokines – such as TNF and IL-6 – enhance leukocyte recruitment 
(Wernersson and Pejler, 2014), which results in the development of the inflammatory 
process. High levels of histamine in blister fluid from untreated patients with BP were 
reported to be 10 to 50 times higher than the blister fluid from other blistering diseases 
and about 100 times higher than the plasma histamine level of other patients and normal 
volunteers (Katayama et al., 1984). As we can see in Figure 7, the IgE autoantibodies to 
COL17 also can be internalized which leads to the number decreased of 
hemidesmosomes at the DEJ in organ-cultured skin in a FcR-independent manner 
(Messingham et al., 2011). Therefore, the direct effect of IgE autoantibodies on basal 
keratinocytes may contribute to weak adhesion strength at the DEJ. Still, the effect seems 
limited, because IgE autoantibodies alone fail to induce apparent dermal-epidermal 
separation in animal models (Fairley et al., 2007; Zone et al., 2007), and although some 
BP patients reveal IgE deposition at the DEJ, the disease severity doesn’t seem to be 
different between IgE positive cases and IgE negative cases (Moriuchi et al., 2015), 
which, again, comes into confronters some mentioned studies about the influence of IgE 
in disease course.  
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Figure 7 – Proposed pathomechanism of IgE autoantibodies in BP. The COL17 ectodomains 
that are released bind to IgE autoantibodies mast cells and eosinophils in the dermis. After 
crosslink between FcɛRI by IgE and the autoantigen, histamines and cytokines are released, 
which lead to a signalling cascade. Moreover, the IgE autoantibodies to COL17 could 
directly bind to COL17 on the basal keratinocytes, inducing internalization of the immune 
complex into cytoplasm. This phenomenon leads to a lack of COL17 and, consequently, a 
decrease in adhesive strength at DEJ (from Ujiie, 2015). 
 
A case report of a 67 years old Japanese man with BP with high levels of IgE anti-BP180 
and anti-BP230 in the serum, and an unmanagenable clinical course, suggests that the 
high levels of IgE autoantibodies anti-BP180 play an important role in BP pathogenesis 
(Akasaka et al., 2016).  Moreover, Ishiura et al. reported that about 30% of 67 BP patients 
had IgE anti-BP180 antibodies and 67% had IgE anti-BP230 antibodies. In this case, the 
IgE anti-BP230 antibodies seem to be strongly associated with local eosinophil infiltration 
(Ishiura et al., 2008). Iwata et al. corroborates this fact with a study where it was 
concluded that IgE anti-BP180 antibodies do relates with disease severity and activity of 
the disease (Iwata et al., 2008). 
These entire findings together still demonstrate that the IgE anti-BP230 antibodies play an 
important role in BP pathogenesis; however, further studies are suggested. 
When concerning the IgG, it was demonstrated that IgG autoantibodies to COL17 could 
deplete COL17 in cultured normal human keratinocytes (Iwata et al., 2009). 
Li et al. affirmed the IgG1 is the pathogenic autoantibody in bullous pemphigoid, using a 
mice model (Li et al., 2010).  
Over the years the attempts of passive transfer of blister-inducing autoantibodies in BP 
have been controversial, meaning that while some authors claim to be successful in this 
task, others seem to fail in it. For instance, Sams and Gleich transfused Rhesus monkeys 
with plasma from three BP patients and they did not have any success reproducing the 
features of BP, in any of the three animals (Sams and Gleich, 1971), while, in 1981, 
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Anhalt et al., demonstrated that the rabbit cornea could be used as a target tissue for BP 
autoantibodies. Results proved that intrastromal injection of BP autoantibodies 
reproduced the clinical, histologic, and immunologic features of bullous pemphigoid 
(Anhalt et al., 1981). Since then, many have been theories for the failure of some and the 
success of others. So, in the present year, Iwata et al. reviewed the animal model theme, 
in order to understand the evolution of these models that have such a high impact in the 
pathomechanisms of ABD. These models also play a crucial role in attesting novel 
therapies efficiency. The authors concluded that it is possible to come to an ideal animal 
model, mostly in mice. They also determined, through an exhaustive research, that there 
are four main pathways to induce spontaneous ABD, namely by transfer of 
autoantibodies, by transfer of autoantigen specific lymphocytes, by immunization or by 
genetic alterations (Iwata et al., 2016).  
For instance, in 2015, Hurskainen et al., designed a genetically modified mouse model, 
deleting NC14A region, which corresponds to NC16A in humans. This deletion led to a 
decrease of the amount of COL17 in skin, but it did not prevent ectodomain shedding. 
Although there was no change in the phenotype, microscopically it was possible to 
observe subepidermal microblisters, rudimentary hemidesmosomes and the detachment 
of the BMZ. Also, eosinophila and high levels of IgE were registered. These ΔNC14A mice 
provide a reproducible BP-related mouse model with spontaneous disruption of self-
tolerance and development of autoantibodies (Hurskainen et al., 2015). 
 
2.3. Each Inflammatory Cell Plays Its Own Role 
It is well known that the triggers underlying the autoimmune response in BP are not fully 
understood. Might BP be a result of a breakdown of peripheral tolerance to BP antigens? 
And would this mechanism be enough to induce autoantibody formation? 
Thoma-Uszynski et al., demonstrated that the majority of thirty-five BP patients had 
autoagressive T and B cells autoantibody reactive with defined extracellular regions of 
BP180 and, to a lesser extent, of BP230. Knowing that NC16A region represents a major 
binding site for autoantibodies in bullous pemphigoid, they were able to conclude that 
NC16A region contains immunodominant epitopes for both autoaggressive T and B cells, 
however, this study stablished that autoreactive T and B cells also recognize epitopes 
located within the COOH and NH2 terminal and central portion of the BP180 ectodomain. 
Summarily, this study defines that T and B cell recognition of the NH2 terminus and 
midportion of BP180 seems to be associated with extensive and limited BP, respectively. 
T and B cell recognition of BP230 seems to be focused on the NH2 and COOH terminal 
domains. Such observations led to the concept that BP180 is the primary autoantigen of 
BP (Thoma-Uszynski et al., 2006). T cells from BP patients were extracted to confirm their 
reaction to BP180. Also it is postulated that, not only T cells are reactive to BP180 as also 
the BP180-specific T cells are of the CD4 lineage (Lin et al., 2000).  
In 2010, a case report mentions a patient that, by immunohistochemistry (IHC), revealed 
the presence of abundant CD45 lymphocytes, surrounding blood vessels, eccrine sweat 
glands and nerves. Also, this patient displayed IgG, IgE and fibrinogen antibodies against 
the BMZ (Abreu-Velez et al., 2010). This case alerts us to the possibility of the existence 
of more factors contributing to BP pathogenesis. 
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There is cooperation between B cells and CD4+ Th cells, which is important for the 
production of antibodies by B cells. Self-antigens of the BMZ - BP180 and BP230 - in BP 
patients are caught by antigen-presenting cells, processed and bound to major 
histocompatibility complex class (MHC) II and displayed on the cell surface. The 
recognition of these epitopes by T cells will trigger the release of various cytokines and, 
consequently, B cells are stimulated to produce autoantibodies (Lo Schiavo et al., 2013). 
It has been postulated that the imbalance between autoreactive Th and T regulatory cells 
(Tregs) is critical to the outbreak of BP disorder, and the difference between patients and 
normal individuals possessing the same autoreactive T cells consists in a deficit of the T 
regulating function (Grando, 2011). There is increasing evidence of dysfunctional Tregs in 
the regulation of the production of pathogenic autoantibodies in BP. Such studies suggest 
that Tregs may represent a great tool to specifically restore immune tolerance in 
autoimmune bullous skin disorders (Hertl et al., 2006).  
Büdinger et al., reported that CD4 memory T cells exhibit a Th1 and Th2 mixed cytokine 
profile and that responses to BP180 were restricted by the BP associated HLA-
DQB1*0301 allele in BP patients. Also, this T cells that are reactive to BP180, were found 
in healthy individuals. However, in the healthy individuals, Th2 cells are absent which 
strongly suggests that autoreactive Th2 cells responses to BP180 are restricted to BP 
patients and are crucial to pathogenesis (Büdinger et al., 1998). It is known that Th1 cells, 
mainly IFN- that are found at an increased amount in sera and blister fluid of BP patients, 
are able to induce production of IgG1 and IgG2 and, for instance, Th2 cytokines, including 
Interleukin(IL)-4, IL-5 and IL-13, have been found to regulate the production of IgG4 and 
IgE. Detection of the three isotypes in BP patients, strongly suggests that both Th1 and 
Th2 cells are involved in regulation of the response to BP target antigens. Also, it’s 
possible to conclude that BP stages can be defined through the Th1/Th2 balance. All 
these findings together leads to the belief that BP is a T cell dependent autoimmune 
disease with the presence of CD4+ lymphocytes, mainly Th2, autoreactive T cells in the 
peripheral blood of patients that recognize the BP180 ectodomain (Giomi et al., 2002; 
Rico et al., 1999). 
Moreover, in a previous study, Leyendeckers et al. 2003, detected and characterized 
BP180 specific IgG+ B cells in eleven out of fourteen blood samples of BP patients 
(Leyendeckers et al., 2003). Also, Qian et al., demonstrated high levels of B-cell activating 
factor (BAFF) in memory B cells, specifically found intracellularly in BP patients. This 
abnormal BAFF production might disturb immune tolerance, allowing survival of 
autoreactive B cells and triggering autoimmune disease, such as BP. So BAFF expression 
in B cells might be relevant for BP pathogenesis (Qian et al., 2014). The depletion of B 
cells in some autoimmune disease boosted further investigation about the potencial of 
drugs that couyld possibly modulate the functions of B cells, for instance, in the treatment 
of some ABD (Browning, 2006). 
 
2.4. Tissue Injury Mechanisms, Blister Formation and Fluids 
The mechanisms that might cause BP autoantibodies to be pathogenic have been 
exhaustively studied and it could imply the complement activation, recruitment of 
inflammatory cells, liberation of proteolytic enzymes and direct interference with the 
adhesion function of the autoantigens. 
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2.4.1. When Complement System Plays a Role: Step 1 
Gammon et al., demonstrated the relevance of leukocytes in BP, using serum samples 
from BP patients incubated with cryosections of normal neonatal human foreskin, 
obtained by routine circumcision of healthy neonates. This interaction causes a 
chemotaxis mediated by pemphigoid antibodies and fresh serum which led to a leukocyte 
migration to DEJ, and this event culminates in the separation of this junction. It was shown 
that this leukocyte chemotaxis and attachment to the junction requires the complement 
activation via classical pathway and evidence the C5 role (Gammon et al., 1981). 
Moreover, it was demonstrated that C5a can interact with mast cells and thus trigger the 
p38MAPK cascade. This cascade will cause the mast cells degranulation, also crucial for 
blistering (Heimbach et al., 2011). 
There are some studies that demonstrate that BP autoantibodies fix complement in vitro 
and in vivo, via classical and alternative pathway, and that C3 and C5 are detected by 
immunofluorescence along the BMZ of perilesional skin in almost all patients with BP 
(Naito et al., 1984; Provost and Tomasi Jr., 1973). Also, it was demonstrated that both BP 
autoantibodies and C3 can be detected at the site of the injury, the lamina lucida of the 
skin (Schmidt-Ullrich et al., 1975). It seems that most serological positive BP sera fix 
complement, via both classical and alternative pathway (Jordon et al., 1985). Once again, 
the role of the complement system activation is emphasized through the observation of 
the levels of total hemolytic complement and of individual complement components in 
blister fluid from BP patients, which are lower than those found in control blister fluids in 
the sera of these patients (Jordon et al., 1973). In 2016, a statistical analysis revealed the 
importance of complement activation. A group of 300 BP patients were studied and about 
83.1% showed C3 deposition along the epidermal BMZ, in their skin biopsy (Romeijn et 
al., 2016). Liu et al. used a mouse model to demonstrate the role of complement in the 
pathogenesis of subepidermal blistering, concluding that there is strong evidence that 
supports the idea that complement activation is crucial for the production of subepidermal 
blisters caused by anti-BP180 antibodies (Liu et al., 1995). So it was obvious that 
complement components are also present in the region of blister formation (Panelius and 
Meri, 2015). 
In order to try to understand by which way the complement would be activated, in 2006, a 
study show the roles of the different complement activation pathways, through a passive 
transfer of antibodies to the murine BP180 (mBP180). So, this data demonstrated that 
activation of the classical pathway is crucial for disease development and that the 
alternative pathway acts in concert with the classical pathway in subepidermal blistering. 
This study points out an important fact, that the contribution of the alternative pathway to 
experimental BP usually is underestimated and that the implication of the lectin pathway 
cannot be fully discharged (Nelson et al., 2006). 
But the controversy re-ignites by analyzing a case control study with two patients 
diagnosed with BP, reporting no complement activation at the BMZ. Direct 
immunofluorescence of the skin showed that IgG4 was the major subclass on the anti-
BMZ IgG antibodies in both cases; moreover, complement fixation (CF) test demonstrated 
that circulating autoantibodies against BP180 from either case did not fix complement, 
whereas sera from common BP patients did. So, these findings suggest that there could 
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be an alternative mechanism complement-independent, in blister formation, making some 
cases complement-independent (Dainichi et al., 2016). Back in 2014, Ujiie et al. also 
demonstrated the involvement of complement-independent pathways, through a 
generation of C3-deficient COL17-humanized mice. It was proven that the deposition of 
Abs, and not complements, is important to the blister induction formation, both in neonatal 
and adult mice (Ujiie et al., 2014). 
 
2.4.2. When Inflammatory Cells Also Interfere: Step 2 
The autoantibodies react with an antigen located in the lamina lucida region of the 
basement membrane zone – anti-BMZ autoantibody – that characterizes bullous 
pemphigoid, triggering seems to be mediated by inflammatory cells (Jordon et al., 1985). 
Hereupon, among inflammatory cells that are able to mediate tissue injury, we have mast 
cells, neutrophils and eosinophils.  
 
a. Mast cells Interference: Step 2.1.  
It was 1978 when Wintroub et al. report the presence and degranulation of mast cells 
(MCs) in BP lesional sites (Wintroub et al., 1978). Such discovery was subsequently 
confirmed by further investigations. This degranulation of the mast cells was also seen in 
lesional skin of mice injected with pathogenic anti-mBP180 antibodies (Borrego et al., 
1996; Chen et al., 2001; Dvorak et al., 1982). Antigen-specific degranulation of mast cells 
from BP patients suggests the mechanism by which IgE may contribute to lesion 
development (Dimson et al., 2003; Fairley et al., 2005). 
Chen et al., ascertained that mice deficient in mast cells, macrophages or neutrophils 
were resistant to experimental BP, whereas in wild-type mice and T or B-deficient mice (or 
both T and B cells) pathogenic anti-murine BP180 antibodies triggered BP skin disease. 
Also, the reconstitution of the mast cells restores the pathogenic activity of anti-mBP180 
IgG (Chen et al., 2002b). 
It was also proven that complement activation is required to induce mast cells 
degranulation. For instance, C3a and C5a fragments are responsible for the mast cells 
degranulation induction. Also, the C5b deficiency completely eliminates mast cells 
degranulation (Chen et al., 2001, 2002b; Muller-Eberhard, 1988).  
Mast cells are responsible for the production of many mediators such as leukotriens, 
platelet-activating factor, TNF-α, mast cell tryptase and many other cytokines, which have 
a linkage to neutrophil influx, direct or indirectly. This is a reflex of high levels of histamine, 
leukotriene B4, IL-1, IL-2, IL-5 and IL-6, and TNF-α in blister fluids (Endo, 1992; Galli et 
al., 1991, 1993; Grando et al, 1989; Katayama et al., 1984; Schmidt et al., 1996a, b). Also, 
pathogenic anti-murine BP180 antibodies are responsible for BP skin lesions in mice mast 
cells-deficient reconstituted with neutrophils, IL-8 or TNF-α (Chen et al., 2001).  
Summing up, all presented studies provide evidence that subepidermal blistering also 
depends on mast cells. Mast cells, through degranulation, play a crucial role recruiting 
neutrophils to the target tissue, following the complement activation that represents an 
essential player in the inflammatory cascade, which leads to blister formation in bullous 
pemphigoid.  
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b. Accumulation of Neutrophils Interference: Step 2.2. 
Neutrophils were found to be essential for dermal-epidermal detachment in the in vitro 
cryosection model of BP (Sitaru et al., 2002; Shimanovich et al., 2004). Cryosection 
models were used for incubation with BP serum, then it was possible to observe that 
complement and peripheral blood leukocytes, neutrophils, line up along the basal 
membrane, thereafter, the dermal-epidermal cohesion breaks down. Experiments that 
were performed in animal models show that, in an early phase, the neutrophil infiltration 
depends on the complement activation, which leads to mast cells degranulation (Chen et 
al., 2001; Liu et al., 1995). Mice depleted of circulating neutrophils no longer were 
susceptible to the pathogenic effects of anti-mBP180 IgG. Also, C5-deficient mice, 
resistant to the pathogenic activity of anti-mBP180 IgG, could become susceptible with 
intradermal administration of a neutrophil chemoattractant – IL-8 and C5a. Such results 
prove that neutrophils recruited to the skin via C5a-dependet pathway play a crucial role in 
subepidermal blister formation in experimental BP (Liu et al., 1997). Springer postulated 
that, when neutrophils chemo attractants are injected into the skin, it will stimulate the 
accumulation of neutrophils increasing the recruitment of additional neutrophils (Springer, 
1994). The amplification stage of neutrophils recruitment could be induced through the 
liberation of several proteases, for instance gelatinase B and neutrophil elastase, which in 
turn are detected in lesional skin and blister fluid of BP patients (Liu et al., 1998, 2000a, b). 
Neutrophil elastase (NE), an enzyme secreted by the initial wave of activated neutrophils, 
was proven to be able to cleave mBP180 within the immunodominant domain NC16A, 
which will generate a 12 kDa digestion product that is chemotactic for neutrophils. The 12 
kDa fragment – called p561 – is chemotactic for neutrophils both in vitro and in vivo. So 
NE might be the major protease responsible for BP180 degradation (Lin et al., 2012). 
It was also demonstrated that β2 integrins were absolutely critical in subepidermal 
blistering experimental BP (Liu et al., 2006).  
It was further proved that the disease severity has a direct correlation between 
neutrophilic infiltration and the degree of subepidermal blistering. The neutrophil 
accumulation has a required threshold for clinical blistering. For instance, a 30% reduction 
in neutrophil influx results in the inhibition of subepidermal blisters (Liu et al., 1997).  
Yamatomo et al., challenged the absolute requirement of leukocytes for blister formation 
of BP. They showed that anti-hamster type XVII collagen IgG and complement could start 
dermal-epidermal junction separation in the absence of inflammatory cells (Yamatomo et 
al., 2002). And so, this finding could initiate another branch in this research. 
 
c. Accumulation of Eosinophils Interference: Step 2.3. 
It was proven that proteolytic enzymes of eosinophils play an important role during the 
initial stages of blister formation in BP (Dubertret et al., 1980; Varigos et al., 1982). 
The infiltration of eosinophils in the developed bullous cavity leads to the direct adhesion 
to basal cells and the release of their granulate content towards these target cells, 
suggesting that eosinophils amplify the formation of DEJ separation, in BP lesions (Iryo et 
al., 1992). 
In about 50% of BP patients, levels of eosinophils in the peripheral blood were higher, 
revealing a clinical condition named peripheral eosinophilia (Bushkell and Jordon, 1983) 
and 70% had high levels of serum IgE (Arbesman et al., 1974). 
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A very recent study accessed the activity of eosinophils in BP patients and found out that 
blood, skin and blister demonstrated a high eosinophil activity. These eosinophils also 
released IL-6, IL-8 and IL-1α in the blister fluid. The major outcome of this study was the 
increased rate of apoptosis in the cultivated BP eosinophils. All of this demonstrates that 
there is an apoptosis activity of eosinophils in the peripheral blood, skin and blister fluids 
(Engmann et al., 2016). 
Messingham et al. utilized clinical samples to prove the relationship between IgG 
autoantibodies and eosinophilia in BP. Samples collected from fourty-eight untreated 
patients diagnosed with BP revealed that peripheral eosinophil count correlates strongly 
with IgE autoantibodies directed against BP180. Expression of FcɛRI – the high IgE 
receptor – by circulating and lesional eosinophils from BP patients provides a new 
perspective for mechanisms of action for IgE in BP. This suggests that expression of 
FcɛRI may contribute to eosinophil degranulation in BP lesions (Messingham et al., 2011, 
2014b). Besides, a recent study demonstrated that FcR variations affects the 
susceptibility to BP, decreasing the reactive oxygen species (ROS) that neutrophils 
release, which translates in a reduced granulocyte responsiveness (Recke et al., 2015). 
Elevated levels of IL-5 and eotaxin in blister fluid of patients with bullous pemphigoid was 
also observed, which could demonstrate that eotaxin level correlates with the number of 
lesional eosinophils and that the high level of IL-5 could indicate an association between 
these cytokines and eosinophil accumulation in BP. IL-5 is related to blister formation and 
eosinophilia in BP and this can be due to the fact that T cells and eosinophils can produce 
this cytokine and, therefore, be the major sources of IL-5 on blister fluid. The IL-5 
promotes eosinophil growth and activation and eotaxin causes eosinophil migration 
(D’Auria et al., 1998; Endo et al., 1992; Shrikhande et al., 2000; Wakugawa et al., 2000). 
Moreover, IL-5 and eotaxin seem to be the main responsible for the increasing of the 
inflammatory response and to contribute to the influx of granulocytes that, through the 
release of proteinases or cytotoxic agents, which includes eosinophil major basic protein 
(MBP) and eosinophil cationic protein (ECP), will ultimately lead to the epidermis and 
dermis separation, at lamina lucida level of the BMZ (Czech et al, 1993). 
In accordance with what was written above, eotaxin specific receptor – CCR3 – has been 
reported to be highly expressed on eosinophils, basophils, and Th2 cells in BP (Frezzolini 
et al., 2002). 
Th2 cells essentially release IL-4, IL-5, IL-6 and IL-10. Through an ELISA assay, Schmidt 
et al., demonstrated, in 1996 that, levels of IL-4, IL-6 and IL-10 were increased in patient’s 
blisters compared to suction blister from healthy controls. This finding seems to be 
important, since IL-4 is responsible for stimulation of B lymphocytes. On the other hand, 
the high level of IL-10 seems to be important to a well-regulated immunological system in 
lesion formation in BP, since this cytokine is known to have a depressant effect on 
cytokine production of Th1 cells and also suppresses the functions of other CD4+ cell 
subtypes, so this may represent a natural effort against excessive tissue inflammation 
(Schmidt et al., 1996b). This is what also happens in PV, where 87.5% of patients with 
active disease demonstrated high levels of IL-10, whilst the blister fluid from 12.5% 
patients in remission demonstrated low levels of IL-10. It was hypothesized that IL-10, in 
both PV and BP, is produced as a local phenomenon (Bhol et al., 2000). A study using 
peripheral blood from pemphigus and pemphigoid patients demonstrated that IL-10 are 
found in lower levels in pemphigus patients whereas no statiscally significance was found 
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between pemphigoid patients. In pemphigus cases this decrease wasn’t associated with 
disease severity but only with the required dosage of steroid therapy, since the decrease 
of B10 cells are caused by therapy (Kabuto et al., 2016). So, it is possible to conclude that 
IL-10 is at high levels in blister fluids but not so much in the peripheral blood of BP and PV 
patients. 
In 1996, a study found out that in blister fluid of BP patients there were high levels of IL-8, 
about 10 times higher than in suction blisters of control subjects, and knowing that IL-8 
has a chemotactic effect on both T cells and neutrophils, this high levels can lead to 
infiltration of these cells (Schmidt et al., 1996a). Again, in 2000, a study indicates that BP-
associated autoantibodies to BP180 ectodomain, somehow, trigger a signal that leads to 
expression and secretion of IL-6 and IL-8 from human keratinocytes (Schmidt et al., 
2000). 
Narbutt et al. conducted a study to evaluate the serum levels of IL-6 in patients with active 
disease (n=19) and in remission (n=24). They found that in both cases the levels of this IL 
was increased comparing with healthy controls (n=19) (Narbutt et al., 2008).  
Another cytokine was studied for its involvement in Th2 lymphocytes and eosinophils 
recruitment during bullous pemphigoid – IL-16. This cytokine was already described as an 
essential chemotactic cytokine for a variety of CD4+ immune cells. It is an 
immunomodulatory cytokine contributing to the regulatory process of CD4+ cells 
recruitment and activation at sites of inflammation during Th2-mediated immune 
disorders, such as autoimmune diseases (Cruikshank et al., 2000; Mathy et al., 2000). 
Seem that IL-16 is mainly expressed by keratinocytes and CD4+ lymphocytes in lesional 
skin of BP patients. These findings suggest that IL-16 serum levels could reflect disease 
activity in these patients. The significant production and release of IL-16 helps to maintain 
and amplify immunological process underlying blister formation (Frezzolini et al., 2004). 
Also, Th17 cells and the released cytokine IL-17 may have a role in the pathogenesis of 
BP, contributing for the neutrophil infiltration and eosinophil recruitment, which cannot be 
explained through the presence of autoantibodies. There is evidence that IL-17 is 
implicated as pathogenic factor in other autoimmune diseases, such as systemic lupus 
erythematous, atopic asthma, etc. IL-17 is important for the initiation and maintenance of 
many autoimmune reactions. It is involved in the production of important pathogenic BP 
factors, such as pro-inflammatory cytokines, matrix metalloproteinases and recruitment of 
neutrophils and eosinophils. It also induces Th2 cells activation (Toosi and Bystryn, 2010). 
In 2011, lesional IL-17 was evaluated quantitatively suggesting that, compared with 
pemphigus; BP shows more Th17 cell-related inflammation and less Treg-related 
regulation. These results could be explained by the difference in pathogenesis between 
pemphigus and BP, being inflammation more crucial for the blister formation in BP than in 
pemphigus (Arakawa et al., 2011). 
Fang et al. also demonstrated how some inflammasome components and IL-18 can 
interfere with disease activity too. They concluded that mRNA levels of inflammasome 
components were up-regulated, when compared with healthy controls. Also, these 
components interfere with autoantibody titers for BP180-NC16A. The IL-18 levels were 
increased in serum, blister fluid and lesional skin, and as with inflammasomes, serum IL-
18 level interfere with anti-BP180-NC16A autoantibody concentrations in patients. All of 
the concentrations decreased dramatically after treatment (Fang et al., 2016).  
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Moreover, a recent study intended to investigate the microenvironment of lesional skin 
and serum of BP patients. The outcome demonstrated a dense deposition of periostin in 
the lesional dermis of BP patients. This increased concentration of periostin could 
stimulate CD163+ tissue-associated macrophages (TAMs) to produce autoimmune-related 
chemokines and cytokines, such as CXCL5 and IL-36 (Fujimura et al., 2016). 
 
d. Proteolytic Enzymes Events: Step 2.4. 
Many studies have been referring high levels of proteolytic enzymes in blister fluid from 
BP patients, such as, neutrophil elastase (NE), cathepsin G (Grando et al., 1989), 
collagenase (Oikarinen et al., 1983; Welgus et al., 1986), plasminogen activators (Gissler 
et al., 1992; Jensen et al., 1988), matrix metalloproteinase-2 (MMP-2, gelatinase A), 
MMP-9 (gelatinase B) and MMP-13 (Niimi et al., 2006; Ståhle-Bäckdahl et al., 1994), 
playing a mechanistic role by degrading connective tissue components of the dermis and 
the DEJ. 
NE is strongly expressed by eosinophils and is thought to proteolytically degrade 
extracellular matrix proteins as well as the extracellular domain on BP180 (Verraes et al., 
2001). MMP-9 is secreted inactive and it’s activated extracellularly, by plasmin, which is 
generated from plasminogen through tissue plasminogen activator (tPA) and/or urokinase 
plasminogen activator (uPA) and other MMPs. This leads to the conclusion that the major 
function of plasmin early in BP development is activating MMP-9 (Liu et al., 2005). 
Schmidt et al., went further and demonstrated the elevated expression and release of 
plasminogen activator (PA) from normal human keratinocytes upon stimulation with 
antibodies to human BP180. Since keratinocytes secret PA, they might play an active role 
in blister formation (Schmidt et al., 2004). In addition to plasmin, the MC-specific serine 
protease MCP-4 (chymase) also could activate MMP-9 (Coussens et al., 1999; Liu et al., 
2005). After MMP-9 activation, it proteolycatilly inactivates α1-proteinase inhibitor – 
inhibitor of NE – which allows the free NE activity (Liu et al., 2000a).  
Very recently, a study was performed as an attempt to find a connection between BP 
outcome and C-X-C motif chemokine 19 (CXCL10) levels, since this chemokine has been 
associated with several autoimmune diseases. Sixteen skin biopsy speciments, sera from 
one hundred and forteen patients and blister fluid from twenty-three were used to 
investigate CXCL10 expression and function. Blister fluids and sera revealed high levels 
of CXCL10. Also, CXCL10 serum levels seem to increase around day 60, but only in 
patients that relapsed within the first year of treatment. An important fact is that 
neutrophils and monocytes from BP patients, but not lymphocytes, reacted to CXCL10 by 
increasing MMP-9 secretion. It is important to note that high levels of CXCL19, BP 
biomarker, play into neutrophil and monocyte-associated MMP-9 release and disease 
relapse (Riani et al., 2016). 
All these findings together indicate that proteolytic enzymes released from inflammatory 
cells damage the BMZ directly, which causes DEJ separation. 
 
e. Direct Mechanisms: An Alternative Step 
There is evidence indicating that cell-matrix adhesion could be disrupted by autoantibody 
binding itself, through the antibody’s variable regions, independently of their fragment 
crystallisable (Fc) portions. The mere binding of the antibody to the BP180 ectodomain 
might trigger blister formation, through the impairment of these molecules, by competing 
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with the natural ligand and by blocking the key binding sites along the BP180 antigen 
(Ghohestani et al., 2001). 
Macropinocytic pathway also could induce the reduction in the adhesive strength and a 
loss of expression of BP180, by internalization.  The BP180 internalization induced by BP-
IgG occurs rapidly, within < 30 minutes. However, it was proven to be insufficient to 
induce blister formation. Since blistering requires various inflammatory responses at the 
cell-extracellular matrix zone, it was speculated that it could first occur the deterioration by 
BP180 internalization. Blister formation in BP requires both BP-IgG – induced BP180 
internalization and FcR-independent and FcR-dependent immune responses (Hiroyasu et 
al., 2013).  
A study was conducted using various FcR-deficient mouse strains which demonstrated 
that tissue destruction seems to be mediated by FcRIV, FcRIII and FcRIIB, whereas 
FcRI was not pivotal. For instance, pharmacological inhibition of FcRIV and depletion of 
granulocytes seems to abolish skin blisters. This also reinforces that Fc receptor (FcR) – 
independent mechanisms may contribute to pathogenesis (Schulze et al., 2014). 
The activation of pro-inflammatory cytokines by autoantibodies might constitute another 
mechanism of blister induction, by activation of intracellular signaling pathways, thus 
resulting in hemidesmosomal disassembly. So, in 2000, Schmidt et al. demonstrated that 
BP IgG induces the release of IL-6 and IL-8 from human keratinocytes, directly modulating 
these cytokines (Schmidt et al., 2000). 
 
2.5. Concluding Remarks 
Although over the years of research animal models have generated discussion topics due 
to their unpredictability, these models revealed to be very important in the study of the 
pathomechanism of BP. These models provide tools that help us to better understand the 
mechanisms underlying the disease.  
As perspective, urges the need to design novel and more specific therapeutic strategies to 
counteract the chronic morbidity and mortality. This new design may arise from further 
investigation of the inflammatory cascade that is generated in the disease.  
The novel therapies may involve the use of monoclonal antibodies able to modulate the 
immune response. Moreover, induction of immunological tolerance could also offer a valid 
alternative, avoiding the use of corticosteroids, for example.  
In short, the Figure 8 summarizes the main pathophysiological mechanisms that happen 
in BP, such as the bind of IgG to BP180, the cleavage of BP180 by NE and the bind of 
BP230 to IgE. Most of these events culminate with mast cell degranulation, which in turn 
will lead to blister formation.  
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Figure 8 – Important pathophysiological pathways in BP summarized (from Hammers and 
Stanley, 2016). 
 
In general, autoantibodies need to interact with factors of the innate immune system, 
which includes complement system and inflammatory cells, in order to induce blisters 
(Sitaru and Zillikens, 2005). 
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Pemphigus vulgaris is a mucocutaneous blistering disease characterized by IgG 
autoantibodies against the stratified squamous epithelium (Kalantari-Dehaghi et al., 2013). 
However, in a small sample of patients with both PV and PF, desmogleins are not 
recognized by IgG, instead IgA against Dsg1 and Dsg3 is present, in these cases it is 
necessary further investigation to determine the impact of the IgA antibodies on 
phenotype and if this could interfere with therapeutic regimen (Mentink et al., 2007).  
A mice model with a deletion of epidermal-specific desmocollin 3 (Dsc3) demonstrated 
that Dsc3 also constitutes an antigen in PV. Moreover, the incubation of patient IgG with 
human keratinocytes led to the loss of intercellular adhesion. This suggests that PV has a 
pattern that could result from autoimmunity of Dsg3, Dsc3 or both. Also, this event was 
later observed in other forms of pemphigus (Mao et al., 2010; Rafei et al., 2011). 
The classic forms of PV are divided in two subtypes, according to antibody profile. These 
are mucosal dominant type of PV that only have anti-Dsg3 IgG autoantibodies and the 
mucocutaneous type of PV that have both anti-Dsg3 and anti-Dsg1 IgG autoantibodies 
(Ding et al., 1997). The role of Dsg4, a new isoform, has been investigated in disease 
development. Dsg4 was reported in thirty (77%) patients of a cohort with 39 PV and PF 
patients’ sera. These results suggest that Dsg4 might have other role besides adhesion 
(Nagasaka et al., 2004). 
In the past decades, studies of autoimmune response in PV have been updated, which 
led to a major outcome: analyzing levels of antibodies to Dsg3 by enzyme linked 
immunosorbent assay (ELISA). This represents an important milestone and a diagnostic 
criterion of PV (Amagai and Stanley, 2012). Desmogleins are transmembrane 
glycoproteins of desmosomes that confer cell-to-cell adhesion within the epidermis 
(Hammers and Stanley, 2016), represented in Figure 9. 
 
 
Figure 9 – A scheme with the intercellular keratinocyte desmosome. The desmogleins, that 
are targets of the pemphigus antibodies, are responsible for the mediation the cell-to-cell 
adhesion. The connection is also mediated by desmocollins. Abbreviations: Dsc, 
desmocollin; Dsg, desmoglein; DP, desmoplakin; KIF, keratin intermediate filament; PG, 
plakoglobin; PKP-1, plakophilin 1 (adapted from Hammers and Stanley, 2016). 
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The desmosomes are complex structures, disc shaped, also known as a macula 
adherens, with is specialized for cell-to-cell adhesion. The intercellular space is wide, with 
about 30 nm. Desmosomes are transmembrane proteins that bridge the space between 
adjacent epithelial cells by way of homophilic binding of their extracellular domains to 
other desmosomal cadherins on the adjacent cell. The desmosome extracellular domain 
is called the extracellular core domain (ECD), and is bisected by an electron-dense 
midline where the desmoglein and desmocollin proteins bind to each other (Amagai, 2003; 
Junqueira and Carneiro, 2013; Waschke, 2008). It is known that desmosomes are 
dynamic structures with an exclusive plasticity, required in some particular vertebrate 
tissues needing strength, extensibility and elasticity, such as epithelium (Celentano and 
Cirillo, 2016). 
 
 
Figure 10 – Molecular structure of desmoglein. The extracellular (EC) region of each 
cadherin member contains four cadherin repeats, which have calcium-binding motifs, with 
about 110 amino-acid residues. Desmogleins have their own unique sequences with 291 
residues. The boxes with the same color have similar amino acid sequences. DTD: 
desmoglein-specific terminal domain; EA, EC anchor domain; IA, intrecellular achor 
domain; IPL, intracellular proline-rich linker (adapted from Amagai, 2003). 
 
Through the use of keratinocyte cDNA expression library with PV serum, it was possible 
to determine that the amino acid sequence of the cell surface 130 kd glycoprotein, PV 
antigen (PVA) had a significant homology with members of the cadherin family of Ca2+ 
dependent cell adhesion molecules, desmoglein, which is now called Dsg 3 (Amagai et 
al., 1991).  
In 1992, Amagai et al. demonstrated that PVA has five ectodomains – EC1 to EC5 – and 
localized the immunogenic domains. These findings defined that the major pathogenic 
epitope was the amino-terminal extracellular domains, a crucial region for hemophilic 
adhesion of cadherins (Amagai et al., 1992), as seen in Figure 10. Moreover, these 
findings suggest a direct inhibition of adhesive interaction of Dsg as an initial molecular 
event of blister formation in pemphigus (Tsunoda et al., 2003). To prove the crucial role of 
pemphigus antigens for keratinocyte adhesion, a genetically engineered mice with Dsg3 
gene deletion were created, which demonstrated the critical role of Dsg3 for adhesion 
(Koch et al., 1997). This kind of discovery allowed the development of ELISA to diagnose 
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PV patients more effectively. A study confirmed that out of fourty-nine PV patients’ sera, 
fourty-six were positive in the Dsg3 ELISA. Moreover, this ELISA also provides a 
correlation of disease activity with serum antibody levels (Ishii et al., 1997). 
Also, a very recent study found out that pemphigus, PV and PF, patients had altered 
levels of prolactin (total and free) and dehydroepiandrosterone sulfate (DHEAS), sex 
hormones. A cohort with fifty-two newly diagnosed pemphigus patients from Theran, Iran, 
was accessed and investigators reported that pemphigus’ patients had higher levels of 
prolactin and lower of DHEAS. Pemphigus patients with a more severe form of the 
disease had increased levels of serum total prolaction (Yousefi et al., 2016). These recent 
findings could be another open door to pemphigus pathogenesis studies, about the role of 
these sex hormones in the course of disease.  
 
3.1. Autoantibodies Interference  
The pathogenicity of circulating IgG antibodies from patients with active pemphigus has 
been confirmed by passive transfer experiments in mice (Anhalt et al., 1982). 
Nineteen PV patients’ sera was characterized and all of them showed high titers of IgG 
autoantibodies, predominantly IgG4 (Ding et al., 1997). A case report of a male newborn 
diagnosed with PV represented a case in which the autoimmune response was studied at 
molecular level, being possible to demonstrate that neonate’s antibody to Dsg3 mainly 
belonged to IgG4 class. In other words, it was once again illustrated the blister inducing 
capacity of anti-Dsg3 antibodies of IgG4 class (Parlowsky et al., 2003). Another study with 
PV patients determined the enrichment of IgG4 in these patients. The Dsg-specific 
antibodies contain about 7.1% of total IgG4 in PV patients, which represent eight-fold 
enrichment of IgG4, when compared with age-matched controls. Also, IgG4 depletion in 
PV sera was responsible for the pathogenicity reduction in a keratinocyte dissociation 
assay (Funakoshi et al., 2012). 
The disease can be induced in cultured human keratinocytes, with recombinant 
monovalent single-chain variable-region fragments (scFvs) cloned from PV patients, 
proving that antibodies directly mediate acantholysis (Payne et al., 2005). 
The transmission of PV during pregnancy, to neonatal babies, is a clear evidence of 
passive transfer experiment in humans (Kardos et al., 2009). For instance, Dsg3 
antibodies per se can induce the skin blistering in the newborn. This is the result of a 
different distribution pattern of the Dsg1 and Dsg3 (Avalos-Díaz, et al., 2000). 
  
3.1.1. In: Cell Adhesion  
As previously referred, some pemphigus antibodies directly interfere with cell adhesion. 
Since the discovery of autoantibodies interfering with desmosomal adhesion molecules it 
has been investigated the autoantibodies direct interference with desmoglein binding, in a 
so called “Direct steric hindrance model” (Bystryn and Grando, 2006; Waschke, 2008). 
It was proved, in 2008, that Dsg3 autoantibodies in PV directly inhibit Dsg3 trans 
interaction. In this experiment it’s possible to confirm that PV-IgG directly interfere with 
hemophilic Dsg3. PV-IgG reduced binding activity of Dsg in ~60%. Also, PV-IgG caused 
keratinocyte dissociation as well as loss of Dsg3 trans interaction (Heupel et al., 2008). 
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Moreover, studies comparing polyclonal PV patients IgG and monoclonal Dsg3 
antibodies, showed that  polyclonal PV IgG causes extensive clustering and endocytosis 
of keratinocyte cell surface Dsg3, while, pathogenic mouse monoclonal antibodies 
compromise cell-to-cell adhesion strength without causing these alterations in Dsg3 
trafficking (Saito et al., 2012).  
Further studies were made in order to find a direct inhibition of adhesion and epitopes 
mapping. A study demonstrated that 77.5% of the dominant epitopes bound by 
pemphigus sera mapped to the N-terminal extracellular domain of Dsg3 which, by analogy 
to classic cadherins, is crucial for adhesion (Sekiguchi et al, 2001). 
Moreover, findings suggest that the disease activity is more correlated with the level of 
immunoreactivity against the mature form of Dsg by ELISA than against the premature 
one. Another interesting finding suggests that much of the immunoreactivity in pemphigus 
sera target very restricted regions of Dsg that are masked by the prosequence, therefore, 
unmasked by proteolytic cleavage of prosequence. This leads us to the pathogenic hot 
spot on Dsg (Yokouchi et al., 2009). Besides the importance of interruption of trans 
adhesion of Dsg, it was also reported that patients could harbor pathogenic antibodies 
that also target the cis adhesive interface within the amino-terminal extracellular domain – 
ectodomain (Di Zenzo et al., 2012). This kind of adhesion of desmoglein could be 
essential in the strengthening of cell-to-cell adhesion, by clustering of the desmoglein in 
desmosome. Another important fact is that pemphigus antibody binding to desmogleins is 
essentially dependent on their normal, calcium-stabilized conformation (Kamiya et al., 
2013).  
 
3.1.2. In: Desmoglein Clustering/Internalization 
Other model that could explain the loss of cell-to-cell adhesion is the desmoglein 
nonassembly depletion hypothesis. This hypothesis tells us that maybe the loss of cell 
adhesion is due to the ability of multivalent pemphigus anti-desmoglein antibodies to 
crosslink and, possibly, cluster desmogleins. The crosslinking results in internalization of 
the nonjunctional Dsg and prevents the newly synthesized desmoglein from being 
incorporated into the desmosome. Ultimately, this lead to depletion of the desmosome of 
desmoglein and thus won’t be able to provide adhesion (Oktarina et al., 2011). PV 
patients have been reported with clustering of Dsg3 by anti-Dsg3 autoantibodies (van der 
Wier et al., 2014). Several studies of cell cultures, such as human squamous cell 
carcinoma cell line and primary human keratinocytes, were made and revealed similar 
results of Dsg3 clustering and depletion in desmosomes (Aoyama and Kitajima, 1999; 
Jennings et al., 2011; Stahley et al, 2014). 
Moreover, Mao et al. demonstrated, using primary human keratinocytes, that even 
monovalent human PV anti-Dsg mAbs reproduce the effects of polyclonal PV IgG on 
Dsg3, meaning that these antibodies can deplete Dsg3 incorporation in newly formed 
desmosomes (Mao et al., 2009). 
Jennings et al. proved that is possible to prevent the process of Dsg3 disassembly 
expressing exogenous Dsg3 with an adenovirus delivery. This could prevent the Dsg3 
loss in the desmosome and also prevent acantholysis (Jennings et al., 2011). 
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3.1.3. In: Cell Signaling & Loss of Cell-to-Cell Adhesion 
Besides the steric hindrance model that could explain the underlying molecular 
mechanisms for the loss of intercellular adhesion, there is a speculation of the plakoglobin 
(PG) involvement, which causes interference of desmosomal cadherin-bound antibody 
with intracellular events. To prove this hypothesis, Caldelari et al. used knockout embryos 
(PG-/-) and control mice (PG+/+), and only PG+/+ keratinocytes responded with keratin 
retraction and loss of adhesion. Also, in these cells, PV IgG binding severely affected the 
linear distribution of plakoglobin at the plasma membrane (Caldelari et al., 2001). 
Later, more studies showed that PG suppresses c-Myc expression and, on the other 
hand, PV antibodies trigger c-Myc upregulation by depletion of plakoglobin and Dsg3. 
Once c-Myc is increased, this will cause a cell proliferation and a weak cell-to-cell 
adhesion. It is possible to inhibit the PV antibodies to cause acantholysis in mice, through 
pharmacological inhibition of c-Myc (Williamson et al., 2006, 2007). 
Another cascade of signaling that has been exhaustively studied in pemphigus 
mechanisms is the p38MAPK signaling pathway, showed in Figure 11. Both, HSP27 and 
p38MAPK has been subject of studies where it is demonstrated that both are 
phosphorylated upon incubation of human keratinocyte cell cultures with PV IgG and, 
also, both are linked to Dsg3 internalization (Berkowitz et al., 2005; Rubenstein and Diaz, 
2006). It is possible to inhibit p38MAPK, using a tandem peptide (TP). Spindle et al. 
proved that this peptide sequence was capable of inhibit both autoantibody-induced 
p38MAPK activation and its association with Dsg3, abolished p38MAPK-induced keratin 
filament retraction, and promoted desmosomal Dsg3 oligomerization (Spindler et al., 
2013). More authors reported that that p38MAPK and HSP27 inhibitors prevent PV 
blistering disease in vivo (Berkowitz et al., 2006). 
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Figure 11 – Proposed model that can explain the PV acantholysis by phosphorylation of 
p38MAPK. The autoantibody binds to Dsg3 and induces the phosphorylation, which is 
associated with keratin filament retraction, actin cytoskeletal remodelling and loss of cell-
to-cell adhesion. These events will provoque the blistering. The keratinocyte p38MAPK 
inhibition could block these events in tissue cuylture and blistering in vivo (adapted from 
Berkowitz et al., 2006). 
 
This signaling cascade was already seen in PV patients’ skin (Berkowitz et al., 2008).  
However, is not fully clarified if p38MAPK activation is a primary event causing 
acantholysis or if it’s secondary to initial loss of cell adhesion. Studies with monoclonal PV 
antibodies (opposing the polyclonal PV IgG) demonstrated that p38MAPK isn’t required 
for loss of intercellular adhesion but it could potentiate endocytosis of Dsg3 and blistering 
(Mao et al., 2011). It is noteworthy that monoclonal pathogenic antibodies rely on steric 
hindrance to cause loss of intercellular adhesion but don’t rely on p38MAPK signaling 
cascade. On the other hand, polyclonal PV IgG could cause Dsg3 clustering and 
endocytosis through p38MAPK-dependent way (Saito et al, 2012).  
The epidermal growth factor receptor (EGFR) also plays an important role in blistering. In 
2013, Bektas el al. showed that EGFR could be activated in primary human keratinocytes. 
The EGFR inhibition were able to lock PV IgG-triggered Dsg3 endocytosis, keratin 
intermediate filament retraction, and loss of cell-to-cell adhesion in vitro, which prevent 
blister formation in the passive transfer mouse model in pemphigus. So, there is a cross-
talk between Dsg3 and EGFR that is regulated by p38MAPK. Pharmacological inhibition 
of EGFR signaling could represent a treatment to prevent blister formation (Bektas et al., 
2013). 
 
3.1.4. Desmoglein Compensation Explanation 
Sera samples from twenty-four patients with mucosal dominant PV and twenty with 
mucocutaneous PV were obtained during clinically active disease and the concentrations 
of Dsg1 and Dsg3 antibodies were measured, by ELISA. This study revealed that all 
patients with mucosal dominant PV were negative against Dsg1 and positive against 
Dsg3, and all patients with mucocutaneous PV were positive against both Dsg1 and Dsg3. 
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This proves that PV patients show a dual status of serum antibodies (Amagai et la., 1999). 
Autoantibody profiling and determination of normal tissue distributions of Dsg3 and Dsg1 
gives us the tools needed to explain the different histological sites of blister formation in 
mucosal PV and mucocutaneous PV – desmoglein compensation model (Amagai et al., 
1996; Mahoney et al., 1999), as exemplified in Figure 12. 
 
Figure 12 - Desmoglein compensation model, for PV and PF. The triangles show the usual 
localization of Dsg1 (green) and Dsg3 (yellow) in the epidermis and mucous membrane. The 
triangle width refers to the relative amount of Dsg present at each cell level. The loss of 
color in a triangle represents loss of function of that particular Dsg due to the presence of 
αDsg1 and αDsg3. When the Dsg1 and Dsg3 function has been inactivated and the other 
Dsg is not present to compensate the loss, blistering occurs. Abbreviations: αDsg1, anti-
Dsg1 antibodies; αDsg3, anti-Dsg3 antibodies; Dsg, desmoglein (adapted from Hammers 
and Stanley, 2016). 
 
What this model tells us is that anti-Dsg1 or anti-Dsg3 antibodies only inactivate their 
specific Dsg. Meaning that, if both Dsg1 and Dsg3 are present, in any level of the 
epidermis, and only one is inactivated, the other will compensate and provide adhesion. 
But if only one desmoglein is present at a particular level of epidermis and it is also 
inactivated, then acantholysis occur (Hammers and Stanley, 2016; Waschke, 2008). 
Using an animal model, it was possible to see that in Dsg3 knockout neonatal mice, skin 
blisters do not occur. This happens because Dsg1 is present in the epidermis to 
compensate for the lack of Dsg3. The opposite happens when anti-Dsg1 antibodies are 
transferred to these mice, which resulted in a severe PV-like blistering (Mahoney et al., 
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1999). So, once again, it was possible to demonstrate that the loss of both Dsg3 and 
Dsg1 induce cutaneous blisters, like those seen in PV patients. 
 
3.2. T Cells Interference 
Several studies strongly support an association between certain human leukocyte antigen 
(HLA) class II alleles and PV susceptibility. Also, these studies demonstrate the 
prevalence of PV in certain ethnic groups (e.g., Ashkenazi Jews). All this suggest that PV 
patients must have HLA class II molecules that are able to present Dsg3 peptides to T 
cells (Ahmed et al., 1990; Sinha et al., 1988; Wucherpfennig et al., 1995; Yan et al., 
2012). So, how do these molecules present Dsg peptides to T cells? It was ascertained 
that the major T cell population was stimulated when antigenic peptides of the 
extracellular domain of Dsg were presented to T cells are the CD4+ memory T cells. When 
stimulated, these cells secreet Th2-like cytokines. Also, it was demonstrated that the 
antigenic response of Dsg3-specific T cells was restricted to HLA class II alleles 
DRB1*1401 and DRB1*0402. These results hypothesized that both alleles are restricting 
elements for T cell response to Dsg3 in patients with PV (Lin et al., 1997). 
A study carried out by Veldman et al., in 2003, concluded that, Dsg3 reactive Th2 cells 
appeared in all of their PV patients, in similar frequencies, whereas, autoreactive Th1 cells 
exceeded the Th2 cells concentrations in chronic active PV. Healthy carriers of HLA class 
II alleles, DRB1*0402 and DQB1*0503, exhibited exclusively Dsg3-reactive Th1 cell 
responses, while healthy carriers of other HLA class II alleles did not. Also, IgG1 and IgG4 
against Dsg3 were directly related to ratio of Dsg3-reactive Th1/Th2 cells. All this 
suggests that appearance of Dsg3-reactive Th2 cells is restricted to patients with PV 
(Veldman et al., 2003). 
An analysis to the peptides that these Dsg3-specific T cells recognize set out that mostly 
come from the amino-terminal extracellular domain of Dsg3. Also, they can share anchor 
residues in positions 1, 4 and 6, and that position 4 is positively charged and is crucial for 
binding to the negatively charged surface (p4 pocket) of DRB1*0402 (Veldman et al., 
2004a). Meanwhile, a HLA class II tetramer-based detection system was developed with 
DRB1*0402 tetramers loaded with immunodominant peptides of Dsg3, which has a great 
potential providing a new approach monitoring ex vivo T cells active autoimmune 
response against Dsg3 in PV patients (Veldman et al., 2006). 
To strengthen the fact that Dsg3-specific CD4+ T cell responds to HLA-DRB1*0403, it was 
showed in a humanized HLA-DRB1*0402 transgenic mouse model that HLA-DRB1*0402 
restricted T cell recognition of human Dsg3 epitopes could lead to pathogenic IgG 
antibodies (that recognize both amino and COOH-terminal epitopes of Dsg3 ectodomain) 
induction, which could cause the loss of epidermal adhesion. These results showed that 
CD4+ T cells recognize immunodominant Dsg3 epitopes, in vivo. Once again we are 
facing another potential therapeutic target; the Dsg3-reactive CD4+ T cells (Eming et al., 
2014). Hennerici et al. conducted a study that aimed to analyse the cytokines derived from 
antigen-presenting cells (APC) and the relation with CD4+ T cell, and also the relation with 
autoantibodies response in pemphigus. Samples were taken from peripheral blood of 
fifteen PV patients and three PF patients. It was observed that plasma concentrations of 
APC-derived immunomodulatory cytokine IL-27 were highly increased, and IL-27 is 
strongly related to Dsg-specific IgG autoantibodies. Moreover, Th 17 cells and T follicular 
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helper (Tfh) cells had high concentrations. Plasma concetrations of IL-21also were 
increased, which is produced by Th 17 and Tfh cells. This suggests that both IL-27 and IL-
21  have a role in pemphigus pathogenesis (Hennerici et al., 2016) and, knowing that 
cytokines are important in mediating T cell function (Giordano and Sinha, 2012) it could be 
important to further investigate the role, and characterization, of IL-27 and IL-21 
(Hennerici et al., 2016). 
Moreover, the CD4+CD25+ regulatory T cells (Treg) also have been suggested to play a 
role in the maintenance of the peripheral tolerance to Dsg3 in mice, suppressing the CD4+ 
effector T cells, Th1 (Veldman et al., 2004b; Yokoyama et al., 2011). 
It is important to note that a couple of studies found a central mechanism of T cell 
tolerance induction within the thymus described for Dsg3 (Mouquet et al., 2008a; Wada et 
al., 2011). Although, the exact contribution for health and disease are not very clear and 
deserve more investigation, in the future.  
A recent study also demonstrated the role of CD163+ tissue-associated macrophages with 
the dense deposition of periostin in lesional dermis of PV patients (Fujimura et al., 2016). 
Findings suggested that periostin interacts with its own functional integrin receptor 
molecules in order to induce production of proinflammatory cytokines from keratinocytes 
to accelerate Th2 type immune responses in allergen induced skin inflammation 
(Masuoka et al., 2012). 
 
3.3. B Cells Interference 
Over time, researchers tried to fulfil the need to understand the function of human 
pemphigus antibodies, cloning the anti-Dsg B cell repertoire from patients with PV in order 
to generate and analyse mAbs. To further demonstrate the importance of the cloning of 
mAbs, sera from a patient with active PV were tested with antibody phage display. It was 
isolated human anti-Dsg mAbs as single-chain variable-region fragments (scFvs), which 
demonstrated binding to Dsg3, Dsg1, or both Dsg3 and Dsg1. Also, these cloned 
antibodies demonstrated that idiotypes on pemphigus antibodies could be shared 
between patients (Payne et al., 2005). 
To better understand how antibodies cause pathogenicity, sera from three patients with 
PV were analysed, by antibody phage display (APD). The heavy chain complementary-
determining region 3 (H-CDR3) of most of the pathogenic mAbs, but not non-pathogenic, 
shared an amino acid consensus sequence, D/E-X-X-X-W (D/E being acidic amino acids 
and W is tryptophan), where tryptophan seem to have a critical position in Dsg-mediated 
adhesion (Yamagami et al., 2010).  
Using human-mouse heterohybridomas, anti-Dsg hybridomas (IgM and IgG) it was also 
possible to evaluate that about 90% were specific for Dsg1 and Dsg3, which indicates 
extensive cross-reaction. This study reveals that variable heavy (VH) gene has more 
impact in pathogenicity and Dsg binding than the variable light (VL) (Qian et al., 2007). 
EBV-transformed B cells were also used to clone Dsg3-specific IgG antibodies from PV 
patients. Some of them revealed to be pathogenic in a keratinocyte culture dissociation 
assay. They also made an epitope mapping where it is possible to be notice that 
pathogenic antibodies disrupted Dsg3 cis interactions, and not the trans (Di Zenzo et al., 
2012). 
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A genetic analysis was also performed in peripheral blood of four PV patients to clone 
Dsg3-specific B cells. The results showed that the variable heavy gene VH1-46 has the 
most important usage, being favoured in anti-Dsg3 B cells, even though these cells use 
various VH genes for autoantibodies production (Cho et al., 2014).  
There is a case report that suggests that localized PV without detectable antibodies can 
lead to systemic PV. Two patients, after suffering from systemic PV, developed long-
lasting localized PV, with no serum anti-Dsg autoantibodies; however, the antibodies 
against Dsg3 were detectable in the systemic stage. The biopsy of localized lesions 
revealed suprabasal acantholysis. So, it is important to stay alert to the possibility that 
localized PV could appear after amelioration of the systemic stage and the decrease of 
pathogenic antibodies. The localized PV responds well to topical immunosuppressive, 
with no need to increase the immunosuppressors dose, such as prednisolone (PSL) 
(Yoshifuku et al., 2016). 
 
3.3.1. B Cells: When They Persist 
Pemphigus patients, with the active disease, revealed clonal expansions of B cells 
(Hammers et al, 2015; Mouquet et al., 2008b). Once the complete remission (with anti-
CD20 antibody), the CDR3 lengths seems to be normalized, which indicates a normal B 
cell repertoire. However, a patient with relapse after remission reveals new clonal 
expansion, and in a patient in incomplete remission the original clonal expansion 
maintains. These findings could suggest that certain specific clones of anti-Dsg B cells 
may be eliminated by adequate treatment. Although, remains the doubt of whether the 
same pathological clones persist or even if new clonal lines could appear in the circulation 
of patients that relapse (Mouquet et al., 2008b). So, Hammers et al. characterized the 
autoimmune B-cell response in patients with active and relapsing disease, cloning the 
anti-Dsg3 IgG+ B cells. The results demonstrated that nontolerant anti-Dsg3 B cell lineage 
persist in patients that relapse. Even in patients in periods of complete remission, off 
therapy, and also in patients in multiple courses of rituximab, an antibody that ablates 
CD20+ B cells. In two patients, in long and complete remission off therapy, it was not 
possible to detect anti-Dsg3 IgG+ B cell clones anymore (Hammers et al., 2015). These 
data is in line with previous findings about anti-Dsg3 B cell receptors not being found in 
remissive patients (Colliou et al., 2013). 
These findings indicate that it’s possible that some clones are hidden, and could reappear 
to cause a relapse. Maybe the loss of B cells ability to tolerate Dsg3 is time-limited, which 
will allow clones of anti-Dsg B cells to escape tolerance and to be able to proliferate in the 
periphery. In the contrary, it is believed that this defect in tolerance for newly B cells 
should not persist and that means that if therapy is capable of destroying all nontolerant 
anti-Dsg3 B cell clones, the newly formed won’t also be able to escape tolerance when B 
cell repertoire is re-established. It was also believed that if all anti-Dsg3 B cells were not 
eliminated, in patients, with therapy, they could proliferate and, by differentiation in short-
term plasmocytes, increase anti-Dsg antibody production and cause the relapse of the 
disease (Hammers and Stanley, 2016). Hammers and Stanley did an analogy between 
cancer and pemphigus, meaning that if we could get rid of all the abnormal cells, we can 
cure the disease (2016). 
 
 
Mechanisms of the disease and Molecular Basis: Pemphigus Vulgaris 
53 
 
3.4. Other Mechanisms Misleading Cell-to-Cell Adhesion 
Not only the autoantibodies or mutations are associated with the disruption of 
desmosomal adhesion. Lately other discoveries were made regarding the toxins influence 
in this kind of disruption in the epidermis.  
Recently, flotillin has been connected with cell-to-cell adhesion, as reviewed by Bodin et 
al. (2014). Flotillin, 1 and 2, are ubiquitous proteins associated with lipid microdomains, 
also called membrane rafts. These proteins are present in many cellular compartments, 
which include the plasma membrane and endosomes. They have been implicated in 
cellular signaling and membrane trafficking processes – endocytosis and endosomal 
trafficking (Banning et al., 2014a). Moreover, Völlner et al. demonstrated that the flotillins 
depletion in human keratinocytes cause an impairment of desmosomal adhesion and a 
decrease of Dsg3 expression. The loss of flotillin seems to induce a mislocalization of the 
Dsg3 pattern, which is very similar to the localization of Dsg3 upon treatment with PV 
autoantibodies. However, Dsg1 showed a decrease in flotillin-2 knockdown cells, whereas 
flotillin-1 knockdown cells demonstrated a high variable expression (Völlner et al., 2016). 
Both flotillin-2 and -1 lose their expression almost entirely in knockout mice (Banning et 
al., 2014b), while the knockdown cell line exhibits loss of only one specific flotillin (Völlner 
et al., 2016). 
The study of apoptosis could also be a tool to better understand the variety and 
complexity of pathophysiologic events (Grando et al., 2009; Schmidt and Waschke, 2009). 
Using TUNEL technique (Terminal deoxynucleotidyl transferase dUTP nick end labeling), 
tissue from fifteen PV patients were analyzed. Positive results were observed in basal 
layer cells in 14/15 (93,3%), while in 13/15 (86,7%) of the cases granular layers that 
formed the blister room were noted and in 12/15 (80%) of the cases the presence of 
positive acantholyc cell was confirmed (Cuevas-Gonzalez et al., 2016). TUNEL assay is a 
tool used to detect apoptosis, since during this event, nuclear endonuclease-digested 
genomic DNA is fragmented into oligonucleases (180 – 200 bp), which allows DNA 
fragments to be identified by the catalytic addition of 16-dUTP to the free ends by terminal 
deoxynucleotidyl tranferase (TdT) (Gavrieli et al., 1992; Sharma et al., 2016a). 
Another study analysed the tissue from twenty-five PV patients with the TUNEL assay. It 
was reported that 76% of the cases revealed acatholytic cells (Deyhimi and Tavakoli, 
2013). 
The implication of apoptosis in the pathophysiology of pemphigus vulgaris could, in the 
future, lead to the development of apoptotic blockers as therapeutics. 
However, a review article from Bektas et al., suggest that apoptosis might not be 
necessary to occur blister induction. In other words, it could be the activation of 
proapoptotic proteins (caspase cysteine proteinases) that sensitize cells for the 
acantholytic effects of pemphigus IgG (Bektas et al., 2010). Although caspases are 
usually implicated in cell apoptosis, they also have other nonapoptotic biologic functions 
(Schwerk and Schulze-Osthoff, 2003) and one of them is precisely regulate the 
desmosome assembly and disassembly. Caspases have been demonstrated to have the 
ability to cause cleavage of desmosome proteins, so this could be important to Dsg 
physiological behaviour in the keratinocytes (Bektas et al., 2010).  
As for BP and PF, so in PV the complement activation seems to be quite important. 
Components of both the classical and the alternative pathway are found in PV lesions 
(Panelius and Meri, 2015). The components C1q, C4, C3 of the complement were already 
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found in PV (Jordon et al., 1985). Not only these components were found but also the 
MAC-neoantigen have been found, both in PV and PF (Kawana et al., 1989). By IIF assay 
of skin biopsies it is possible to see deposition of C3 and IgG in keratinocytes (Sitaru et 
al., 2007). 
 
3.5. Concluding Remarks 
As I aforementioned, direct and indirect mechanisms contribute to loss of desmoglein-
mediated adhesion, which leads to pemphigus acantholysis. We can ascertain that 
acantholysis initiates with cellular signaling pathways and not by direct inhibition of Dsg 
binding. Also, some mechanisms causing acantholysis are found to be exclusive in PV, so 
they don’t contribute for acantholysis in PF, despite the similarity of both diseases. 
As I reported, there are many possibilities regarding the mechanisms that could possible 
trigger blistering in pemphigus diseases but still there are only few certainties about how 
exactly this happens. 
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Pemphigus Foliaceus is the most superficial version of pemphigus. This variant shows 
cutaneous lesions and virtually no involvement of mucous membranes associated with 
subcorneal cleavage and autoantibodies against Dsg 1 (Mihai and Sitaru, 2007), the 
antigen with ~ 160 kDa (Koulu et al., 1984), in which PF antibodies seem to bind to a 
calcium sensitive epitope of Dsg1 (Eyre and Stanley, 1987). Contrary to what happens in 
PV, where patients have Dsg3 and Dsg1-specific antibodies, in PF it seems that only Dsg 
1 is reported, due to desmoglein compensation, as it is possible to see in Figure 13 
(Hammers and Stanley, 2016). The sera of a PF patient were used to isolate anti-Dsg1 
mAbs as single-chain variable fragments (scFvs). The scFvs proved to cause blistering 
both in mice and human epidermis models, which demonstrates that a single monoclonal 
antibody is able to corrupt Dsg1 function and, accordingly, cause the disease. The scFvs 
isolated showed affinity to bound to conformational epitopes in the amino terminal of 
Dsg1. This study also proved the restriction of the heavy-chain gene usage of all anti-
Dsg1 clones (Ishii et al., 2008). 
 
Figure 13 – The desmoglein compensation theory in PF. The yellow triangles represent the 
usual localization of Dsg3 in the epidermis (skin) and mucous membrane. The width of the 
triangles indicates the relative amount of desmoglein present at each cell level. Loss of 
color in the triangle represents loss of function of that particular Dsg due the presence of 
αDsg1, in this case. Abbreviations: αDsg1, anti-Dsg1 antibodies (adapted from Hammers 
and Stanley, 2016). 
 
4.1. Blister Formation Mechanisms 
Experiments in animal models reported a clear pathogenicity of circulating IgG antibodies. 
More specifically IgG4 subclass seems to be predominant in PF patients (Rock et al., 
1989). 
Moreover, PF can be induced both in mice and in human skin organ culture. These 
experiments demonstrate that antibodies can directly induce acantholysis (Rock et al., 
1990). As represented in Figure 15 and mentioned above, when, in a particular level of 
epidermis, only one desmoglein is present that will easily lead to acantholysis. So, 
assuming that PF is mainly characterized by Dsg 1 autoantibodies, when this desmoglein 
is inactivated, superficial blisters will occur. However, passive transfer experiments in 
mice models with PF anti-Dsg1 antiobodies have shown that the deep epidermis can 
express Dsg3 too, and this will help to maintain adhesion at that epidermis level (Wu et 
al., 2000). 
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PF pathophysiology is much similar to described above for PV, so direct inhibition of cell 
adhesion also happens in PF patients. Epitope maping studies with PF patient’s points out 
that most dominant epitopes mapped the amino-terminal ectodomains of Dsg1, which are 
crucial to cell-to-cell adhesion (Sekiguchi et al., 2001).  
A case report also suggests that, not only desmogleins have an impact in PF 
pathogenesis, but also desmocollins (Dsc) have an important role. This case reported IgG 
reactivity specifically against desmocollins. This strong reactivity was confirmed by ELISA, 
repeated several times, with serum samples taken before and after treatment. All these 
taken together give a strong suggestion of the pathogenic Dsc1. This case gives us an 
alternative direction in pemphigus’ diagnosis, in cases without detectable anti-Dsg 
autoantibodies (Geller et al., 2016).   
Again, as detailed above for PV, the Dsg disassembly depletion hypothesis is also crucial 
to PF pathophysiogy. The concept of this hypothesis, even when applied to PF, is the 
same as I explained for PV, the loss of cell-to-cell adhesion is due to anti-Dsg antibodies 
to crosslink and agglomerate desmogleins (Oktarina et al., 2011).  
The p38MAPK signalling cascade can also be linked to Dsg1 internalization, and its 
pharmacological inhibition can block blister formation in PF, facts that have been proven 
by passive transfer mouse models (Berkowitz et al., 2008a). It was ascertained that the 
hypothesis reported in acantholysis in pemphigus patients seems to work independently 
(Hammers and Stanley, 2016). 
 
4.2. Different Forms Of PF 
Pemphigus Foliaceus comprise different clinical forms, sporadic and edemic being two of 
them (Joly and Litrowski, 2011). The sporadic form is rare, with only 20% to 30% of 
pemphigus cases with and incidence of one case per million inhabitants per year, in 
Europe and USA (Joly and Litrowski, 2011). Among the additional clinical forms of PF, 
Fogo Selvagem is also well-known and shares clinical, histo and immunopathological 
features and is classified as a subtype of PF (Eyre and Stanley, 1988), which was 
described by Cazenave in 1844 and firstly reported in 1903 in Brazil (Sampaio et al., 
1994). Fogo selvagem fits the endemic form of PF (Aoki et al., 2011). The endemic 
pemphigus foliaceus (EPF) has a unique epidemiologic profile, including endemic areas, 
familial cases, with no differences in gender distribution (Hans-Filho et al., 1999).  
The cause of FS seems to be related to environmental factors (e.g., molecular mimicry 
due to infections transmitted by insects) (Otten et al., 2014). It mainly occurs in rural areas 
of Brazil and, usually, vanishes after urbanization of the endemic areas (Culton et al., 
2008). It is also possible to find the endemic PF in other countries such as America – 
Colombia (Abrèu-Velez et al., 2003), Venezuela, Peru, Ecuador and Paraguay - and also 
in Northern Africa (Tunisia) (Morini et al., 1993). This EPF form seems to have different 
patterns, Columbia pemphigus and Tunisian pemphigus (Joly and Litrowski, 2011). 
Fogo selvagem is a superficial cutaneous form of pemphigus and histologic results reveal 
subcorneal acantholysis. In these cases, patients seem to lack mucosal involvement, 
contrary to what happens in PV. Serological results demonstrate pathogenic anti-Dsg1 
autoantibodies in patient’s serum (Amagai et al., 1995; Rock et al. 1990; Roscoe et al., 
1985). 
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Moreover, FS mainly focuses in peasants dedicated to outdoor activities, and also has a 
greater incidence with geographic and familial clustering (Diaz et al., 1989; Hans-Filho et 
al., 1996). 
 
4.2.1. Fogo Selvagem 
Brazilian investigators from the University of Brasilia evaluated and treated many patients 
with FS, over the last four decades (Ribeiro et al., 2005; Rocha-Alvarez et al., 2007). 
Culton et al. have been systematically collecting clinical and serological data from FS 
patients from the ameridian reservation of Limão Verde, as well as normal individuals that 
live in reservation and around it and they found that 55% of ameridian’ normal individuals 
have anti-Dsg1 antibodies (Warren et al., 2000), which can be related to physical 
proximity to this reservation (Culton et al., 2008). Fogo Selvagem reveals remarkable and 
unique features like geographic and temporal clustering of cases and the increased 
incidence in young adults and children. Also, this pemphigus form has a familial cluster 
(Moraes et al., 1997). 
It has been reported that a significant number of FS patients and healthy inidviduals that 
live in the endemic areas demonstrated increased levels of IgM anti-Dsg1. This suggests 
that environmental antigenic exposure might induce FS (Diaz et al., 2008). Possibilities 
have been suggested to explain the persisting IgM autoantibodies in these individuals; 
one of them is the polyclonal activation of IgM memory B cells (Bernasconi et al., 2002; 
Reynaud et al., 2012). Studies have demonstrated that both IgE and IgG4 antibodies 
against sand fly are present in FS patients. Also, it was suggested that IgG4 reacts to both 
exogenous and endogenous antigens (Qian et al., 2012). If an IgE anti-evironmental 
antigen was developd, this could help as a useful marker to early detect individuals at risk. 
Moreover, when comparing IgE anti-LMJ11 (sand salivary gland antigen, explained in 
Triggers in PF) levels in individuals before and afetr FS onset, the pre-FS demonstrated 
lower levels of anti-Dsg1 IgE, meaning that LJM11 is the main target of an IgE response. 
FS patients, besides having IgG4 anti-Dsg1, also have IgG4 anti-JLM11 antigen from 
sand fly (Qian et al., 2015). 
There are three theories that determine if IgG4 anti-Dsg1 and anti-LJM11 responses are 
associated. First, and most importante, is that the immune responses to Dsg1 and LJM11 
have two IgG4 antibodies population and these two populations overlap somehow. 
Second, is that IgG4 responses are independet and, third one, is that IgG4 has the same 
response to Dsg1 and LHM11 and all IgG4 antibodies are cross-reactive (Qian et al., 
2012).   
 
4.3. B cell Response 
The anti-Dsg B cell repertoires have been cloned from PF patients, as well as from PV 
patients, generating monoclonal antibodies (mAbs), using the APD (Ishii et al., 2008). In a 
PF patient, in whom autoantibodies against Dsg1 cause the blistering, it was possible to 
clone mAbs, using the APD and isolate antigen-specific mAbs. These monoclonal 
antibodies were directed against mature Dsg1 (matDsg1), as seen in previous studies 
about Dsg3 and PV patients, on the cell surface of keratinocytes and precursor Dsg1 
(preDsg1) in the cytoplasm. This study shows that individuals without PF don’t have B cell 
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tolerance to preDsg1 and the loss of tolerance to mature Dsg1 isn’t due to epitope shifting 
of anti-preDsg1 B cells. So, people without pemphigus also have B cells that code for 
antibodies against preDsg1, but lack antibodies against the mature cell surface protein. 
This suggests that B cell tolerance in normal people is for the exposed, matDsg1 
(Yamagami et al., 2009). So, when B cell loses tolerance for Dsg1 that will allow clones of 
anti-Dsg1 B cells to escape and prolipherate in periphery, however, this will not happen 
with newly formed B cells and so if therapy is efficient enough all nontolerant anti-Dsg1 B 
cell will be eliminated. But if not all were eliminated, the clones will then proliferate and 
cause a relapse of disease (Hammers and Stanley, 2016).  
Also, studies confirmed that idiotypes on pemphigus antibodies could be shared across 
patients. Moreover these studies suggested that Dsg binding mainly select the variable 
heavy (VH) and not the variable light (VL) region (Ishii et al., 2008).  
Besides the cloning studies, the heterohybridoma was also used to investigate PF 
aetiology, more specifically, the endemic form Fogo Selvagem. A cohort with nine PF 
patients was used to collect hybridomas that secret IgM or IgG. It was reported that these 
anti-Dsg1 autoantibodies showed specificity toward Dsg1, so anti-Dsg1 response in FS is 
mainly managed by antigen (Qian et al., 2009). 
Also, the cross reactivity of epitopes on LJM11 and Dsg1 IgE reacts against Dsg1. So, the 
chronic stimulation of LJM11 antigen and IL-10 production can promote IgG4 antibodies 
development, which in turn cross react to both LJM11 and Dsg1 (Qian et al., 2016). 
  
4.4. T cells Response 
Mechanisms of T cell tolerance were already demonstrated for Dsg1, within thymus. It 
was reported that Dsg1 is expressed by CD19+ CD63+ cells, so thymic expression of a 
tissue-specific autoantigen that could be involved in an autoimmune disease can also 
participate in the tolerance induction of Dsg1-specific T cells (Mouquet et al., 2008). 
 
4.5. Other Mechanisms Leading to Blister Formation 
The mechanism that leads to neutrophilic infiltrates and pustule formation in PF is still not 
clear, however, hypothesis have been made, like the possibility that complement 
activation could stimulate neutrophil recruitment (Matsuo et al., 2001; Panelius and Meri, 
2015). Also, the IL-18 role in neutrophil chemotactic promotion was also suggested as a 
mechanism in pemphigus variants (O'Toole et al., 2000). 
Very recently, it was found that levels of vascular endothelial growth factor (VEGF) were 
increased in PF patients with erythroderma (Miyamoto et al., 2016). Erythroderma is a 
clinical skin condition present in patients with other cutaneous disorders, and this sharing 
disorders may be due actions of signal protein, for instance, VEGF. This protein is 
released by keratinocytes after skin damage to intervene in repair responses (Creamer et 
al., 1996; Elias et al., 2008). This result suggests that maybe the blood vessel 
endothelium in PF pathogenesis. It should be noted that it was also found an association 
between anti-Dsg1 and VEGF which could indicate that VEGF has a suppressive 
response upregulation, during erythrodermic phase in PF patients (Miyamoto et al., 2016). 
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Recently, a case of a twenty-four years old female patient was reported with an atypical 
PF form, with neutrophilic pustules. Only a few cases were reported (Méndez-Flores et al., 
2016). 
 
4.6. Concluding Remarks 
All these findings abou FS patients’ points to salivary gland protein components from sand 
fly as FS’ trigger. Suggesting that, non-infectious antigens can induce autoantibodies to 
harm the host. This could represent the only pemphigus form with the environment that 
directly influences the mechanisms that trigger this disease. It is also important to note 
that we are talking about the most endemic form, with a specific incidence. The mean age 
of onset is also affected, as well as the environment in which those who suffer most from 
this disease live. 
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5.1. Clinical Evaluation 
Physical assessment is the first milestone concerning pemphigus tracking. Examination of 
the skin, mucous membranes and nails of the patients should be astutely done. Along with 
these observations, patients should be questioned about symptoms that might suggest an 
extraoral mucosal involvement. Also, there should be a careful review about patient’s 
medical history and medications, since it is necessary to discriminate whether idiopathic 
or drug-induced pemphigus is present (Celentano and Cirillo, 2016). 
The Tzanck smear can provide rapid cytologic information. Tzanck smear is a simple tool 
and cheap ancillary used for diagnosis. In ideal conditions, this test is performed on a 
fresh blister, with less than 24 hours old, and the material is gently scraped from the 
vesicles’ base, blister or pustule, onto a slide. It’s allowed to air dry and stain with different 
dyes (Giemsa, toluidine blue and methylene blue) (Durdu et al., 2008; Kelly and Shimoni, 
2009). 
In 2016, Zhou et al. conducted a study to evaluate the diagnostic value of indirect 
immunofluorescence microscopy (IIF), ELISA and Tzanck smear test for pemphigus 
diagnosis. They studied a cohort with thirty-three patients with pemphigus and sixty-one 
controls. The sensitivities and specificities of all the three techniques are summarized in 
Table 1. 
 
Table 1 - Sensitivity and specificity value for each assay (from Zhou et al., 2016).  
Technique Sensitivity (%) Specificity (%) 
Tzanck smear 96.7 60.0 
IIF 84.8 91.8 
ELISA 84.8 96.7 
 
These results are in line with results of some previous studies (Durdu et al., 2008; 
Zagorodniuk et al., 2005). This study revealed the same sensitivity value for IIF and 
ELISA; however the specificity value of ELISA was higher.  
Although the three techniques can be used in pemphigus diagnosis, the three can also 
present some drawbacks that probably could affect the diagnosis. For instance, IIF has an 
overall sensitivity dependent on the type of substrate used (Delmonte et al., 2001). In 
ELISAs’ case, the technique only detects circulating antibodies but no cytological 
message presented (Anand et al., 2011).  
Tzanck smear test relies on acantholysis process. This information coupled with the one 
aforementioned, offers a more immediate answer, which makes it a more rapid and 
valuable cytological diagnostic technique (Zhou et al., 2016). 
 
5.1.1. Bullous Pemphigoid Diagnosis 
Early on in the disease, it can present an acute or subacute clinical picture and mostly be 
associated with intense pruritus (Feliciani et al., 2009). Clinically, BP patients demonstrate 
generalized inflammation of blistering skin. The blisters usually are tense, and heal 
without scarring formation. They generally arise on the distal extremities, the trunk and 
intertriginous areas. Moreover, oral and ocular mucosa involvement is not common, and, 
even if present, doesn’t have any clinical significance (Otten et al., 2014).   
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Elderly people have a priority regarding BP, meaning that this disease should be 
suspected in this age group. Patients’ exhibit generalized itchy erythematous papules 
urticarial and/or skin blistering. These blisters are subepidermal and have inflammoatory 
cell infiltrates, eosinophils or neutrophils.  
BP diagnosis is confirmed by IIF, which has to reveal a linear deposition of IgG and C3 at 
DEJ of patients’ perilesional skin. Furthermore, it is necessary to see if circulating IgG 
autoantibodies bind to epidermal side of 1 M NaCl-split skin. Adding to this, ELISA is used 
to measure circulating autoantibodies against BP180 and BP230, and could be used to 
monitor and guide decisions in diseases’ course (Otten et al., 2014). The diagnosis of 
drug-induced bullhous pemphigoid (DIBP) is almost the same as for classical BP (Ruocco 
and Sacerdoti, 1991). 
A study with fourteen BP patients investigated the correlation between clinical severity 
and BP180 ELISA indices. The commercially available BP180 ELISA kit were better 
following disease activity when compared with IIF, so this system unveiled a great tool to 
evaluate disease activity and determine the effectiveness of the treatment in BP patients 
(Tsuji-Abe et al., 2005). Another recent study provided an initial “proof of concept” in the 
use of Reflectance confocal microscopy (RCM) as an accurate, rapid and non-invasive 
method for BP diagnosis (Samhaber et al., 2016). This technique is an in vivo skin 
imaging that at a cellular level helps us to visualize horizontal planes from the epidermis to 
upper dermis (Ahlgrimm-Siess et al., 2008; Rajadhyaksha et al., 1999). This kind of 
technique helps physicians examine many lesions very quickly and due to the non-
invasive characteristic of the technique, it is possible to follow up the natural evolution of 
any lesion (Grönemeyer et al., 2014). 
 
a. Scoring Systems: Quantifying Disease Extension 
It was developed for BP a system that measures disease activity in order to standardize 
clinical assesements, the BP Disease Area Index (BPDAI). This system has scores for 
skin and mucous membrane activity and the damage score are included to help 
physicians separate lesions that do and do not represent active disease. Additional 
importance is given to arms and legs and less to face and scalp. Even though it’s rare to 
see mucous membrane involvement in BP, their evaluation is contained in the 
questionnaire with the purpose of comparing the disease activity to extend of mucous 
membrane involvement in different ABD. Prutitus has a prominent place as it is the main 
symptom of BP, and the BPDAI measures the severity of this symptom, and only pruritus 
related to BP is considered in the system definition (Figure 14). For instance, if the patient 
has some disability, like dementia, that can stop him from completing a reliable visual 
analog scale rating, the degree of pruritus is inferred based on excoriations alone. This 
itch evaluation is not intended to be combined with the objective part of BPDAI (Figure 
15) (Murrell et al., 2012). 
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Figure 14 – Subjective BP Disease Area Index (BPDAI) pruritus score. Visual Analog Scale 
(VAS) (from Murrell et al., 2012). 
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Figure 15 – Objective BP disease area index (from Murrell et al., 2012). 
 
BPDAI reliability, validity, responsiveness, and minimal clinically important differences 
were already investigated and this system demonstrated excellent results (Wijayanti et al., 
2016). 
 
5.1.2. Pemphigus Vulgaris Diagnosis 
Usually, PV initiates in the oral cavity and is characterized by flaccid blisters and erosions, 
which causes pain. These events could also cause weight loss and malnutrition. Blisters 
can be painful and sometimes, itchy (Amagai et al., 1999; Hertl et al., 2015; Jamora et al., 
2003). 
About 80% to 90% of PV patients can develop oral lesions, and among these, about 60% 
of the oral cases can represent the first sign of this disease (Arpita et al., 2015). 
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Usually lesions prevail in seborrheic areas, like chest, face, scalp and interscapular 
region. It is noteworthy that this disease usually doesn’t have an association with major 
pruritus, contrary to the fingernails, which can be involved (Hertl et al., 2015). 
Despite being a rare manifestation, there are references that report cases of patients with 
esophageal PV. Howerever, this rare occurrence could simply be a misdiagnosis or 
originate from the low activity of PV in this area, which in turn could represent an alarm 
signal to start diagnosing in a more attentive and careful manner (Khamaysi and Eliakim, 
2008). 
Diagnosis of patients with PV needs to be considered when in presence of persistent 
blisters and erosions of mucous membranes and skin. The suspicions could be 
strengthened by a positive Nikolsky (Celentano and Cirillo, 2016). Nikolsky sign needs to 
be tested applying some pressure in perilesional or normal skin in order to observe if 
blisters can be extended or induced in normal-appearing skin, which characterizes the 
pemphigus group diseases (Arndt and Feingold, 1970; Doubleday, 1987). Although it is 
well stablished that the mucosal involvement is the main characterization of PV, there are 
some case reports that introduce patients that, clinically, only show blisters and erosions 
in the skin without mucosal involvement. These specific cases suggest that these rare 
phenotypes can be due to a weak anti-Dsg3 IgG when in presence of strong anti-Dsg1 
IgG autoantibodies. This suggestion is postulated using the desmoglein compensation 
theory (Yoshida et al., 2005). 
There are two cases reported of a fifty-nine and a thirty-five year old man with PV 
manifestation in the penis. It has been described that PV manifests with genital lesions, 
but the penil involvement as a first manifestation hasn’t been studied and reported 
enough. This represent a challenge since erosive penile lesion are usually associated with 
infections aetiology, so the patients were subjected to antivirals and antibiotics first, with 
no response, obviously (Stieger et al., 2013). 
 
a. Scoring Systems: Quantifying Disease Extension 
Knowing that over two thirds of the clinical trials have been registered in the last decades, 
we reached an urge for objective measures of disease activity, in order to standardize 
clinical assessments among investigators. Hence, two pemphigus scoring systems were 
developed, which are currently in clinical use: Autoimmune Bullous Skin disorder Intensity 
Score (ABSIS) (Daniel et al., 2012; Pfütze et al., 2007) and Pemphigus Disease Area 
Index (PDAI) (Daniel et al., 2012; Rosenbach et al., 2008). ABSIS system has a maximum 
score of 206, in which up to 150 points reflect the percentage body surface area 
involvement weighted by the severity of the involvement in each specified are, up to 
eleven points for the extend of mucosal involvement and up to fourty-five points the 
patients’ subjective level of discomfort associated with foods. PDAI could reach a 
maximum score of 250, in which up to 120 points is for the skin disease, up to 120 points 
is for mucosal disease and up to 10 points for the scalp involvement. Also additional 
thirteen points could be added for the skin damage (Payne, 2016). 
Boulard et al. (International Pemphigus Study Group) defined PDAI and ABSIS cut-off 
values for moderate, significant and extensive disease, in which moderate included those 
with PDAI < 15 or ABSIS <17, significant with PDAI scores between 15 and 44 or ABSIS 
between 17 and 53, and finally extensive disease with PDAI ≥ 45 and ABSIS ≥ 53. It is 
noteworthy the authors’ intention to describe disease extent instead of disease severity. 
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These results were based in a multicenter study of 96 consecutive incident cases of 
pemphigus over a 34 month period, from 31 dermatology centers in six countries (Boulard 
et al., 2016).  
Another study, with thirty-seven patients from four dermatology centers, in Japan, were 
made and they proposed the following scale: PDAI scores of 0 to 8, 9 to 24 and  ≥ 25, as 
mild, moderate and severe, respectively. The cut-off scores were based on their sensitivity 
and specificity, towards assessments of disease severity (Shimizu et al., 2014).  
Nevertheless, Payne keeps the description of the distribution of pemphigus disease 
activity scores independently from the measures of disease severity, validating the cut-off 
values based on the statistically significant differences in median PDAI, ABSIS, 
Physician’s Global Assessment and Dermatology Life Quality Index scores, in each 
subgroup (Payne, 2016). 
Recently, a study intended to evaluate the three systems, PDAI, ABSIS and PVAS 
(another system, called Pemphigus Vulgaris Activity Score), the reliability of these indexes 
and the convergent validity according to anti-Dsg values. They concluded that between 
the three indexes, PDAI had the highest validity, making it highly recommendable to use 
in multicenter studies for rare diseases, such as pemphigus vulgaris. This study was 
made with a large number of patients with pemphigus vulgaris (Rahbar et al., 2014). 
 
5.1.3. Pemphigus Foliaceus Diagnosis 
Clinically speaking, PF only affects skin, while PV affects mucous membranes (mucosal 
PV) and later involves the skin (mucocutaneous PV) (Ding et al., 1997). In PF, the 
blistering lesions tend to be in seborrheic areas, such as trunk, face and scalp. The onset 
manifestation is usually characterized by scattered, small superficial blisters, that can 
easily scale into crusted erosions with puff pastry-like or cornflake appearance (Hertl et 
al., 2015; Otten et al., 2014). 
In PF, like in PV, Nikolsky sign is also positive. However, the diagnosis needs to be 
confirmed by demonstration of intercellular deposition of tissue-bound and by circulating 
autoantibodies (with DIF and IIF, respectively). ELISA is used to assess the molecular 
specificity of circulating autoantibodies, using recombinant Dsg1 (Otten et al., 2014). 
 
5.1.4. Laboratory Analysis 
A simple standard laboratory work plan is well established regarding the pemphigus 
screening. 
In a simple manner, this should include: lesional skin/mucosal biopsy for hematoxylin and 
eosin (H&E) staining; a perilesional skin/mucosal biopsy for direct immunofluorescence 
(DIF); and/or serum collection for indirect immunofluorescence (IIF) and enzyme-linked 
immunosorbent assay (ELISA). The samples should be treated very careful and in a 
differentiated way. Samples taken for biopsies should be on an intact lesion and a punch 
biopsy (4mm). Some clinicians use the “stab-and-roll” technique, in which they use a size 
15 scalpel blade to keep the epithelial roof in the sample. This sample should be placed 
immediately in a solution of 10% buffered formalin. The tissue sample used for DIF 
microscopy has to be taken from the perilesional area, in order to contain both epithelium 
and stroma. This sample should be placed in an optimal cutting temperature (OCT) 
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compound, frozen at -20°C and then stored at -80°, until processing (Celentano and 
Cirillo, 2016). But if OCT compound isn’t available, the sample could be, alternatively, 
placed in normal saline-soaked gauze and maintained at 4°C, or in Michel’s medium, 
which can maintain the sample at room temperature for about 6 months (Vodegel et al., 
2004). Sample taken for biopsy with transmission electron microscopy (TEM) and 
immune-mapping is treated the same way as the routine histopathology. The sample 
needs to be placed, at that moment, in an electron-microscopy-specific medium and in 
OCT, respectively (Celentano and Cirillo, 2016). 
For ELISA and IIF, assays are required 5-10 mL blood samples without anticoagulants, 
which are then centrifuged in order to separate plasma – contains gamma globulins – 
from blood cells (Celentano and Cirillo, 2016). 
 
5.1.5. Histologic Recognition 
 
Bullous Pemphigoid Recognition The analysis of patients’ lesional skin should reveal a 
supedpidermal cleavage, which is associated with a dense inflammatory infiltrate, 
composed mainly of neutrophil and eosinophil granulocytes (Otten et al., 2014). The IIF 
technique allows the BP differentiation from others subepidermal autoimmune blistering 
diseases that also have autoantibodies that bind to the dermal side of salt-split skin (Aoki 
et al., 2010), Table 2.  
Nowadays, the ELISA systems using recombinant BP180 and BP230 are largely 
employed to characterize the IgG autoantibodies in patients with BP (Kobayashi et al., 
2002; Sitaru et al., 2007a; Yoshida et al., 2006).  
As an alternative, BP180 and BP230 specific IgG autoantibodies can also be detected by 
immunoblotting, using epidermal or keratinocyte extracts (Mihai and Sitaru, 2007). 
 
Table 2 – Diagnostic Criteria for BP.  
Diagnostic Means Findings 
Clinic Tense blisters, erythematous plaques and pruritic papules 
Histology Sub-epidermal blister with an inflammatory infiltrate 
consisting mainly in eosinophils and neutrophils 
DIF Linear depositions of C3 and IgG at DEJ 
IIF (esophagus) IgG autoantibodies bind to epidermal side 
ELISA BP180 and/ or BP230-specific IgG autoantibodies 
 
Pemphigus Vulgaris Recognition There are a few histopathological characteristics in 
pemphigus vulgaris which facilitate the diagnosis, as summarized in Table 3. Those 
features include intraepithelial cleavage with loss of keratinocytes adhesion – acantholysis 
– mainly localized in the suprabasal region. The retention of these keratinocytes along the 
BMZ leads to an appearance that seems like a “row of tombstones”. There is also an 
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inflammatory infiltrate in the dermis, which contains eosinophils (Celentano and Cirillo, 
2016; Hertl et al., 2015). 
 
Table 3 – Diagnostic criteria for PV 
Diagnostic Means Findings 
Clinic Mucosal/skin blistering, inflammation, erosions 
Histology Acantholysis followed by inflammatory infiltrate, 
intraepithelial separation (suprabasal layer), “row 
thombstones” 
DIF Intraepidermal deposits of IgG and/or C3, in a “cobblestone” 
or “fish-net” intercellular binding pattern 
IIF (esophagus) Binding of IgG autoantibodies to epithelial cells with an 
intercellular pattern 
ELISA IgG autoantibodies specific for desmoglein 3 (mucosal) +/- 
desmoglein 1 (mucocutaneous) 
 
Pemphigus Foliaceus Recognition Regarding PF, there are histologic characteristics 
that support the diagnosis, such as intraepithelial acantholysis beneath the stratum 
corneum or within the granular layer. Also, neutrophils can be present within the blister 
cavity and a mixture of neutrophils and eosinophils in the superficial dermis (Celentano 
and Cirillo, 2016). IIF is used to detect intercellular deposits of IgG and C3, whereas 
serum IgG autoantibodies bind to substrates, like esophagus and human skin, with an 
intercellular pattern. IgG autoantibodies recognize Dsg1, and levels of Dsg1-specific 
autoantibodies could be correlated with the disease activity, Table 4 (Hertl et al., 2015; 
Ishii et al., 1997). 
 
Table 4 – Diagnostic criteria for PF. 
Diagnostic Means Findings 
Clinic Fragile blisters and crusty erosions (preferentially in 
seborrheic areas) 
Histology Subcorneal cleavage with acantholysis 
DIF Intreepidermal deposits of IgG (and/or) C3 with an 
intercellular pattern 
IIF (esophagus) IgG autoantibodies bind to epithelial cells with an 
intercellular pattern 
ELISA Dsg1-specific IgG autoantibodies 
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5.2. Assays 
5.2.1. Direct Immunofluorescence Microscopy (DIF) 
The aim of this technique is to detect any in situ accumulation of immunoreacts, which 
usually are Ig’s and/or complement components, in the perilesional skin (Chiorean et al, 
2014; Otten et al., 2014).  The deposition of distinct immunoreactants in the patients’ skin 
could be detected using a fluorochrome – labeled antibodies (e.g., specific for human IgG, 
IgA, IgM and C3) (Chiorean et al., 2014). Immunofluorescence microscopy remains the 
gold standard for pemphigus, because tissue fixed intercellular antibodies is present in 
about 90% of the patients. Pemphigus vulgaris and pemphigus foliaceus presents similar 
intercellular binding of IgG and/or C3 found in a typical “cobblestone” or “fish-net pattern” 
in the epidermis/epithelium (Chiorean et al., 2014). 
Knowing that some countries and laboratories don’t have access to many important 
techniques to diagnose some forms of pemphigus, such as DIF, a study was conducted to 
compare periodic acid-Schiff (PAS) staining and immunofluorescence patterns, with a 
cohort of five cases of BP and five cases of PV. PAS is a method used to detect 
polysaccharides, such as glycogen, and mucosubstances, such as glycoproteins, 
glycolipids and mucin in tissues (Warnock et al., 1988). Having knowledge of the “The 
Altered Glycan Theory of Autoimmunity”, that suggests that each autoimmune disease 
should have its own glycan signature, it makes sense to use the PAS technique 
(Maverakis et al., 2015). Also, a 98% positive correlation between DIF and PAS was 
found in all samples. This indicates that, when it’s not possible to perform DIF, PAS can 
be used in alternative, in addition to hematoxylin and eosin (H&E) staining (Abreu-Velez et 
al., 2016). 
 
5.2.2. Indirect Immunofluorescence Microscopy (IIF)  
In this assay, the aim is to detect circulating autoantibodies in patients’ sera, targeting skin 
constituents. The patient’s serum is added to normal epithelial subtract in two steps 
incubation. The main epithelial subtract used is the monkey esophagus, since it is well 
established that this type of subtract affects the sensitivity of the test. In PF and PV, the 
best subtracts are monkey and guinea pig esophagus, respectively. It is noteworthy that 
more than 80% of the patients with PV and PF have circulating autoantibodies, making 
this assay reliable for these autoimmune blistering disease diagnoses (Payne and 
Stanley, 2012). 
 
5.2.3. ELISA 
This assay is a sensitive and easy-to-perform test that allows the characterization of the 
autoantibody specificity (Mihai and Sitaru, 2007). ELISA has a high demonstrated 
sensitivity and specificity for BP and PV, respectively (Tampoia et al., 2012). This 
technique measures specific autoantibodies in the patients’ serum, which is incubated in 
microtiter plate wells and coated with the antigen of interest. The autoantibodies that 
match will bind to the antigen. Then, the enzyme conjugated secondary anti-IgG antibody 
added will change color in proportion to the reaction. As said before, in PV and PF, the 
levels of anti-Dsg1 and anti-Dsg3 in serum of the patients could be related with the 
disease activity (Cirillo et al., 2012). This assay could be an important tool for a more 
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targeted treatment (Zone et al., 2009). It is significant to note that high levels of anti-Dsg1 
and anti-Dsg3 could remain increased, even in phases of remission (Abasq et al., 2009). 
There are now ELISA kits commercially available for specific detection of serum IgG to 
Dsg1 and 3. The sensitivity of these tests reaches an impressive 90%, far more sensitive 
and specific than IIF (Payne and Stanley, 2012). 
 
5.2.4. Some Additional Testing 
Immunoblotting – Western Blotting – and immunoprecipitation are very sensitive assays 
and specific for autoantibodies detection. These techniques use recombinant 
autoantigens or keratinocyte extracts from healthy human skin. Moreover, protein 
microarrays have been used as a powerful technique for detection of a large number of 
autoantibodies, in autoimmune blistering diseases (Kalantari-Dehaghi et al., 2013a). 
Immunoprecipitation usually is more useful for immunoserological follow-up and as a 
serological confirmatory test, since it’s more sensitive than immunoblotting (Celentano 
and Cirillo, 2016). Maybe the future lies in protein arrays, thanks to the complexity of the 
autoantibody profile (Celentano and Cirillo, 2016). 
 
5.3. Concluding Remarks 
Since the detection of tissue-bond and serum autoantibodies play an essential diagnostic 
role in autoimmune blistering disease, the characterization of molecular specificity of 
autoantibodies allows the development of reliable diagnostic algorithms. These algorithms 
can help clinicians in streamline this group of diseases, as we can see in Figure 16. 
 
Figure 16 – Diagnostic Algorithm for ABD. 
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Over the years, BP has been associated with other malignancies, with several reported 
cases of pemphigoid associated with malignancies (PAM). Despite this, the correlation 
remains shrouded in controversy. The main theory that explains this association is that 
antibodies directed against tumor-specific antigens of malignant cells may cross-react with 
antigens, like the BP antigens, in the basement membrane zone, which could lead to 
blister formation. About forty cases of PAM were identified by Balestri et al. very recently. 
Of the forty cases, seven have conections with hematological malignancies and the other 
thirty-three with solid tumors (Balestri et al., 2016). 
The incidence of malignancies in BP patients seems to be higher than in general 
population, ranging from 5.8% to 19%. It is also possible to observe a greater incidence in 
Europe (Venning and Wojnarowska, 1990; Cozzani et al., 2001), first, and the in East Asia 
(Ogawa et al., 1995; Peiying et al., 1993; Chang et al., 1996), despite the reduced number 
of studies regarding the matter.  
 
6.1. Concerning Bullous Pemphigoid 
6.1.1. BP and neurologic conditions 
In the past, many reports have demonstrated an association between BP and some 
neurologic conditions. It has been estimated that about 36% of all BP patients had at least 
one neurologic disorder (Cordel et al., 2007). However, it is not well understood the 
underlying mechanism in this association, but it certaintly cannot be attributed to elderly 
age, since previous studies reported this same association in middle-aged patients. It is 
noteworthy that patients with more than 80 years that have neurologic diseases also have 
10 times more probability to develop BP (Korman et al., 1991). It seems that BP tends to 
be associated with neurologic disorders that involve autoimmune mechanisms, like 
Parkinson and Alzheimer, since specific antibodies have been found accumulating within 
neurons in Alzheimer’s disease, which can initiate neuronal degeneration. This 
degeneration, which leads to a break of tolerance, could explain the delayed BP 
development, after onset of neurologic symptoms (Bastuji-Garin et al., 2011). A very 
recent study associates BP180 autoantibodies with a more severe dementia, Alzheimer 
disease, suggesting a shared role of BP180 autoantigen in neuro-dermatological 
interactions and reinforcing the association between BP and neurodegeneratives 
disorders (Kokkonen et al., 2016). Some authors also reported a significant risk of 
cerebrovascular disease, such as Parkinson and dementia, developing subsequent to a 
BP diagnosis (Brick et al., 2014; Lai et al., 2016; Taghipour et al., 2010). 
Stinco et al. reported that association between BP and Parkinson’s disease is statistically 
significant, since a higher prevalence of BP in hospitalized patients with Parkinson’s 
disease was demonstrated (Stinco et al., 2005). Rates of Parkinson’s disease among BP 
patients have also been reported as increased in more recent studies (Bastuji-Garin et al., 
2011; Cordel et al., 2007), making this information consistent. A wide study that aimed to 
assess BP risk in patients (n=868) with some sort of neurological disorders, such as 
stroke, Parkinson’s disease, multiple sclerosis and epilepsy, concluded that all of them, 
except epilepsy, have direct association with the disease, which supports a possible 
causal linkage (Langan et al., 2011). It has been reported a strong association between 
multiple sclerosis and BP (Försti et al., 2016).  
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There is one Portuguese study that correlates neurologic diseases and BP.It reports that 
35.1% of the patients had a stroke at some point, 37.7% had demetia and 5.2% had 
Parkinson’s disease. All the neurologic conditions, except Parkinson’s, presented an 
association with BP (Teixeira et al., 2014). Lai et al. also made a research to evaluate the 
risk that BP patients had for neurologic diseases with a pool of 23369 BP cases. Following 
the above, this study confirms a signification association between the BP cases and 
neurological diseases (Lai et al., 2016). 
 
6.1.2. BP and psychiatric disorders 
Some psychiatric disorders have been associated with BP, such as the bipolar and 
unipolar disorders, schizophrenia and personality disorders (Försti et al., 2016). The 
frequency of these diseases has been found to be increased; however, the association 
with BP is still statistically not significant (Bastuji-Garin et al., 2011). It was also 
demonstrated that schizophrenia has a high frequency in women with BP (Chen et al., 
2011).  
 
6.1.3. BP and other immune disorders 
Koerber Jr, in 1978, reported the coexistent of psoriasis and bullous pemphigoid in six 
case reports (Koerber Jr et al., 1978) and in 1985, Grattan accesses a record of sixty two 
BP patients to determine if psoriasis and BP have, in fact, any association. He found that 
seven BP patients, 11%, had psoriasis but none of the controls had it. So it was possible 
to infer that the incidence of psoriasis in BP patients was significantly higher than 
expected, suggesting a linkage between the two diseases (Grattan, 1985). In a report 
case of a seventy-seven year old male patient with psoriasis later diagnosed with BP, 
Iskandarli et al. suggested a rule that they called “no psoriasis, no BP”, which means that 
maybe BP can be a sign of active psoriasis, at least in this case. For instance, the 
occurrence of these two diseases in the patients could mean that active psoriasis induced 
BP, and psoriasis-induced BP can be a sign of psoriasis activity (Iskandarli et al., 2015). 
Many other studies have confirmed concomitant psoriasis and bullous pemphigoid in 
several patients, and since pathogenic relationship between psoriasis and BP is not that 
clear, it has been suggested that the autoimmune process responsible for BP lesions 
could be induced by UV light therapy, topical corticosteroids, and/or the inflammatory 
processes that occurs in psoriasis (Person and Rogers III, 1976; Wilczek and Sticherling, 
2006). Some investigators think that maybe psoriasis vulgaris and BP occur together due 
to a combined action of the epidermis affected by psoriasis and the effects of antipsoriatic 
therapy. These combined might initiate production of autoantibodies that will attack the 
BMZ, in individuls prone to it. It is a fact that the majority of these reported BP cases in 
literature happened after antipsoriatic therapy, like anthralin, psoralens, sun exposure, 
PUVA therapy, among others (Ruocco et al., 2013b). 
BP also seems to be linked to alopecia, vitiligo, and dermatitis herptiformis – Duhring, PF 
and PV. Although the coexistence of BP and PV or PF is very rare, there is such a case 
reported in the 1990’s (Korman et al., 1991). 
As aforementioned, eosinophils play a crucial role in BP, and are also a source of tissue 
factor (TF), that is an initiator of blood coagulation. Marzano et al. reported that the 
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coagulation cascade is activated in BP and there is a correlation between the disease 
severity and eosinophilia, which indicates that eosinophils also play a role in coagulation 
activation via TF. These events increased risk of thrombotic complications in BP (Marzano 
et al., 2009). 
BP is also associated with diabetes mellitus. Jedlickova et al. found that the frequency of 
diabetes mellitus was increased in BP patients with more than eighty years, but they didn’t 
find any statistical significance (Jedlickova et al., 2010). 
Although allergy and BP have different mechanisms, growing information has been 
gathered that indicates an association between these two abnormalties, which suggest 
that these two disorders might share the same pathophysiologic mechanism (Rottem et 
al., 2002). However, there was established a link between allergy and autoimmunity - the 
antibodies IgG4 and IgE. While IgE has a crucial role in allergic diseases, IgG4 can block 
an inflammation induced by allergens, blocking antibodies (Gleich et al., 1982). These 
observations can be demonstrated taking immunotherapy as an example: levels of IgE 
decrease whereas IgG4 levels increase, after therapy (Golden et al., 1992). Also, these 
alterations in IgE and IgG4 levels could be attributed to IL-10, produced by T cells, being 
exposed to allergens (Akdis and Akdis, 2015). Being IgG4 antibodies the most important 
pathogenic autoantibodies in PV, PF/FS and BP, as aforementioned, this can represent 
the link between allergies and ABD. 
It is also possible that the relation between IgE and IgG4 antibodies is a consequence of 
the sequential isotype switch from IgM through IgG4 to IgE (Jabara et al., 1993). This 
divergence between IgG4 and IgE may be good to patients who suffer from allergies; 
however, it has a negative effect in FS patients, exacerbating the IgG response which will 
lead to pathogenic IgG4 autoantibodies (Qian et al., 2016). 
Another important fact is that, sometimes, it can happen that three or more autoimmune 
disorders are developed in the same patients, which is called multiple autoimmune 
syndromes (MAS) (Anaya et al., 2012), This syndrome was firstly described by Humbert 
and Dupond (1988). However, the pathogenesis of this syndrome is still unclear, so it has 
been proposed that the presence of one autoimmune disorder can lead to detection of 
other pre-existing disorders, such as vitiligo, thyroiditis, and bullous pemphigoid in the 
patient (Mohan and Ramesh, 2003). Sundaram et al. reported a case of an eighty-one 
year old male that suffered from rheumatoid arthritis, with vitiligo over the hands, later also 
diagnosed with BP. In this case, not only the patient had BP as he had two more 
diseases, which turned his condition into a treatment, diagnosis and pathomechanisms 
challange. Once again, it is unclear if BP was induced by the other autoimmune disorders. 
Further research is needed to understand this disease entity and to evaluate if BP can be 
prevented in these cases (Sundaram et al., 2014).  
There are several reported cases of BP linkage with other autoimmune diseases, such as 
Sjögren's syndrome (Yamamoti et al., 1998), rheumatoid arthritis (Sundaram et al., 2014), 
systemic lupus erythematosus (Stoll and King Jr., 1984), multiple sclerosis (Masouyé et 
al., 1989; Stinco et al., 2005), , thymoma (James, 1984), psoriasis (PašIć et al., 2002), 
nephrotic syndrome (Hoorn et al., 2015) and primary biliary cirrhosis (Guerra-Uribe and 
González-Huezo, 2016). However, there are all rare occurrences. 
A potencial link between BP and amyotrophic lateral sclerosis (ALS) was also studied, 
and although the pathogenesis of BP and ALS is not well understood, it is possible to find 
some immunological aberrance (Nakane et al., 2016). 
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The tense, pruritic blisters that characterizes BP, sometimes can be preceded by 
prodromal pruritic, urticarial or eczematous eruptions. This can lead patients to develop 
pruritus without blisters, as a prodrome of BP (Alonso-Llamazares et al., 1998). Very 
recently, a seventy-five year old Japanese woman with a ten month history of widespread 
pruritic nodular eruptions was diagnosed with BP (Yoshimoto et al., 2016). It was 
determined that when BP is associated with this nodular lesions, it is called pemphigoid 
nodularis, which is a rare type of pemphigoid (Ross et al., 1992; Yung et al., 1981). In 
1986, a case of BP after an eleven year history of autoantibody-negative prurigo nodularis 
was also reported (Roenigk and Dahl, 1986). These two cases suggest that pemphigoid 
nodularis might start with prurigo nodularis and then evolve into production of 
autoantibodies anti-BP180 and/or BP230.  
Very recently, a case of a seventy-five year old female with lymphocytic colitis that was 
then diagnosed with BP was also reported (Sperl et al., 2016).  
Another study seems to find a different cluster between PV and autoimmune thyroid 
disease (AITD), rheumatoid arthritis and type 1 diabetes, PV and systemic lupus 
erythematous (SLE), and AITD and rheumatoid arthritis. It could suggest that there are 
common genetic elements across these clinically distinct diseases. Indeed, the 
prevalence of AITD, rheumatoid arthritis and type 1 diabetes are increased in PV patients, 
when compared with the general population (Parameswaran et al., 2015). 
 
6.1.4. BP and pulmonary diseases 
A study from Langan et al. confirmed that BP patients had three times more probability to 
have pneumonia and pulmonary embolism. It is suggested that the greater risk for 
pneumonia in these patients maybe due to the use of high oral cortisteroids doses for BP 
treatment (Langan et al., 2009). In 1979, Savin also made an association between BP 
deaths and bronchopneumonia and pulmonary emboli (Savin, 1979). 
 
6.1.5. BP and cardiovascular disorders 
Since BP treatment can interfere with blood preasure and heart diseases, it is suggested 
that both hypertension and ischemic heart disease might play a role in BP patients. Some 
drugs used in hypertension are reported to induce BP (Jedlickova et al., 2010; Pietkiewicz 
et al., 2015). 
 
6.1.6. BP and neoplasia 
A recent and in-depth epidemiological study by Ong et al., from 1999 to 2011, with a 
cohort of 2.873.720 patients with malignant cancers, was performed. Curiously, the cohort 
used was not found to be at greater risk of concurrent or subsequent BP than the control 
cohort. However, patients with BP appear to be at greater risk in specific sub-cohorts of 
patients with kidney cancer, laryngeal cancer or lymphoid leukaemia. They also reported 
that patients with BP as a primary diagniosis had no increased risk for malignant cancers, 
similar to previous findings in the study (Ong et al., 2014). Very recently, a case of BP in a 
sixty-seven year old man diagnosed with pancreatic neoplasm, a lymphoepithelial cyst, 
was also reported. After the excision of the cyst, a fast improvement occurred without 
resorting to treatment, which suggests that maybe BP involved the cyst. It was 
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hypothesized that maybe the cyst triggered BP (Chadwick et al., 2016). A case report of 
an eighty two year old Japanese woman strengthens the bond between gastric cancer 
and BP. She was diagnosed with both diseases and, after surgery for gastric cancer, BP 
improved dramatically (Noguchi et al., 2014).  
Currently there are more theories that try to explain the linkage between malignant 
neoplasms and BP, graphically shown in Figure 17. The first, and most important one, 
explains that there is a possibility for antibodies directed against tumor-specific antigens of 
that malignant cells to cross-react with BP antigens in the BMZ. This event can lead to 
blister formation. The mechanism behind this cross-reaction could be explained by 
laminin-332, an essential protein for keratinocytes attachment to epidermal basement 
membrane. Aware of it, laminin-332 also is expressed by some tumors, like 
adenocarcinomas (colon, breast, pancreas, and lung) to promote tumor growth, invasion 
and metastatic behavior (Endo et al., 2010; Kikuchi et al., 2011). Another theory refers the 
possibility that tumor cells may secrete a hormone-like substance that causes damage to 
the epithelial BMZ, which in turn may lead to production of anti-basement membrane 
antibodies. The third theory suggests that there is an intervention of an external agent, like 
a virus or something similar, which can be tumorigenic and induce damage to BMZ. 
Lastly, the appearance of a cancer could occur due to production of antibodies with 
capacity to cross-react with the BMZ of the skin (Dahl and Ristow, 1978; Patel et al., 
2012; Venning and Wojnarowska, 1990). Again, some authors refer the possibility of a 
genetic predisposition, since human leukocyte antigen (HLA) DR13 has been found more 
commonly in patients with both BP and malignancy, when compared with patients only 
with BP (Venning et al., 1990). Recently, Tukaj et al. reported the pathological role of heat 
shock protein 90 (Hsp90), which is a cell stress-inducible molecule that participates in the 
development of malignancies and autoimmune blistering diseases, especially in BP. The 
selective Hsp90 inhibitors have been proposed for treatment of both conditions (Tukaj et 
al., 2015). 
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Figure 17 - Representation of the theories that try to explain the linkage between malignant 
neoplasms and BP: (a) Antibodies directed against tumor-specific antigens of malignant 
cells cross-react with antigens (like BP antigens) in the basement membrane zone (BMZ). 
(b) Tumor cells secrete a hormone-like substance that could damage the epithelial BMZ. (c) 
Virus or other agent which is tumorigenic and at the same time induces BMZ damage 
(adapted from Balestri et al., 2016). 
 
There should be a bigger concern from physicians about PAM and an oncological 
screening should be carried out in early-onset pemphigoid. They should screen patients 
that had cancer, patients with symptoms neoplasm-related, and BP patients in 
immunosuppressive therapy (Balestri et al., 2016). 
Ruocco et al. studied fourty-five BP patients, from 2006 to 2011, to determine the 
neoplasms incidence and correlate them with BP disease. They reported that 22.2% of all 
BP patients had some sort of neoplasm, lung cancer being the most frequent, in 6.6% of 
the patient, and prostate and uterus cancer being the next, with 4.4% each, as 
summarized in Figure 18 (Ruocco et al., 2013). 
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Figure 18 – Incidence of malignancies in BP (adapted from Ruocco et al., 2013). 
 
There is a unique case report of an eighty-two year old diagnosed with BP that was then 
also diagnosed with spindle cell carcionoma of the gallbladder. BP has been associated 
with some neoplasias, but, for this one in specific, it was the first time, and some authors 
have suggested that this kind of association could make us think of possible factors of 
internal malignancies in BP patients (Umekoji et al., 2010).  
 
6.2. Concerning Pemphigus Vulgaris 
The most important comorbidities associated with pemphigus are insomnia, Cushing 
syndrome, adrenal insufficiency, inability to swallow due to mucositis infections with 
herpes and fungi. This conclusion was made upon a very wide USA cohort with 
87.039.711 hospitalized patients (Hsu et al., 2016). 
 
6.2.1. PV and neoplasia 
Bernard et al. studied a cohort of 85 patients with thymoma, an uncommon neoplasia 
derived from the epithelial cells of the thymus, and found out a high relation between this 
disease and autoimmune diseases, in which 47/85 (55%) cases of thymoma had an 
autoimmune disease, and one of the patients had pemphigus. They also suggested that 
preexisting autoimmune diseases are not a risk factor for developing autoimmune 
manifestations after thymectomy. There are some theories that try to explain this 
association, although all of them are based in the failure of positive and negative selection 
of T-lymphocytes in the thymus – “escape theory”, “genetic theory” and the “AIRE 
(autoimmune regulator) theory” (Bernard et al., 2016).  
Also, in Japan, a fifty-four year old man with thymoma was diagnosed, eight months 
before, with PV (Saraya et al., 2015).  
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6.2.2. PV and viruses 
Knowing that viruses have a huge implication in PV patients life, a study tried to access 
and compare levels of IgG antibodies against herpes simplex virus type 1 and 2 (HSV1 
and HSV2), cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in the sera of twenty-
five PV patients and twenty-seven healthy individuals. The comparison of the levels of 
anti-EBV, anti-CMV and anti-HSV2 IgG showed high titers of antibodies in PV patients, 
but not in the controls. The level on anti-HSV1 was a bit increased but the difference 
between PV patients and controls were not significant (Ghalayani et al., 2015). Other 
studies have been done over the years that could corroborate the presence of viruses in 
PV patients (Barzilai et al., 2007; Kalra et al., 1999; Kurata et al., 2014; Tufano et al., 
1999).  
Moreover, it is not clear if the presence of these viruses could induce PV in patients. The 
most probable is that this presence is a consequence of the disease and, hence, the 
treatment. Viral infections can only be casual ou be a reflection of the lack of normal 
epithelial barrier, or it might reveal a pathogenic link (Ruocco et al., 2014). 
 
6.2.3. PV and pulmonary diseases  
Despite being extremely rare, autoimmune bullous disease associated with interstitial lung 
disease (ILD) cases are repored for PV. Bai et al. reported one of the rare cases with this 
association. A fifty-three year old Chinese female with PV developed ILD after a relapse of 
PV. It seems that this association occurs only when autoimmune bullous diseases relapse 
or aren’t under control (Bai et al., 2016). Also, in 1989 a case was reported of a fifty-two 
year old Japanese female with PV that developed ILD too (Usuba et al., 1989). ILD also 
developed in a seventy-three year old female, in this case with BP (Yoshioka et al., 2012). 
 
6.2.4. PV and oral mucosa diseases 
As aforementioned, PV affects the oral mucosa, and there is a report that describes a 
case of a forty-seven year old male diagnosed with PV that was later diagnosed with 
periodontitis (Pradeep et al., 2010). Periodontitis is known as a multifactorial disease 
plaque induced inflammation that involves and destroys the supporting alveolar bone, 
cementum and periodontal ligament (Beukers et al., 2016). This case reinforces the huge 
need in periodontal follow-up by dental professionals in order to prevent this kind of 
painful periodontal disease progression.  
 
6.2.5. PV and infections  
A retrospective study with one hundred and fifty five PV patients, sixty eight males and 
eighty seven females, from 2009 to 2011, reported a high prevalence of infections in 
them. Thirty-three of all patients had infection at admission (Staphylococcus aureus and 
Escherichia coli) and nine acquired nosocomial infections. Also, thirty seven had oral 
candidiasis and fifteen had localized herpes simplex. This high prevalence of infections in 
these patients suggests that infection is directly correlated with disease severity and 
presence of diabetes mellitus (Esmaili et al., 2013). 
A study tried to correlate the pathogenesis of PV with Mycobacterium tuberculosis, 
screening the sera of sixty PV patients and twenty eight controls. It was found that seven 
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PV patients (11.7%) and none of the controls revealed presence of IgG against this 
bacillus. This means that PV patients seem to be more prone to exposure to M. 
tuberculosis, since maybe PV patients are sensitized against this bacterium, which means 
that M. tuberculosis contributes to PV pathogenesis (Ali et al., 2016). 
 
6.2.6. PV and other diseases  
Recently, it was raised an important issue that possibly links endoplasmic reticulum (ER) 
stress and anti-Dsg1 in PV. It was reported that the majority of the forty two oral biopsy 
specimens from PV patients had correlation with development of ER stress, in the course 
of the disease (Mihailidou et al., 2016). This stress in the ER causes functional 
disturbances, leading to evolutionarily conserved cell stress responses – the ufolded 
protein response - which wil cause cell death (Xu et al., 2005). 
 
6.3. Concerning Pemphigus Foliaceus 
The prevalence of metabolic syndrome (MetS) and its components were assessed form 
both PF and PV. A cohort with one hundred and forty seven patinets (48.9 % PF and 
51.1% PV) living in the northeatern region of são Paulo, Brazil, was compared twith 
Brazilian casuistic samples. Although the results didn’t find any significant difference 
between prevalence of MetS, it did find a quite high prevalence of each component of 
MetS, such as high blood pressure in PV male patients, and in both genders for PF; 
diabetes mellitus in both genders and both diseases; obesity in PV and PF female 
patients; and, hyperglyceridemia in both genders for both diseases again. So the 
components per se are more prevalent in PF and PV than in control group and this 
suggests that more investigation is needed to assure if this syndrome can or cannot be 
associated with pemphigus (Ambiel and Roselino et al., 2014). 
 
6.4. Concluding Remarks 
Despite the difficulty of associating BP with other disease, it is inevitable that one is more 
contested than others. For instance, a considerable number of BP patients have been 
associated with neurologic disorders; however, it has also been much discredited. It is still 
not clear if the association is merely casual. 
This chapter, onde agauin, reinforces the fact that it is necessary further research about 
the underlying mechanisms between these associations. Also, Very little is known about 
BP association with psychiatric diseases, and many cases have been reported. 
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7.1. Bullous Pemphigoid Inducing Factors 
A great majority of cases don’t have an obvious precipitating factor that could induce BP. 
However, in some cases, with a meticulous clinical history, it is possible to detect some 
agents that could be responsible for inducing this disease. 
It was once observed that a recognizable factor that could precipitate BP was present in 
no more than 15% of patients, which once again lead us to think that inducing factors can 
only account for a minority of all the BP cases (Venning and Wojnarowska, 1995). 
Moreover, since the mechanisms that could be responsible for BP are unknown, it is 
possible to assume that most are related to factors that could locally disrupt the basal 
membrane zone of the skin (Lo Schiavo, et al., 2013). 
 
7.1.1. Drug Induced 
The term drug-induced bullhous pemphigoid (DIBP) used to describe cases of BP with 
clinical, histological and immunopathological characteristics that are similar to idiopathic 
diseases’ characteristics. These are induced by the systemic ingestion, or even by local 
use, of some drugs. Furthermore, a genetic susceptibility might play a role, because only 
few people develop the disease after the intake of certain offending drugs (Kanahara and 
Agrawal, 2016; Vassileva, 1998).  
The course of this BP is not uniform, and it’s possible to discern two types: an acute and a 
chronic. The acute self-limited form shows a definitive resolution after withdrawal of 
responsible drug, and with or without steroid therapy. The chronic form usually seems to 
be precipitaded by the drug administration and, during time course, ends up assuming the 
classic BP characteristics (Ruocco and Sacerdoti, 1991). Since it is possible that drugs 
can act as triggers in BP patients having genetic susceptibility, two main mechanisms are 
implicated: the modification of the immune response and the alteration of the antigenic 
properties of the epidermal basement membrane. This means that the production of 
autoantibodies against the basal membrane zone can be induced by drugs, which act like 
haptens that bind to proteins in lamina lucida and change their antigenic properties. 
Moreover, drug can also stimulate an autoimmune response by structurally altering 
molecules and uncovering hidden epitopes (Ruocco and Secerdoti, 1991). 
Systemic and topical treatments can equally induce BP, and they can be grouped 
according to their chemical structure. The majority of systemic drugs has or releases 
sulfhydryl groups (thiols: penicillamine (Popadic et al., 2009), captopril (Mallet et al., 
1989), penicillin and derivates (Hodak et al., 1990; Wozniak et al., 2006). The sulfhydryl 
groups’ key role could be within the drug precursor or within a catabolized metabolite. It 
seems that the biochemistry of free sulfhydryl groups is crucial for drug-induced BP 
(Walsh et al., 2005). Thiol group seem to allow the molecule to combine with proteins in 
the lamina lucida, acting as a hapten, and resulting in the autoantibody formation to BMZ 
proteins. Another explanation is that certain sulfur-containing drugs could cause a dermo-
epidermal split without immune mediation. Besides, there are some sulfur-containing 
drugs (like penicillamine) that could interfere with Treg cells, which will cause a decrease 
in the suppressor cell activity, with subsequent exacerbated production of different 
autoantibodies against the BP antigens (Durdu et al., 2011; Popadic et al., 2009). 
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More drugs can be associated, such as drugs that contains a phenol ring, some 
cephalosporins and aspirin (Durdu et al., 2011) and non-thiol non-phenol drugs – 
angiotensin-converting enzyme inhibitors other than captopril (Smith et al., 1993), majority 
nonsteroidal anti-inflammatory drugs (Laing et al., 1998), nifedipine (Ameen et al., 2000; 
Brenner et al., 1999). 
The suspicious that a common drug like aspirin could trigger BP led to believe that, 
maybe, this drug act as a hapten, which alters the antigenicity of the laminda lucida or 
even that could maybe attach to a cell site and lead to autoantibodies’ formation (Durdu et 
al., 2011). 
Recently, several BP cases were reported to be associated with dipeptidyl peptidase-IV 
(DPP-4) inhibitors, which are used for type 2 diabetes mellitus (Aouidad et al., 2013; 
Attaway et al., 2014), more specifically, cases associated with linagliptin and vildagliptin-
metformin use (Mendonça et al., 2016; Pasmatzi et al., 2011; Sakai et al., 2016). Taking 
into account the cases of vildaglipin-induced BP, awareness during gliptin therapy could 
prevent cases of BP development (Keseroglu et al., 2016). But until now, the clinical and 
immunological characteristics of DPP-4 inhibitor related to BP have not been clearly 
elucidated.  
Interferon-gamma (IFN-) that is released from lymphocytes test might help physicians to 
better diagnose drug-induced pemphigus (Brenner and Goldberg, 2011). This kind of 
diagnosis is based on skin reactions resolution of the eruption, upon cessation of the drug 
suspected by the assay (Goldberg et al., 2004; Halevy et al., 2005).  The IFN- released 
from the patient’s lymphocytes is evaluated after in vitro incubation with and without the 
suspected drug. Thye patient’s lymphocytes are separated from heparinized venous 
blood. Ultimately, the IFN- can be detected by ELISA assay. The IFN-  is used to detect 
an immune sensitization to a culprit drug and identify it among all different drugs that the 
patient is taking (Brenner and Goldberg, 2011).  
 
7.1.2. TNF-α Blockers 
Treatment with TNF-α blocker has been reported to be associated with many cases of BP 
(Bordignon et al., 2009; Kluk et al., 2011; Toosi and Bystryn, 2010b). Tumor necrosis 
factor-alpha (TNF-α) is an important regulator of inflammation and it’s responsible for the 
increased production of pro-inflammatory molecules, such as IL-1, IL-6, IL-8, etc, and 
adhesion molecules (e.g. intercellular adhesion molecule-1, P-selectin, E-selectin) 
(Wajant et al., 2003). Likewise, it is well known that TNF-α can promote apoptosis. 
Therapy with TNF-α antagonists is proven to be effective in treating inflammatory 
disorders (Esposito and Cuzzocrea, 2009; Victor and Gottlieb, 2002). TNF-α down-
regulation by TNF- α blockers (e.g., adalimumab and etanercept) could be implicated in 
BP development on patients with a propensity for this disease. It is necessary to outwit BP 
in patients under treatment with biological agents, such as efalizumab therapy (Duong et 
al., 2010; Wilmer et al., 2016). 
TNF antagonists are used in patients with psoriasis, with shown efficiency, so it can be 
pertinent to use this therapy in BP patients, especially when BP coexists with psoriasis 
(Cusano et al., 2010; Yamauchi et al., 2006). 
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What is most important to retain about this topic is that, since this therapy reveals efficacy 
in other immunobullous disorders, the efficacy of this same therapy in BP should be 
established too. 
 
7.1.3. Contact Pemphigoid 
The external use of some preparations of the skin or mucous membrane has been 
reported to induce cases of BP. These preparations have such an irritating effect (for 
example benzyl benzoate) or allergic contact hypersensibility (like 5-fluorouracil) that have 
been proposed as a triggering effect for BP (Bart and Bean, 1970; Piletta et al., 1994; 
Stransky et al., 1996; Vassileva, 1998). 
 
7.1.4. Vaccinations Contribution 
Not many cases of vaccinations have been implicated in inducing BP, although there’s still 
some cases correlated with it: anti-influenza vaccine and swine flu vaccination (Mérida et 
al., 2005; García-Doval et al., 2006; Walmsley and Hampton, 2011), tetanus toxoid 
booster and tetracoq vaccine (Baykal et al., 2001). Being the vaccination so widely used 
and carefullu developed, it is unlikely that they could activate anti-BMZ antibody 
production. But, as Lo Schiavo et al. questioned: why have reports of BP triggered by 
vaccination been rarely reported when vaccination practice is so common? Maybe, 
vaccination only induces BP in patient’s genetically prone to it, with an immunologic 
predisposition or even with subclinical BP (Lo Schiavo et al., 2013). 
 
7.1.5. Induction by Physical Agents 
Over time, many studies have been connecting BP induction with ultraviolet (UV) light – 
UVB or psoralen with UVA – radiation therapy (RT), thermal or electrical burns, or surgical 
procedures (Dănescu et al., 2016; Khandpur and Verma, 2011; Korfitis et al., 2009). 
Moreover, in these cases, BP could become generalized or localized to the injuried site – 
immunocompromised district (Ruocco et al., 2009). 
 
Radiation Therapy Involvement It is within the female population with breast 
cancer, where the majority of BP radiation therapy induced cases have been registered 
(Kluger et al., 2016). In a cohort with twenty nine breast cancer patients, about 72% 
developed BP (Nguyen et al., 2014). This could mean that maybe radiation has the ability 
to change antigenic properties and induce autoantibody production by altering the BMZ, 
unmaking antigens. Or maybe it is possible that patients have circulating low titre anti-
BMZ antibodies, and all this together with tissue damage caused by RT can enhance 
deposition of these autoantibodies, through alteration of blood vessels’ permeability. It is 
known that radiation alters MMP-9 values and growth factors (such as VEGF) and that it 
can cause an induction of local modifications of the immune system. It is possible that, 
sooner or later after RT, BP appears and after the first onset in the irradiated area, it could 
become generalized. This fact could be explained by the epitope spreading. Then, an 
immune response spreads to cover different sites on the same autoantigen and even 
different autoantigens (Binitha et al., 2014; Campa et al., 2016; Isohashi et al., 2011; Mul 
et al., 2007; Srifi et al., 2011). 
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Ultraviolet radiation Experiments with organ-cultured normal human skin revealed 
that BP antigen could probably be susceptible to UVB irradiation, and this could lead to 
configurational changes in these antigens (Muramatsu et al., 1994). Also, this kind of 
event could occur with UVA therapy too (Washio et al., 2005), in which serum levels of IL-
1 raise leading to polyclonal activation of B cells. It has been demonstrated that many BP 
cases often appeared after anti-psoriatic treatments – sun exposure, PUVA, UVA and 
UVB therapy (Barnadas et al., 2006; Caca-Biljanovska et al., 2016; Kao et al., 2008). 
Washio et al. reported a case of a thirty five year old white man diagnosed with psoriasis 
that developed blisters on his extremities, after UVB phototherapy all over the body. This 
could be an indicator that maybe UV radiation alters BMZ antigenicity, exposing or 
releasing altered antigens. Furthermore, these antigens could stimulate antibody 
formation against BMZ (Washio et al., 2005). With all these findings it’s possible to infer 
that UV therapy could be the most likely trigger of BP. 
 
Photodynamic therapy Photodynamic therapy (PDT), also called 
photochemotherapy, is a form of phototherapy involving light and a photosensitizing 
chemical substance, used clinically to treat psoriasis, atherosclerosis and malignant 
cancers, in particular skin (Chen et al., 2002; Morton et al., 2013; Saini et al., 2016). An 
eighty eight year old man was diagnosed with BP, after topical PDT for a large Bowen’s 
disease on his left cheek. There is only one more case reported of localized BP 
associated with PDT (Morton et al., 2013; Rakvit et al., 2011). So, it is possible that PDT 
can induce BP in predisposed individuals or, for instance, cause damage in the basement 
membrane and antibody formation. 
 
Burns Thermal or electrical burns are known to be one of the physical BP inducers. 
Usually, BP develops in the affected areas and, later on, extends to other skin areas. 
However, it is important to discern BP lesions from physical injuries. One factor that could 
help to link a burn to BP occurrence is that, for example, patients don’t have a relapse 
once the triggering factor (electrical ou thermal burn) is eliminated (Bachmeyer et al., 
2010; Balato et al., 1994; Damevska et al., 2014; Kluger et al., 2011; Morita et al., 2015; 
Xu et al., 2008). 
 
Surgical Procedures In this case, BP is confined to the accidentally traumatized 
area (Ruocco et al., 2009). The injuries that have an association with BP, often appear 
after different types of surgical procedures, such as percutaneous endoscopic 
gastrostomy (PEG) (Nozu and Mita, 2010), urostomy (Batalla et al., 2011; Torchia et al., 
2006), surgeries near the venous site in hemodialysis patient (Yesudian et al., 2002), 
among others (Neville and Yosipovitch, 2005). 
These sorts of events may happen because of the damage to the dermal-epidermal 
junction and antigen exposure, which triggers an immune response. The skin around the 
PEG tube is frequently inflamed by gastric juice and chronically irritating skin can induce 
activation of the immune system, and this could mean a huge difference between PEG 
and tracheal tube, since traqueal tube has no association with BP (Nozu and Mita, 2010).  
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7.1.6. In Transplant Patients 
This association is rare to happen, however, there are a few cases reported in the 
literature. The most important association is made between BP and renal transplant. 
Usually, the patients responded only to systemic corticosteroids and the skin lesions in 
some cases improved after graft removal. This might be a strong suggestion that renal 
allograft has something to do with BP pathogenesis, maybe because of the autoantibody 
production due to renal allografts. This production could be the result of chronic allogeneic 
stimuli. Also, it is possible that an immune cross-reactivity between skin and the kidney 
has an important role. Because sometimes antigenemia due to chronic rejection can occur 
in transplantation, this might have contribution to BP pathogenesis. It is noteworthy that, 
since renal transplantation patients take immunosuppressants to avoid rejection, these 
drugs may also have something to do with BP development. Tregs play an important role 
in autoimmunity and graft tolerance, since Th and B cells are directly suppressed. Tregs 
are found in decreased levels in peripheral blood, after tracolimus traeatment (Abou-
Jaoude et al, 2005; Chen et al., 2009). Tracolimus, also called FK-506, is an 
immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of 
organ rejection (Kino et al., 1987). Since, Tregs need low-dose IL-2 (responsible for 
promoting development and proliferation of T cells) signals in order to survive, tracolimus 
acts inhibiting the production this interleukin, so suppression of Tregs numbers occur. The 
Tregs deficiency, indirectly contributes to autoantibody induction (Chen et al., 2009). Also, 
a case report described a case of BP after liver transplantation, for liver failure, in a child 
with Coomb’s positive autoimmune hemolytic anemia and giant cell hepatitis (Kerkar et 
al., 2006). A case of a twenty eight year old woman with tuberous sclerosis complex 
(TSC) diagnosed with BP was reported. And despite the lack of association between BP 
and TSC in this case, it is important to say that this patient underwent renal 
transplantation after bilateral bephrectomy, so, once again, we could be in the presence of 
another case diagnosed with BP after renal transplantation (Mandel et al., 2016). 
 
7.1.7. Infections Association 
Over time, investigators seem to find a link between BP pathogenesis and some 
infections, in particular herpes virus infections. Patients with BP have been reported 
having human herpesviruses (HHV), such as cytomegalovirus, Epstein-Barr and HHV-6. 
Detection of these viruses seems to happen in vesicular fluid, while in the patients’serum 
the detection of antibodies to HHV-8 occurs. However, one of the viruses’ characterisitcs 
makes us question its etiopathogenic role – their latency in specific set of cells (Drago et 
al., 2005). Other viruses have also been implicated in BP induction, such as hepatitis B 
and C (Sagi et al., 2011). Also, Torque Tone virus has already been reported with high 
incidence in BP patients’ sera, however, the role in the disease is still not very clear 
(Blazsek et al., 2008). A virus can induce autoimmune disease, by damaging the infected 
cells. Furthermore, the new antigens can derive from the incorporation of fragments of the 
cell membrane into the envelope of the virus. Another possibility is that viruses may share 
epitopes with its host, which could lead to the development of cross-reactive 
autoantibodies – molecular mimicry. Additionally, viruses could also activate polyclonal B 
cells to produce autoantibodies, and interfere with T cells and their lymphokine production 
(Drago et al., 2005). 
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7.2. Pemphigus Vulgaris Inducing Factors 
Similar to what happens with BP, in PV there is no underlying agent that could induce this 
disease, leading us to think that this could happen spontaneously. But, in fact, if we 
meticulously study the patients’ medical files we can find some possible associations.  
 
a. Drugs: feasible inducer 
The drug intake represents the most common cause of triggered pemphigus. The likely 
drugs to cause disease are thiols and phenols, among other non-thiol and non-phenol 
drugs (Ruocco et al., 2013a). Drugs containing thiol group are indicated as causative in 
precipitating a real antibody-mediated PV, since the infiltration of thiols in keratinocytes 
leads to changes in the molecular structure and alters the antigenic conformation of 
membrane desmogleins. Also, thiols could cause an immune imbalance and amplifying 
the acantholytic self-injury (Ruocco et al., 1993; Ruocco and Ruocco, 2003). The most 
common thiol drugs triggering pemphigus are penicillamine, captopril, and penicillin and 
derivates (Ruocco et al., 2013a). Concerning the non-thiol and non-phenol drugs, enalapril 
(angiotensin-converting enzyme (ACE) inhibitors), nonsteroidal anti-inflammatory drugs, 
nifedipine and, most important, biologic modifiers of the immune response, like vaccines, 
interferons (IFN) and other cytokines are the most likely PV trigger (Ruocco et al., 2013a). 
There are several reports of PV patients associated with influenza, tetanus and diphtheria 
vaccinations, some with a fatal outcome (Ruocco and Ruocco, 2003). There is one study 
that reported pemphigus antibodies in the sera of non-pemphigus patients that did IFN-α 
therapy for awhile (Baroni et al., 2011). 
A case report refers a sixty three year old white man that suffered from a relapse of PV 
after topical application of ingenol mebutate gel, representing the first case of this kind. 
Russo et al. postulate that, maybe, this happens because of the proinflammatory activity 
of this topical drug (Russo et al., 2016). 
Antihypertensives are also suspected to trigger/sustain PV/PF. About 62.50% of AH 
positive PV patients took ramipril and about 93.33% of AH positive PF patients took 
enalapril, both potentially noxious drugs for AH (Pietkiewicz et al., 2015). However, it was 
reported that the calcitriol, a hormonally active vitamin D metabolite, can protect 
keratinocytes from captopril-induced cell detachment and apoptosis (Zeeli et al., 2011). 
 
b. Virus Part 
As mentioned earlier for BP, herpes virus infections are indicated as possible inducers in 
PV (Ruocco and Ruocco, 2003). A study with 20 PV patients reported Herpes simplex 
(HSV), Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) circulating in 
lymphomonocytes and in some patients’ skin lesions. This could indicate that herpetic 
infections might induce upregulation of humoral and cellular pro-inflammatory factors, as 
aforementioned (Tufano et al., 1999). However, viral infections only induce PV 
ocassionally or, perhaps, only exacerbate the autoimmune disorder in genetic susceptible 
patients. 
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c. Physical Triggers 
When we talk about physical agents that could possibly induce pemphigus, there is no 
way to dissociate from the physical agents implicated in BP cases, since there is an 
obvious resemblance. Agents like sunburns, ionizing radiation, thermal and electrical 
burns, as well as surgical and cosmetic procedures, are porved to be inducers in 
individuals PV’ predisposed (Ruocco et al., 2013a).  
Again, similarly to what happens in BP, the UV radiation is the main cause in pemphigus 
induction. Therapy with ionizing radiation can also trigger PV, as previously reported in 
literature (Robbins et al., 2007). The thermal and electrical burns that induce pemphigus 
lesions, similar to what happens with ionizing radiation, usually lie within or in the adjacent 
tissue of burned areas. Later, they tend to extend to other regions of the skin and, 
sometimes, to oral cavity (Tan et al., 2006). It seems that there is no relation between PV 
and any specific surgical procedure, since it manifestated following a series of various 
procedures (electrosurgery, hair transplantation, facelift, etc). Nonetheless, dermobrasion 
and chemical peels seem to favour acantholysis in PV susceptible individuals, maybe 
because the procedures include chemicals containing phenol (Ruocco et al., 2013a). 
 
d. Allergens Playing a Part 
Allergic contact dermatitis (ACD) can be a mediator in PV exacerbation, through some 
chemical sensitizers, such as photographic developing, dry cleaning, industrial solvent 
work, gardening, and more. There are some reported cases of PV after contact with 
pesticides, for instance (Vozza et al., 1996). Brenner et al. conducted an international 
survey that reported the pesticides’ exposure as a potential cause for an increased risk for 
PV (Brenner et al., 2001). Another interesting fact is that PV is more common in 
nonsmokers than in smokers. It seems that nicotine, as a cholinergic agonist, acts like a 
protection factor against cell-to-cell detachment (Valikhani et al., 2007b). 
 
e. Emotional stress  
Cytokines and neurotransmitters are responsible for the communication between nerve 
fibers and cutaneous cells, which represent a unique neuroimmunocutaneous system 
(Misery, 1997), and this well-designed system is responsible for a pathogenic link 
between emotional stress and an autoimmune skin disorder, with some cases being 
reported. Some of these cases correlated the onset of the disease in patients with 
personality disorders experiencing a stressful event (Cremniter et al., 1998; Morell-Dubois 
et al., 2008). The most prevalent stress events causing induction of PV are environmental 
disasters, war, terrorism, relative’s death and sexual aggression (Ruocco et al., 2013a). 
 
7.3. Pemphigus Foliaceus Inducing Factors 
As mentioned earlier, the affinity in the development of IgE and IG4 antibodies could 
transpire due to the sequential isotype switch from IgM over IgG4 to IgE. The switch of 
both isotypes is promoted by Th2 cytokines – IL-4 and IL-13. The chronic antigenic 
stimulation induces secretion of IL-10 that shifts the balance of the class switch towards 
IgG4 (Jeannin et al., 1998). The imbalance of IgE and IgG4 brings benefits to patients 
with allergies, but the same cannot be said about autoimmune skin diseases such as FS, 
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in which this process could trigger a massive IgG response that could lead to generation 
of pathogenic IgG4 autoantibodies. Moreover, an environmental allergen could probably 
trigger IgE responses in FS, and the antibodies directed against this allergen cross-react 
with epidermal Dsg1 (Qian et al., 2016). 
A recent study searched for triggering environmental antigens, in patients with EPF, Fogo 
Selvagem. It was suggested that the exposure to hematophagous insect bites could 
possibly constitute a precipitating factor for FS development. In endemic regions, FS 
patients and healthy individuals demonstrated IgM autoreactivity response from early 
childhood, that later restricts to IgG4, in FS patients. So, this search for triggering 
environmental antigens, led to a discovery in which IgG4 and IgE autoantibodies, from the 
patients with FS, cross-react with a salivary antigen from sand flies, which proves that 
these antibodies evolve from the naïve B cells. This also demonstrates that this non-
infectious environmental antigen could be an initial target of the autoantibodies response 
in Fogo Selvagem (Qian et al., 2012, 2016).  Qian et al proposed that there is a possible 
mechanism that might trigger the development of anti-Dsg1, as seen in Figure 19, by 
environmental antigens. This mechanism could be LJM11, a sand flies salivary gland 
antigen (SGLL) component recognized by humans. Probably, this component stimulates 
naïve B cells to undergo class switch in order to generate an initial IgE response directly 
agains the LJM11 component. Since there is cross-reactivity between the epitopes of 
LJM11 and Dsg1, the initial antibody response – IgE response – also rests to Dsg1. 
Moreover, the chronic stimulation of LJM11 antigen and consequent production of IL-10 
may induce the development of IgG4 antibodies, that also reacts to both LJM11 and 
Dsg1. There are two outcomes expected fot those IgG4 antibodies: are pathogenic in FS 
or trigger further developmente of IgG4 autoantibodies via epitope spreading (Li et al., 
2003; Qian et al., 2016). 
 
 
Figure 19 – Environmental antigens, like LJM11, triggering the development of cross-
reactive antibody response and subsequent FS, in individuals prone to (from Qian et al., 
2016). 
 
It is common knowledge that the use of topical herbal supplements to improve health has 
had great success in the last decades. One of these supplements is the popular St. John’s 
wort, or Hypericum perforatum. However, these kind of “homemade medicine” can trigger 
multiple adverse effects, with a well-known photosensitizing and, possible, 
immunomodulatory effect (Bedi et al., 2002; Klemow et al., 2011). This flowering plant has 
a rate of 50% probability to cause adverse effects, which are mild and transient (Ernst, 
2000). Even though we know that this herbal drug has its own adverse effects, such as 
allergic reactions, gastrointestinal disturbances, among others, the mechanism of action is 
still unknown, and so this drug can potentially cause autoimmune diseases, since it may 
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increase activity of macrophages, neutrophils, natural killer cells, and proinflammatory 
cytokines, like IL-1 and TNF-α (Ernst et al., 1998; Lee and Werth, 2004). Photoxicity is a 
very common side effect of this herbal drug, which can induce pruritic skin rash 
(Imbernón-Moya et al., 2016). A case of a thirty seven year old woman with PF was 
temporarily associated with the herbal drug, after she started taking St. John’s wort, one 
week before the appearance of skin lesions. However, the cause-effect cannot be fully 
established, so further studies are needed (Imbernón-Moya et al., 2016).  
 
7.4. Nutrition May Interfere - Transversely Speaking 
Factors derived from our daily diet have been implicated to play a part in pemphigus 
induction, with a variety of substances that are present in different foods that we regularly 
eat being the culprit. These substances are believed to play a role in causing the induction 
of some pemphigus cases, more properly in patients with genetic predisposition 
(Lakdawala et al., 2013). 
Some molecules with active thiol groups could contribute to induce pemphigus. For 
example, some plants, like those belonging to the Allium group, contain active compounds 
with stable disulphide and thiol groups. The Allium group includes some important 
vegetables such as onions and garlic, so it is suggested that this kind of food can 
contribute for this induction (Brenner and Wolf, 1994; Chorzelski et al., 1996; Ruocco et 
al., 1996). 
Also, a gluten free diet has been indicated to possible improve condition of pemphigus 
and BP patients, in cases where there is underlying gluten sensitivity (Fedeles et al., 
2010). Antigliadin antibodies (AGA) have already been described in pemphigus patients, 
in the past (Kumar et al., 1992). 
It seems that diet doesn’t have a direct involvement in BP induction, since no triggers are 
suspected (Lakdawala et al., 2013). A case of dyshidrosiform pemphigoid induced by 
nickel in diet was reported, which was resolved by a nickel-free diet. However, it is 
noteworthy that some BP patients have gluten intolerance, proven by the presence of 
antigliadin antibodies in patients’ sera. This, once again, seems to be resolved with a 
gluten-free diet (Fedeles et al., 2010). 
 
We cannot say the same for pemphigus. 
A forty nine years old man gives us the perfect example of the consequences from heavy 
garlic consumption, which worsened pemphigus already diagnosed. In this case, the 
garlic-free diet eased symptoms of the disease. Also, the recurrence occurred due to 
ingestion of a garlic meal (Ruocco et al., 1996). Another case was reported with oral 
lesions associated with leek ingestion (Chorzelski et al., 1996). 
A study made in vitro reported that three garlic’ compounds – allylmercaptan, 
allylmethylsulfide and allylsulfide – caused acantholysis in skin specimens at 6mM 
concentration (Brenner et al., 1995). 
Another compound that has been implicated in pemphigus induction is phenols. There are 
case reports of patients diagnosed with pemphigus due to topical applications of phenol-
containing chemicals (Goldberg et al., 2001; Kaplan et al., 1993). India has the higher 
rates of younger age cases diagnosed, which can be explained by the high consumption 
of foods with high levels of phenols, like mango, cashew nuts and black peppers (Brenner 
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et al., 2000, 2006). Tannins-containing foods have also been suggested to play a role in 
pemphigus induction. This plant’s polyphenolic compound is present in some daily foods 
and drinks, such as mango, guarana, raspberry, cranberry, blackberry, avocado, peach, 
ginger, ginseng, tea and red wine (Tur and Brenner, 1997, 1998). This compound may be 
behind the high occurrence of endemic pemphigus in Amazonian Brazil (Fogo Selvagem), 
due to increased amounts of this compound being dissolved in the water systems that 
serves the Amazonian natives (Tur and Brenner, 1997). And since food with high tannin 
concentrations is also widely consumed in India, this may cause a high incidence of 
pemphigus there, similarly to what happens with phenols. There is a report of an in vitro 
cultured skin to which was added tannic acid that produced many cytotoxic effects, one of 
them being acantholysis (Brenner et al., 2000). By high-performance liquid 
chromatography (HPLC) the levels of tannic acid (TA) and gallic acid (GA) in blister fluid 
of 4 groups of patients were measured. The groups were made according to dietary 
habits, such as regular diet, diet rich in tannins, diet free of tannins and pemphigus 
patients. The group with a diet rich in tannins demonstrated high tannin metabolites in the 
skin. In this study, an in vitro acantholysis system revealed that TA is able to cause 
acantholysis (Feliciani et al., 2007). 
Isothiocyanates, chemicals derived from hydrolysis of glucosinolates, are found in 
vegetables of the Cruciferae group, which includes mustard, broccoli, turnip, cabbage and 
cauliflower. This chemical may contain groups of allyl, benzyl or phenyl and they could be 
immunologically active and behave like thiol-containing drugs (Wittstock and Burow, 
2007). The allyl isothiocyanate is the main compound of mustard oil, known to cause 
blistering of mucous membranes (Le, 1964). This kind of components could be implicated 
in the induction of pemphigus; however, to date no cases of pemphigus due these 
chemicals have been reported. 
Phycocyanin is a blue pigment protein present in algae like Spirulina platensis. These 
“algae” are a cyanobacteria sold as a dietary supplement (Lupatini et al., 2016). Also, it 
was reported that spirulina has as an immunomodulatory effect that mainly stimulate the 
innate immune system (Hirahashi et al., 2002). There are case reports with this alga and 
immunoblistering disorders. One is from a fifty seven year old man with chronic PV that 
experienced a severe extension after intake of spirulina supplements, while another case 
is from an eighty two year old healthy woman who experienced a mixed immunobullous 
disorder with features of PV and PF, 1 year after she started taking spirulina supplements. 
In the first case, the extension improved after treatment and discontinuation of spirulina 
intake, and in the second case the woman recovered (Lee and Werth, 2004; Kraigher et 
al., 2008). Very recently, Sarre et al. found an association between BP and hypovitamosis 
in older patients, in cases with increased comorbidity cluster.  We are now aware of the 
role for vitamin D in the regulation of immune responses (Baeke et al., 2010). Only a few 
studies had already focused mainly in the association between low serum 25-
hydroxyvitamin D (25OHD) concentrations and BP (Marzano et al., 2012, 2015; Tukaj et 
al., 2012), all with somewhat contradictory conclusions. Marzano et al., both in 2012 as in 
2015, reported a significant association and Turkaj et al. reported no association at all. 
The big difference in Sarre et al. study is the comorbidity burden, which seems to 
influence this association, so this study is consistent with previous evidence of the 
association between vitamin D and autoimmune disorders (Sarre et al., 2016).  
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7.5. Concluding Remarks 
There are already some tools that help physicians find out what possible causes of 
induction of these three ABD. 
Along with all the possible triggers that have already been described, it seems that 
pregnancy can exacerbate pemphigus but, often, to a mild degree. On the other hand, 
pemphigus seems to cause a higher incidence of abortion (Lin et al., 2015). 
Also, there are many suggestions that can help the patients to avoid the blistering or to 
find an adequate treatment. For instance, in patients that are genetically prone to 
pemphigus, it would help if they could distance themselves from the environmental 
triggering factors, helping in the management of the disease. This could also improve the 
efficacy of treatments, avoid relapses and, most likely, result in a cure. 
As mentioned, FS is the pemphigus form with the strongest link with the environment and 
this fact could result in the possibility to use FS as a great model to study the impact of 
environmental antigens in the autoimmune disease development. 
Another concern is the wide use of herbal supplements that could possible trigger these 
ABD. Maybe more scientific studies about this matter are needed, in order to prevent 
future blistering diseases cases. These immunostimulatory supplements exacerbate pre-
existing autoimmune disease, like pemphigus, or maybe precipitate the disease in 
individuals with certain genetic predisposition. Either way, it might be necessary to study 
its influence. It was also alarming to see that there are some cases of vaccinations that 
could induce disruption of the membrane architecture, leading to the generation of anti-
BMZ antibodies. And since this relationship remains obscure, it could be interesting to 
study and deepen this connection.  
Also, and since the link between BP and certain drugs is not clear, it might be useful to 
screen BP patients for drug induction, so it could be possible to prompt discontinuation of 
the culprit drug. This cessation could result in a more quick and effective recovery of the 
patient. Studies have been made in order to find an evident association between BP and 
drug intake, like Tan et al. (Tan et al., 2016). 
Moreover, for all that was mentioned above, PDT should be added to possible BP 
triggers.   
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By now, it is well established that pemphigus has a strong genetic predisposition; 
however, the inheritance is still not clear and seems to be rare. This fact could happen 
because more than one gene causes the disease or maybe because of additional endo 
and exogenous contributing factors (Gazit and Loewenthal, 2005). The real proof of this 
genetic event is the high incidence in Jews, mainly among Ashkenazi (Krikler, 1970). One 
of the first reports about this genetic event demonstrated a major association between 
pemphigus and HLA in Jews, more specifically HLA-A10 (Krain et al., 1973). A study from 
1979 already reported a prevalence of HLA-DRW4 in 91% of Jews with PV, reporting an 
extremely high incidence and association, in what the authors classified as an “HLA 
concordant” disease in Jewish patients (Park et al., 1979). The reason why Jewish 
population is so associated with pemphigus is their isolation, intermarriage, proselytism 
and genetic drift (Loewenthal et al., 2004). 
Over the years there has been a great interest in genetic associations with pemphigus 
pathogenesis. The crucial link lies within the major histocompatibility complex (MHC) 
genes, essentially the HLA class II (Brochado et al., 2016). 
There are many populational studies that correlate HLA class II alleles with PF and PV. 
 
8.1. Jewish community  
There is a tremendous interest in genetic studies relating the Jewish community and 
pemphigus disease. The first genetic association in Jewish patients comprised HLA-A26, 
HLA-B38, HLA-DRB1*0402, HLA-DQB1*0302. These haplotypes are the most commonly 
found in Jewish groups (Mobini et al., 1997). 
The haplotypes HLA-DRB1*0402, DQB1*0302 have been commonly associated with 
Jewish PV patients worldwide, whereas the haplotypes HLA-DRB1*1401/ HLA-
DRB1*1404, DQB1*0503 have been linked to non-Jewish PV patients, generally speaking 
(Fridkis-Hareli, 2006). 
It is important to keep in mind the strong association between PV and PF to HLA class II 
genes, as was already mentioned. However, a study found out that, HLA-G in Jewish 
communities is also strongly associated with the disease (Gazit et al., 2004). This is 
interesting since this gene, besides belonging to nonclassical HLA class I, is suggested to 
have a crucial role in immune tolerance in pregnancy, being expressed in the placenta 
(Menier et al., 2000). It is still not clear exactly how HLA-G can affect PV pathophysiology. 
However, it is known to participate in immunological cascades that lead to production of 
anti-Dsg antibodies (Gazit et al., 2004). 
Hopping to find some genetic association besides the HLA class II genes, a study used 
sixteen microsatellite probes to scan the entire MHC region and screen samples from 
thirty wight PV patients and seventy six healthy controls. Maerkers were, again, reported 
to be associated with the class II region but the HLA-A region was also mapped, highly 
related to PV. So these results give an insight to the importance of gene, or genes, other 
than class II, in initiation of the autoimmune cascade, meaning that the activation or the 
suppression of these genes could be a trigger mechanism to start this cascade (Slomov et 
al., 2003). Again, in 2005, another study tried to find association between PV and HLA 
class I TAP genes, using thirty seven patients Jewish Israeli and thirty seven healthy 
Jewish Israeli. The two risk alleles TAP2*C and TAP2*D were identified and estimated to 
be 37.8% in patients and 5.3% in controls. So, it was possible to conclude that TAP2 
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genes are responsible for susceptibility in developing PV (Slomov et al., 2005). Also, an 
analysis to one hundred and fifty five pemphigus patients, from a medical centre in Israel, 
revealed that only 37% of the sample represents Non-Ashkenazi Jews, another niche of 
great interest to study. This study reinforces the link between pemphigus and HLA genes 
(Mimouni et al., 2008). The Ashkenazi Jews have been studied because they represent 
the highest prevalence of pemphigus vulgaris, for a long time now (Brautbar et al., 1980). 
For instance, Seidenbaum et al., reported that of the patients studied in the cohort, about 
75% were Ashkenazim (Seidenbaum et al., 1988). 
 
8.2. Population Studies 
8.1.1. Africa 
Tunisia Genetic studies were also conducted for Tunisian patients. A study with 90 PF 
patients found that DRB1*0301 allele confers susceptibility to Tunisian PF, which is 
surprising since DRB1*03 wasn’t associated with the endemic or sporadic form of PF. The 
cohort was divided in two groups, one with patients from the north (sporadic PF form) and 
on with patients from the south (endemic PF occurence). They concluded that DRB1*03 
allele is the main susceptibility allele of the Tunisian EPF.  Moreover, the DRB1*04 allele 
is the most important conferring susceptibility with higher significance in the south group 
than in the north group.  The differences that this study reported in north and south group, 
suggest that PF might occur in two forms, in Tunisia, a sporadic and an endemic form 
(Abida et al., 2009). 
 
Morocco Attempting to find a link between high prevalence of pemphigus and a specific 
genetic factor in morocco, a study with a cohort of fifty two pemphigus Moroccan patients 
(seventeen PV and eleven PF) was conducted. An increase in DRB1*04, DRB1*14 and 
DQB1*03 allele frequencies and a decrease of DRB1*15 and DQB1*06 allele frequencies 
was found. However, these values are similar to those commonly found among other 
populations. Furthermore, the HLA-DRB1*15/DQB1*06 haplotype revealed protective 
effects in this population whereas DRB1*04/DQB1*03 and DRB1*14/DQB1*05 haplotype 
induced susceptibility to pemphigus disease. These results reinforce a genetic 
predisposition to pemphigus. Nonetheless, in this population the genetic factors continue 
to not explain the high prevalence of disease in Morocco (Brick et al., 2007). 
 
8.1.2. Europe 
Spanish González-Escribano et al. reported a study with 26 Spanish Caucasian with PV 
that was HLA typed. Twenty three of them were HLA-DR4 and twenty one had the 
DRB1*0402 allele, so the frequency of this allele was 81%. They also noticed another 
fact: HLA-DR13, which is present in 27% of Spanish general population, wasn’t present in 
these PV patients. It was possible to conclude that in Spanish population, PV is mostly 
associated with HLA-DRB1*0402 and, on the other hand, DRB1*13 seems to be 
conferring protection to Spanish population (González-Escribano et al., 1998). Another 
study investigate Jews lived in Spain for more than 1500 of years. Many of these Jews 
converted to Christianity, which favoured admixture with the Spanish. This study proves 
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that the same HLA haplotype – DRB1*0402 and DQ0302 – is present in both Jewish and 
Spanish PV patients. This suggests that they had the same founder (Loewenthal et al., 
2004).  
 
Italy A study with thirty two Italian, sixteen of which Sardinian, PV patients reported two 
PV susceptibility haplotypes: HLA-DRB1*0402, DQA1*0301, DQB1*0302 and HLA-DRB 
1*1401, DQA1*0104, DQB1*0503, being thah the first haplotype was the most prevalent 
among Sardinian patients. They concluded that the strength of the allele associations to 
PV lies on DRB1*0402 and DQB1*0503 alleles. Similar to what happens to Spanish 
population, there is an allele HLA-DR3 that seems to confer protection against PV 
(Carcassi et al., 1996). 
Another study involving eighty seven Italian patients, of which sixty one had PV and 
twenty six had PF, was conducted. This study revealed an increase of DRB1*04 and 
DRB1*14, in both PV and PF patients. Both pemphigus forms demonstrated a high 
association with DRB1*1401. They also concluded that, in these cohort, PV and PF 
shared DRB*1401 and DQB1*0503 susceptible HLA alleles. Also, they determined that 
DRB1*0402 is only associated with PV (Lombardi et al., 1999). 
 
France French population was also studied, represented by a cohort with fifty seven 
patients, thirty seven of them with PV and twenty with PF. The results concerning PV were 
in line with previous studies from other countries. However, concerning PF, it was 
demonstrated that DRB1*01012 and DRB1*0404 are susceptible molecules for the 
French population (Loiseau et al., 2000).  
 
8.1.3. Asia 
Turkey When the Turkish population was studied for the HLA subtypes, it was possible to 
conclude, in a cohort of twenty five PV patients and one hundred nd thirteen healthy 
controls, that 68% of the patients had the allele HLA DRB1*04, against 30.97% of the 
controls, making it more prevalent in infected patients. The allele HLA DRB1*14 was also 
expressed with an increased frequency in the patients, with 32% against 8.85% in the 
control group. Also, the frequency of the haplotypes HLA DRB1*04/HLA DRB1*03 and 
HLA DRB1*14/DQB1*05 was significantly higherin the PV patients of this cohort. It was 
not possible to identify alleles or haplotypes that could confer some form of protection to 
PV in this cohort. So, all of these alleles and haplotypes described are indicated to be 
responsible for genetic susceptibility in Turkish population (Tunca et al., 2010). 
Iran A group of fifty two PV Iranian patients revealed that HLA-DRB1*04 and HLA-
DRB1*1401 alleles are two major PV susceptibility factors, in Iranian population. This 
cohort only covered non-Jewish patients (Shams et al., 2009).  
 
Pakistan Pakistani population was also studied and it was found a strong association 
between DRB1*04 and PV (Khan et al., 2015). 
 
Japan A group with seventeen Japanese PV patients was also investigated and it was 
concluded that DRB1*0403, DRB1*0404, DRB1*0406 or DRB1*1401, DRB1*1405, 
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DRB1*1406 alleles were present, either one at a time or both simultaneously (Yamashina 
et al., 1998). 
 
8.1.4. America 
Venezuela The genetic susceptibility was also studied in Venezuelan patients, with a 
cohort of sixty six non-Jewish patients, in which forty nine were diagnosed with PV (50% 
of patients had mucosal involvement and the other 50% had cutaneous phenotype) and 
seventeen were diagnosed with PF. DRB1*0402 and DRB1*1401 were statistically 
significant to associate with PV and PF. Moreover, a haplotype analysis revealed that 
DRB1*0402 usually co-exist with DQB1*0302 and DRB1*1401 with DQB1*0503. These 
results demonstrate that DRB1*0402 is the most relevant responsible for pemphigus 
susceptibility in Venezuelan patients (Sáenz-Cantele et al., 2007). 
 
Brazil A cohort with thirty wight EPF patients living in endemic areas was conducted to 
evaluate HLA genes.  The variant HLA-DRB1*010 was found to be the main susceptibility 
factor to trigger the disease, and only two amino acids distinguish DRB1*0102 from 
DRB1*0101. The two amino acids seem to be responsible for the formation of a functional 
epitope, causing T cell recognition, and thus determining disease susceptibility (Moraes et 
al., 1991). Later, another study with one hundred and twenty eight EPF patients was 
conducted, and it was found that the more significant alleles among patients were HLA-
DRB1*0101, HLA-DRB1*0102, HLA-DRB1*0103, HLA-DRB1*0404, HLA-DRB1*0406, 
HLA-DRB1*0410, HLA-DRB1*1406 and HLA-DRB1*1601 (Pavoni et al., 2003). On the 
other hand, a study with forty eight FS patients revealed that the haplotypes DR7,DQw2 
and DR3,DQw2 seem to confer protection against EPF (Petzl-Erler and Santamaria, 
1989). Also, concerning PV, the allele HLA-DRB1*0402 and HLA-DRB1*0804 and the 
HLA-DRB1*14 group have been implicated in PV susceptibility (Weber et al., 2011). 
As aforementioned, little attention has been given to HLA class I in pemphigus. The HLA-
B*16 was the only allele associated with PF susceptibility in Brazilians (Petzl-Erler and 
Santamaria, 1989). But very recently, a study with one hundred and sixty nine patients 
from São Paulo, Brazil, concluded that HLA-A*11 and HLA-A*33 allele groups confer 
susceptibility to PF, whereas HLA-A*02 is responsible for protection against PF. They also 
found an increased frequency of HLA-B*14 allele in PF patients, and a high frequency of 
the HLA-B*38 allele group in PV patients. Concerning the PV patients, they also found out 
that the allele group HLA-B*15 confer protection against the disease. For the first time it 
was described HLA-DRB1*14:01 alleles for susceptibility and HLA-DRB1*07:01 alleles for 
protection against PV disease. Moreover, they found the new genetic variant HLA-
DQB1*0602 that is also associated with PV protection in this population. So, the HLA-
DRB1*0102 and the HLA-DRB1*0402/HLA-DRB1*1401 alleles are the major etiologic 
fraction values in PF and PV, respectively. Until now, there were only a few reports linking 
the Brazilian population with HLA class I alleles in the disease’s pathogenesis and this 
findings are truly important to better understand the value of these genes in the 
pemphigus process (Brochado et al., 2016).  
The genetic predisposition in FS led researchers to conduct studies with Brazilian 
Mestizos and Xavante Indians that demonstrated particular HLA alleles. These specific 
alleles confer increased risk for the disease. The Terena Indians show some genetic 
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particularities. A cohort with twenty Terena Indians revealed that nineteen of them were 
positive for DRB1*0404, 1402 or 1406 which is concordant with Xavante findings. 
However, Mestizos had an association with DRB1*01. What is interesting in these alleles 
for all three populations is that all shared the same amino acid sequence at position 67-74 
on the third hypervariable region of the DRB1 gene: LLEQRRAA. These findings suggest 
that inheritance of this sequence might be involved in FS susceptibility (Moraes et al., 
1997). 
 
 
8.2. BP Also Has Something To Do With Genetics 
Although this relationship is somewhat tenuous, there are some studies looking for a 
concret answer. Recently, in 2015, a study with German population found out a link 
between mitochondrially encoded ATP synthase 8 gene (MT-ATP8) and BP. This could 
give a new insight about novel strategies to handle therapeutic approaches (Hirose et al., 
2015). 
Another study from 2015 investigated the possible link between CYP2D6 gene 
polymorphisms and BP cases. It seemed important to see if cytochrome 450 had an 
important role in BP pathogenesis. Seventy one BP patients were investigated and it was 
possible to identify the gene alleles: CYP2D6 (CYP2D6*1, CYP2D6*3, CYP2D6*4), of 
which CYP2D6*3 and CYP2D6*4 had a higher frequency than in controls. So this could 
mean that there is a relative risk for BP development four times higher in patients with 
these polymorphisms, especially with CYP2D6*3 presence (Rychlik-Sych et al., 2015). 
 
8.3. Familial Cluster 
Studies in families with pemphigus could provide further information of the genetic and 
environmental factors involved in pathogenesis. However, familial cases are barely found 
in the literature. The majority of the familial cases so far have been between mother and 
daughter and between siblings, so this constitutes the confirmed occurrence. The HLA 
typing studies demonstrated the same HLA alleles of HLA-DR4 (DRB1*04) and HLA-
DQB1*03 in both cases (Eskiocak et al., 2016). The first Turkey case was reported 
between a brother and a sister, from Armenian origin. Both revealed histologic 
examination, clefts with acantholytic cells. Also there was an IgG and C3 deposition.  
Genetic analysis also had similarities, proving a genetic influence. Brother and sister 
presented localized lesions, essentially in exposed body areas (Gokdemir et al., 2006). 
Some of the cases found in literature are summarized in Table 5 and as it is possible to 
confirm, there are not so many. 
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Table 5 – Some familial pemphigus vulgaris cases found in the PubMed database. PF: 
pemphigus foliaceus, and PV: pemphigus vulgaris (adapted from Eskiocak et al., 2016). 
Disease Patients Relation Localization Author, Date 
PV Three brothers, two brothers and 
a brother and sister 
Spain Bordel-Gómez 
et al., 2006 
PV Two sisters Greece Stavropoulos et 
al., 2001 
PV Brother and sister Turkey Gokdemir et al., 
2006 
PV Brother and sister Turkey Kavak et al., 
2005 
PV and 
PF 
Daughter with PF and mother with 
PV, one sister with PF and other 
sister with PV 
Japan Yamamoto et 
al., 2011 
 
8.4. Involvement of other genes 
More recently it has been reported the participation of ST18 gene in PV, being up-
regulated in the skin of PV patients. This event could be explained by the discovery of a 
PV-associated variant in the promoter region of the gene, variant responsible to increase 
gene transcription in a p53/p63 manner (Vodo et al., 2016). The ST18 gene is indicated to 
act as transcriptional regulator and is expressed in many normal tissues (Jandrig et al., 
2004). These findings could lead us to a novel genetic pathway in order to better 
understand PV pathogenesis and potential treatment targets for this disease. Moreover, 
another study found a correlation between ST18-associated variants that might 
predispose to PV within some specific populations. This correlation was confirmed in Jews 
and Egyptians, where this gene was found overexpressed in patients’ skin (Sarig et al., 
2012). 
Another finding with PV patients with Slovak origin confirmed associations between 
twentyn two single nucleotide polymorphisms (SNPs) in thirteen cytokine genes and PV. 
Unfortunately, only a weak association was found between TNF-α and IL-10 gene 
polymorphisms, which might give some contribution of genetic susceptibility to PV patients 
(Javor et al., 2010).  
Capon et al. also demonstrated an association between PV patients and the Dsg3 gene, 
conferring susceptibility.Conducting a cohort with sixty two PV patients and one hundred 
an fifty four healthy controls from U.K. and another cohort with twenty eight PV patients 
and ninety eight healthy controls from northern India, they reported a significant 
association between PV and the DSG3*TCCTC haplotype, in the U.K. sample, and an 
association between the DSG3*TCCCC related haplotype and PV, in the India sample. 
Also, they found out that all British and all Indian patients with DSG3 risk haplotypes also 
carried at least one copy of a HLA allele. This demonstrated that the genetic variants of 
Dsg3 might be an additional predisposing factor to PV (Capon et al., 2006). 
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The non-classical HLA-E plays a role in autoimmunity, so the association with PV was 
investigated with fifty two Caucasian Ashknazi Jewish PV patients. HLA-E*0103X was 
found increased in these patients, providing the first reported data as a marker for genetic 
risk in PV patients (Bhanusali et al., 2013). 
It was also studied the possibility of a linkage between a single nucleotide polymorphism 
(SNP) in the promoter region of TNF-α at position -308, affecting G to A transition, and 
pemphigus. The idea was to analyse the distribution of this SNP in North Indian cohort. 
Success was not achieved, since there was association with pemphigus risk in population 
at large. However, TNF-α could contribute to autoimmune phenomenon in pemphigus, 
being one of its multifactorial aetiology (Dar et al., 2016). 
 
8.5. Concluding Remarks  
All these data combined should be sufficient to clarify that genetic susceptibility does play 
an important role in these AIBD pathogenesis.  
Also, the phenomenon of family aggregation should be better studied, so that one can 
definitively discern whether or not there really is a familial clustering that could de 
important for the patients’ family and if this familial clustering could interfere with 
treatment, that is, if it could confer some kind of resistance. The occurrence of PV in first-
degree relatives could indicate new paths for the importance of genetic predisposition.   
Overall, nowadays, it is practically safe to say that genetics is a susceptibility factor. 
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The main therapeutic backbone in pemphigus is the systemic corticosteroids that usually 
are combined with other immunosuppressants, such as azathioprine, mycophenolate 
mofetil or intravenous immunoglobulin (IVIg) (Daniel and Murrell, 2014). And although the 
immunosuppresants like azathioprine, mycophenolate mofetil, cyclophosphamide, 
cyclosporine, intravenous immunoglobulin (IVIg), and plasma exchange aren’t enough for 
disease remission, they help in relapse decreasing it by 29% (Atzmony et al., 2015). 
First of all, it is necessary to set some parameters before cortisteroid or 
immunosuppressive therapy. These are: complete blood count, creatinine, blood 
electrolytes, transaminases, gamma GT, alkaline phosphatase, total serum protein, 
albumin, fasting serum glucose, hepatitis B, C, HIV and chest x-ray. Moreover, there is 
also a set of optional analysis, such as: serum IgA deficiency, which is recommended to 
be ruled out before IVIg therapy; analysis of TPMT activity, before azathioprine therapy; 
optinal abdominal sonography, osteodensitometry, which is needed before glucocorticoid 
treatment; ocular examination; β HCG, to rule out pregnancy in women (Hertl et al., 2015). 
Corticosteroids could be devastating to the patient’s organism (Poetker and Reh, 2010). 
However, since they seem to be a crucial therapy for pemphigus, the side effects need to 
be well understood and controlled. 
 
9.1 First-line Treatments 
9.1.1. Corticosteroids 
Since the discovery of prednisolone – and other corticosteroids – they have been widely 
used in pemphigus treatment (Fine, 1995). It is used as a first-line treatment, a systemic 
corticosteroid therapy, at 0.5 mg to 1.5 mg/kg/day. Usually, to control PV, a higher dose of 
prednisolone is required than to control PF. It is agreed that if PV is not controlled within 2 
weeks, a higher dose can be used, up to 2 mg/kg, but this is an optional choice (Hertl et 
al., 2015).  
Two case reports of females with PV - with forty three and sixty seve years old – attest 
that they responded well to oral prednisolone, in the treatment of systemic lesions. Also, 
when localized lesions appeared in both patients, this medication continued to be effective 
(Yoshifuku et al., 2016). 
A French multicentre study compared topical therapy with 40g clobetasol propionate 
cream applied daily, to systemic treatment with 1mg/kg prednisolone, and reported that 
the topical glucocorticosteroid therapy had a better result, concerning disease control and 
mortality rate in active BP (Joly et al., 2002).  
 
9.2. Second-line Treatments  
9.2.1. Immunosuppresants 
Additional immunosuppressive compounds, like azathioprine and mycophenolate mofetil, 
are used in pemphigus treatment (Almugairen et al, 2013; Hammers et al., 2013) in 
association with systemic corticosteroids (e.g 1.0-1.5 mg/Kg of prednisolone) (Hertl et al., 
2015). 
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In mycophenolate mofetil administration, the usual dose is 2g/day, with the possibility to 
start with 500 mg daily and to raise the dose by 500 mg per week, until reaching the final 
dose of 2g/day (Hertl et al. 2015). A study with thirty one PV patients and eleven PF 
patients reported rates of remission in both diseases with mycophenolate therapy, 71% in 
the first group and 45% in the second one (Mimouni et al., 2003). 
Azathioprine (AZA) is usually administrated at 1 to 3 mg/kg/day (Hertl et al., 2015). 
However, in the first week it’s usually administrated at about 50 mg/day in order to detect 
idiosyncratic reactions (in that case, the medication is immediately stopped) (Ruocco et 
al., 2013). After the first week, the dose can be raised to desired dose. It’s important to 
highlight that the activity of thiopurine methyl transferase (TPMT) needs to be monitored 
prior to azathioprine treatment (Meggitt et al., 2011; Hertl et al., 2015). Thiopurine methyl 
transferase has a major role in thiopurine drugs metabolism, like azathioprine (Fujita and 
Sasaki, 2007; Lee et al., 1995). Adults with high rates of TPMT activity can be treated with 
normal doses of azathioprine, up to 2.5 mg/kg/day. However, patients with intermediate or 
lower rates of TPMT activity should be more cautious in azathioprine intake, receiving a 
lower dose, up to 0.5 to 1.5 mg/kg/day or not be treated at all if the patient lack of TPMT 
activity (Hertl et al., 2015). Defects in the TPMT gene will eventually lead to enhanced 
bone marrow toxicity which could cause myelosuppression, anaemia, bleeding tendency, 
leukopenia and infection (Fujita and Sasaki, 2007; Lee et al., 1995). AZA also had some 
severe side effects, such as leukopenia, thrombocytopenia, anemia, pancytopenia and 
hepatotoxicity (Ruocco et al., 2013). It is noteworthy that drugs do have interactions with 
azathioprines, such as allopurinol, which are xanthine oxidase inhibitors (Meggitt et al., 
2011). This drug component is administered, among others, in situations of inflammatory 
diseases (Pacher et al., 2006). 
Cyclophosphamide is usually prescribed at 500 mg as intravenous (Zivanovic et al., 
2010). Cyclophosphamide pulse therapy is thought to be safe and effective, but only in 
alternative cases of pemphigus, both PF and PV, of difficult control and response 
(Fernandes and Zubaty, 2005). Also, cyclophosphamide is effective in BP patients 
(Ruocco et al., 2013). 
Azathioprine and cyclophosphamide revealed to be similarly effective in the pemphigus 
vulgaris treatment after about six months of therapy. The main difference is that 
azathioprine show a slower onset of action, with improvements seen in six months, 
whereas cyclophosphamide show a faster onset of action with improvements seen in 
three months (Sardana et al., 2016). The most alarming information is the reports of 
patients dying when receiving cyclophosphamide, concerning cardiotoxicity (Sardana et 
al., 2016). This adjuvant immunosuppressive compound is administered only if patients 
didn’t achieve remission with main corticosteroid therapy and AZA or mycophenolate 
mofetil, suffer from severe side effects with previous therapy or if the patient have rapid 
disease progression (Meurer, 2012). 
In BP patients, leflunomide is also used as a therapy. Leflunomide acts more like an anti-
inflammatory than an immunosuppressive and it is more used in BP than in other 
pemphigus. Usually, 20 mg are administered, combined with 20 mg of prednisone, every 
day for 5 weeks. After 5 weeks of therapy, the corticosteroids begin to taper and 
leflunomide is reduced to 10 mg per day (Ruocco et al., 2013). There are reports of 
patients that have only responded to high prednisone doses, but have respondeded well 
to leflunomide (Sehgal and Verma, 2013). 
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There is a compound that seems to be more efficient in treating BP patients than 
pemphigus ones – Methotrexate (MTX), a drug used to treat cancer and autoimmune 
diseases (Culton and Diaz, 2012). MTX has a lower incidence of infections in patients 
when compared to those treated with cyclophosphamide, mycophenolate mofetil or AZA. 
MTX is usually used twice a week in oral doses with 5 to 25 mg, and it seems to work very 
well a as systemic monotherapy, being safe and effective as a BP therapy. It is indicated 
for patients with contraindication for ‘systemic corticosteroids’, for the elderly with multiple 
clinical problems and for patients with a mild or limited form of the disease (Gürcan and 
Ahmed, 2009). However, MTX also have its side effects, including pancytopenia and 
hepatotoxicity, so patients with renal disorders and without any acid folic supplementation 
are at a great risk (Culton and Diaz, 2012). 
Dapsone, a glucocorticoid-sparing agent was reported to be effective in the maintenance-
phase of PV (Baum et al., 2016b; Werth et al., 2008). In elven patients treated with 
dapsone, eight were successfully treated, presenting an efficiency of about 73% (Werth et 
al., 2008). Dapsone is a great therapy in the maintenance phase of PV disease, since it 
reduces the steroid dependence in patients (Heaphy et al., 2005). These 
immunosuppressant compounds are also used in BP treatment, as corticosteroid-sparing 
agents, and the complete remission of the disease can be achieved (Tirado-Sánchez et 
al., 2012). In BP treatment, 100 mg per day can administered, with 60 mg of prednisone. 
However, dapsone dose can be increased (50 mg weekly to a maximum of 200 mg per 
day) if there is no improvement. Adverse effects can be reversible and depend on the 
dose (Ruocco et al., 2013). There is a case report of a fifty year old woman, diagnosed 
with PV that evolved to a drug-induced hepatitis after dapsone use (Quaresma et al., 
2015). So, despite dapsone being a relatively safe drug, a laboratorial monitoring is 
important in order to identify side-effects during its use. 
 
Table 6 – Few possible combinations for treatment of autoimmune blistering skin diseases 
(adapted from Schmidt and Zillikens, 2011). 
Disease Treatment 
Pemphigus Vulgaris 
Pemphigus Foliaceus 
Prednisolone (1.0-2.0 mg/kg/d*1)*2 + Azathioprine or 
Mycophenolate mofetil or Cyclophosphamide 
Bullous pemphigoid Clobetasone propionate 0.05% cream /10-30 g/d)*3 
+ Dapsone or Doxycycline or Azathioprine or 
Methotrexate 
*1: initial dosage, can be lowered depending on the clinical response. 
*2: alternatively. 
*3: it was shown that clobetasone propionate 0.05% cream (10–30 g/d) in a tapering 
dose is just as effective as prednisolone (0.5 mg/kg/d); with fewer side effects. 
 
9.3. Third-line Treatments 
9.3.1. Rituximab - anti-CD20 antibody  
Nowadays, rituximab is used as a third-line treatment (Hertl et al., 2015); yet, some 
studies to make this medication as a first-line treatment are underway. It can be combined 
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with intravenous immunoglobulin (IVIg) or immunoadsorption. Rituximab’s efficacy derives 
from factors such as CD20 being expressed in high levels on B cells and not internalizing 
or sheding from plasma membrane after mAb treatment (Glennie et al., 2007). Anti-CD20 
antibody is used to cause the depletion of CD20+ peripheral B cells, which last for at least 
half a year. After that, the B cells repertoire reconstitution, with naïve and transitional B 
cells, will derive from the stem cell pool (Colliou et al., 2013). This therapy seems to be 
effective in both PV and PF treatment (Cianchini et al., 2007) and is also effective and well 
tolerated in BP patients (Kasperkiewicz et al., 2011). Nontheless, the high costs still limit 
the use of this biologic compound to patients’ treatment resistance or life threatening 
disease (Cianchini et al., 2007). 
This monoclonal antibody is usually administrated 2 x 1g intravenous, with two weeks 
apart, or 4 x 375 mg/m2, each with one week apart (in Ahmed et al., 2006; Hertl et al., 
2008, 2015; Joly et al., 2007; Kasperkiewicz et al., 2012). And since rituximab can be 
administrated along with IVIg or immnunoadsorption, it is important to know their 
recommendations. IVIg can be prescribed at 2g/kg/month and the immunoadsorption is 
performed in two cycles in four consecutive days, with 4 weeks apart (Behzad et al., 2012; 
Hertl et al., 2015; Kasperkiewicz et al., 2012; Zillikens et al., 2007).  The IVIg therapy also 
provides an alternative for BP patients that resist to corticosteroid therapy (Amagai et al., 
2016). Side effects with IVIg are usually lower than 1%, and that includes headache, back 
pain, chills, flushing, fever and hypertension, all of them related to the rate of infusion and 
not to the dose (Lo Schiavo et al., 2010). Transfusions may also lead to moderate effects 
like fever and chills, during first transfusion. Thirty to one hundred and twenty minutes 
after infusion, patients can possible feel nausea, pruritus, angioedema, asthenia, 
hypotension, headache, bronchospasm, vomiting, throat irritation and dizziness, which 
can all be solved if the transfusion slows down or gets interrupted. Still, some aggravated 
reactions can occur with a fatal outcome. Hepatitis B reactivation with fulminant outcome, 
cardiac arrhythmias, renal toxicity, bowel obstruction and perforation, among others, has 
been described in BP patients (Lo Schiavo et al., 2010). 
Additionally, IVIg) helps in decreasing levels of pathogenic anti-Dsg antibodies (Danieli 
and Schoenfeld, 2014). This decrease happens so quickly that the explanation for the 
mode of action could be explained by induction of general increase in the antibodies’ 
catabolism, which includes the pathogenic ones (Czernik et al., 2008). It was reported in 
2005 that the keratinocyte detachment and death in PV from a sort of synergistic action of 
apoptosis effectors and the IVIg therapeutic activity is, in part, mediated by the stimulation 
of events of anti-apoptosis (Arredondo et al., 2005). 
Heelan et al. reported that the median time to relapse, after the first treatment cycle of 
rituximab, was 15 months, in which all patients demonstrated a notable improvement 
(Heelan et al., 2014).  
Patients treated with rituximab earlier in disease may have higher chances of having 
better outcomes, maybe due to the ability of destroying all nontolerant anti-Dsg B cell 
clones (Colliou et al., 2013; Lunardon et al., 2012). 
Eming et al. believed that, presumably, the drug has the ability to downregulate Dsg3-
specific CD4+ Th cells (Eming et al., 2008). This could open new perspectives of drug 
action mechanisms for this drug (Zambruno and Borradori, 2008). 
Rituximab proved to result in disease control by decreasing B cells, precursors of short-
lived plasma cells that can produce pathogenic antibodies. Also it was possible to 
 Treatment 
 
151 
 
determine that a lower peak serum of BAFF levels, right before B cell recovery, seems to 
predict an early relapse of skin blistering, so this could be an indicator for earlier treatment 
with rituximab (Hall III et al., 2013). Also, the use of rituximab enables a lower initial dose 
of oral prednisolone, reducing total dose. Adverse effects of this therapy were rarely 
reported (Sharma et al., 2016). 
A study with rheumatoid arthritis (RA) patients administered with rituximab showed that 
these suffered a depletion of all B cell populations. However, after a mean of 8 months 
after treatment B cell repopulation occurred and this repopulation mainly originated naïve 
mature and immature B cells. So, this treatment indeed induces a depletion of all 
peripheral blood B cell populations, at least in RA patients (Leandro et al., 2006). And the 
same happens in pemphigus patients (Mouquet et al., 2008). However, a study with 
systemic lupus erythematous (SLE) treated with rituximab demonstrated that the 
reconstitution of B cell, after depletion, may be functionally immature, where mostly are 
transitional B cells. These results demonstrate the peripheral blood memory reconstitution 
and that happens because the reconstitution is dominated by immature transitional B cells 
(Anolik et al., 2007). More studies about B cell depletion after this kind of treatment is 
needed to enhance the ability to rationally tailor the therapy in patients with autoimmune 
diseases. 
Rituximab has been demonstrated to be a promising first line therapy for pemphigus, and 
so have other biologic medications, like veltuzumab, obinutuzumab, ofatumumab, 
ocaratuzumab and belimumab (Huang et al., 2016). 
 
9.3.2. Depletion of autoantibodies: an adjuvant strategy 
Therapy based on plasma exchange (TPE), also known as plasmapheresis, has the 
potential to remove harmful large molecular-weight substances, such as autoantibodies, 
whereas, immunoadsorption (IAS) is used as a blood-purification technique that 
selectively removes immunoglobulins (Ig) from separated plasma through high-affinity 
adsorbers (Honoré et al., 2014). 
Although plasmapheresis and immunoadsorption show high efficacy to quickly remove the 
excess of pathogenic antibodies from the serum, they are still used as adjuvants. They 
have the necessity to act combined with systemic immunosuppression in order to prevent 
the rebound of newly synthesized antibodies (Turner et al., 2000; Kasperkiewicz et al., 
2012b). This technique involves the removal of large amounts of plasma during several 
days and it is done during hospitalization. However, plasmapheresis has a high cost and 
it’s associated with potential morbidity. For this reason, it should not be recommended as 
a routine therapy for BP (Ruocco et al., 2013b). A case report of a sixty three year old man 
with refractory BP that went through double filtration plasmapheresis shows that, in fact, 
the skin lesions did improve, however, factor XIII and fibrinogen levels decreased and 
deficiency of these factors can possibly cause lethal bleeding due lack of coagulation 
capacity. So plasmapheresis was switched by selective plasma exchange, an improved 
plasmapheresis that uses membrane plasma separator with smaller than ordinary pores. 
This new therapy also demonstrated good results without decrease factor XIII and 
fibrinogen levels. This therapy can represent an alternative for classic plasmapheresis, 
reducing pathogenic antibodies, as intended, and without decreasing levels factor XIII and 
fibrinogen, which take a long time to recover (Nasu et al., 2016). 
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9.3.3. Gold Salts 
The introduction of gold for pemphigus treatment, intramuscularly, has generated positive 
results over time (Iranzo et al., 2007; Lange et al., 2007). The intramuscular injections are 
made of gold sodium thiomalate or autothioglucose and are administered once a week, in 
single doses with 50 mg to 1g, whereas Auranofin is an oral preparation, administered 3 
mg twice every day. Auranofin seems to be less toxic than the injections, but also less 
effective (Ruocco et al., 2013). Nevertheless, this therapy had serious toxic effects in 
about 42% of the patients (Pandya and Dyke, 1998). 
The use of this therapy is not recommended for pemphigus patients, being banned with 
the use of other immunosuppressive agents (Hammers et al., 2013; Ruocco et al., 2013). 
 
9.3.4. Tetracyclines and Nicotinamide 
The use of these two agents could be helpful when we have mild cases of pemphigus 
disease. It is administered as an association of 2g per day of oral tetracycline or 0.5 to 
0.20g per day of minocycline, together with 1.5g per day of nicotinamide (see Harman et 
al., 2003 and included references). Moreover, concomitantly tetracycline administration as 
a combinatory therapy will help the dosage of immunosuppressant be tapered more 
rapidly (Sapadin and Fleischmajer, 2006). Tetracycline also demonstrated to be a useful 
alternative in BP cases (Walsh et al., 2005).  
 
9.4. Supportive treatment: additional options 
Besides all medication mentioned above, there are also some additional measures 
available which may complement the main treatment. 
Sometimes, intralesional injections of cortisteroids are administered, such as 
triamcinolone acetonide, which could play an important role in isolating lesions of oral 
mucosa, lips and skin, for instance. It is also possible to apply potent topical cortisteroids, 
like clobetasol propionate, or calcineurin inhibitors, and oral corticosteroids, like 
triamcinolone acetonide gel, directly in the lesion, in oropharyngeal erosions bcombined 
with systemic therapy (Cohen et al., 2006; Hertl et al., 2015; Iraji and Banan, 2010). 
Another extra recommendation is that, in case of erosive lesions, patients take analgesics, 
such as paracetamol, metamizol and opioids, and even gels containing local anaesthetics 
can be used for application. A dental care is also absolutely required (Hertl et al., 2015).  
The bullae that didn’t suffered erosion and remained intact should be punctured and in the 
wound sprays or lotions containing corticosteroids and antibiotics like gentamicin should 
be applied. Sometimes, baths with aseptic solutions like potassium permanganate are 
also necessary, in concentration 1:10 000, or even chlorohexidine. In cases with oral 
lesions that resist to systemic therapy, it’s also used topical corticosteroids, like clobetasol 
propionate. Another option is the intralesional injections with triamcinolone acetonide (10 
mg/mL). Sometimes, these oral lesions also cause discomfort during food intake, so it’s 
also recommended the application of anaesthetic nebulizers like benzocaine (Ruocco et 
al., 2013). Nowadays there are some innovative alternatives that try for the 
reepithelization of the lesion caused by the disease. We’re talking about epidermal growth 
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factor (Tabrizi et al., 2007), nicotinamide gel (Iraji and Banan, 2010) and pimecrolimus 1% 
(Tyros et al., 2013). 
In the case of patients in long-course therapy with cortisteroids, it is also highly 
recommended that they are screened for osteoporosis and, if necessary, manage 
prophylaxis. Management of glucocortisteroids for the smallest dose for the shortest time 
as possible is also taken into account, in order to minimize osteoporosis risk. To prevent 
further damages, patients also need to take vitamin D and calcium supplements, and in 
case of patients at risk, such as post-menopausal women, treatment with 
bisphosphonates is recommended. Patients should also be careful and take regular 
ophthalmologic evaluation. They can also take oral topical antifungals for prophylaxis of 
oro-intestinal conditions. A psychological support should also be given to patients, to try to 
alleviate the condition and to give them tools to overcome their situation. Moreover, 
physiotherapy sometimes is necessary in patients with prolonged cortisteroid therapy 
(Hertl et al., 2015). 
 
9.5. Future perspectives 
Along with all the treatment options available, new studies have been made hoping to be 
able to minimize the damage of steroids therapy.  
Omalizumab, monoclonal antibody (mAb), a recombinant humanized mAb anti-IgE 
(Balakisski et al., 2016), has already been proposed as a viable alternative for BP 
patients, for instance. Still, it needs further studies to evaluate if it can be used as a 
monotherapy or as an adjuvant agent (Fairley et al., 2009).  
Also, ustekinumab, a mAb that prevents interaction of IL-23 and IL-12 with their 
respective receptors, so will block the Th1 and Th17 differentiation. As aforementioned, 
Th17 initiates the inflammatory cascade in BP, so this new approach can represent a new 
hope (Lo Schiavo et al., 2013). In a typical case of BP associated with psoriasis that 
relapsed, ustekinumab demonstrated good results controlling the disease (Loget et al., 
2016). Treatment with IL-17 inhibitors is already used in patients with psoriasis, a disease 
that, like BP, is caused by an exacerbated production of inflammatory cytokines. Two 
more anti-IL-17 are under clinical trials, since February 2015 – brodalumab and 
ixekizumab. These biological agents have been demonstrated efficient and safe. These 
drugs can also be useful in PV and BP treatment (Wasilewska et al., 2016). 
Likewise, the chimeric antigen receptor (CAR) was tested to be used as PV therapy. 
Human T cells were engineered to express chimeric autoantibody receptor (CAAR). 
Though still under study, this therapy could represent a new hope in PV therapy 
(Ellebrecht et al., 2016).  
Because of the controversy caused by the standard pemphigus treatment, innovative 
strategies have been developed. As aforementioned, a tandem peptide could target the 
trans adhesive interfaces of desmogleins to crosslink them and stabilize adhesion, 
inhibiting skin blistering and activation of p38MAPK pathway, through PV-IgG (Spindler et 
al., 2013). 
Another novel tool could be the manipulation of plakophilin-1. Tucker et al. demonstrated 
the key role of manipulation of plakophilin-1 (PKP-1) expression, which is an intracellular 
armadillo protein, capable of linking desmosomal cadherins to keratin intermediate 
filaments of keratinocytes. It was reported that when they enhanced the PKP-1 
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expression, this protein could protect keratinocytes from pemphigus vulgaris IgG-induced 
loss of cell-to-cell adhesion. Moreover, PKP-1 seems to cluster Dsg3 with the 
desmosomal plaque protein desmoplakin, and transform ‘desmosome adhesion from a 
calcium-dependent to calcium-independent and hyper-adhesive state’ (Tucker et al., 
2014). Similar results could be obtained inserting a point mutation, S2849G, into 
desmoplakin, which causes an inhibition of both Dsg3 depletion from cell surface and 
keratin filament retraction, caused by PV-IgG. This inhibition occurs due to preventing 
protein kinase C-dependent phosphorylation of desmoplakins, at that specific site. We can 
be in the presence of a new pharmacological tool in pemphigus, since protein kinase C 
inhibitor Bim-X compound seems to have the same inhibitor effect (Dehner et al., 2014).  
The inhibition of various signalling pathways that have implication in pemphigus antibody-
induced acantholysis could represent a key role in a new therapeutic approach (Mao et 
al., 2014). 
Moreover, the future of ABD treatment might undergo pharmacological protection of 
mitochondria and/or compensation of the injured mitochondrial functions. This can 
became a new approach to develop personalized non-hormonal therapies to treat ABD 
(Kalantari-Dehaghi et al., 2013b). The use of engineered Fabs also appears to be a great 
strategy for ABD treatment, since it can block pathogenic epitopes leading to more 
specific therapies (Wang et al., 2010). 
The effect of pilocarpine has also been under perspective for PV treatment. This M1 
muscarinic acetylcholine receptor agonist was reported to improve pemphigus 
acantholysis, inhibiting PKC-dependent serine phosphorylation of β-catenins and tyrosine 
phosphorylation of p120-catenin. This study also reinforces the major role of the 
acetylcholine (Ach) signaling center line in regulation and coordination of different events 
that assemble and disassemble the intercellular junctions of keratinocytes (Chernyavsky 
et al., 2008). 
There is another therapy that targets the complement cascade (Ricklin and Lambris, 
2007) that could be applied in BP cases, however, has not yet been properly evaluated in 
these cases (Hammers and Stanley, 2016). 
 
9.6. Concluding Remarks 
It is known that our knowledge about pemphigus has suffered a tremendous progress 
over the years, however there are many obstacles when analysing outcomes of 
treatments. So, consensus statements are needed for better clinical evaluations of 
pemphigus’ patients (Murrell et al., 2008).  
Frequently, pemphigus is a fatal skin disease, fact that was studied by Ahmed and Moy. 
They accessed the data from thirteen patients’ autopsies that died from this disease, at 
the UCLA Hospital, between 1965 and 1980. It was concluded that infection was the most 
frequent cause of death, being septicaemia the most important one, being present in 9/13 
of the cases (69.2%). Staphylococcus aureus was found to be the most important 
organism. Moreover, nine patients also had pneumonia. These patients were on long-term 
high doses of cortisteroids, which could also mask the symptoms of inflammation (Ahmed 
and Moy, 1982). 
The severe harmful effects and complications that the corticosteroid hormone (CH) 
therapy entails do not always produce a positive balance between treating and not 
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treating the patient. It is very clear that there is an urgent need for better and novel 
therapies that could possibly help in keratinocyte adhesion or that maybe could 
antagonize pemphigus autoantibodies. 
 
9.2 Final Disclaim 
This chapter bases itself on the information conveyed by the indicated references, 
information contained therein and interpretation made by the author of the same, and 
should not be used outside the context of this work. The author disclaims any 
responsibility for the inappropriate use of the information in particular concerning the 
therapy. The aforementioned drugs may have one or more side effects, and their use 
must include appropriate precautions for each active principle, their association with them, 
and should be prescribed by experienced health professionals and through appropriate 
monitoring. 
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Bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus seems to be scattered 
all over the world. In Africa predominates the PF, and in some parts of Asia and America. 
In the other hand, BP and PV appear to be widespread in Europe and Asia.  
For instance, in North Africa and Middle East countries, represented in Figure 20, the 
predominant subtype may varies: PV is more common in Egypt, Sudan, Morocco, Syria, 
Kuwait, Saudi Arabia and Yemen; and PF is predominant in Libya and endemic in Tunisia, 
and within Morocco is more common in Marrakech (Saleh, 2015). 
 
 
Figure 20 – Countries of North Africa and Middle east with reported PV, PF and/or 
BP. 
 
Over the years, researchers and clinicians have been facing difficulties in establishing 
mortality rates of patients with pemphigus, around the globe.  
When we talk about pemphigus, a mystery remains concerning the rates, since the 
mortality decreased from 75% (pre-corticosteroids), in the 1950s, to 30% (Bystryn and 
Steinman, 1996). Many studies reported mortality rates between 4.8% and 25.9%, mainly 
due complications of long-term immunosuppression (Ahmed and Moy, 1982; Uzun et al, 
2006). For instance, in the 50’s, if a pemphigus patient was left without treatment, the next 
2 years the mortality rate was 50% and at the end of 5 years the mortality rate raised to 
100% (Mimouni et al., 2008). Confirming the mortality rates, a study with 138 PV patients 
and 551 matched controls, conducted in 2008, concluded that in one year the mortality of 
these patients was 12%, which was three times higher than controls (Langan et al., 2008). 
It also important to differentiate the mortality of patients admitted with a primary diagnosis 
of pemphigus and the ones admitted with a secondary diagnosis of pemphigus. So, Hsu 
et al., 2016 conducted a study in the U.S.A., using the International Classification of 
Diseases, Injuries and Causes of Death (ICD-9) codes, regarding the inpatient mortality in 
pemphigus. They analysed a cohort of 87 million admissions, between 2002 and 2012, 
which represented 20% of US Hospital admissions. These analyses led to the conclusion 
that 1.6% of the admissions were primarly due to pemphigus diagnosis. For a secondary 
admission it was about 3.2%. And this value was higher than controls. In these last cases, 
the admissions were mainly due to comorbidities, such as infections (Hsu et al., 2016). 
BP has been reported to have 20% to 40% mortality rate in the first year after the 
diagnosis (Hübner et al., 2016). 
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The incidence of pemphigus depends on what country or region are analysed, ranging 
from 0.5 to 32 per million per year. Differences are also found if we compare the incidence 
between gender, age and, in several situations, ethnicity (see review in, Alpsoy et al., 
2015). The annual incidence of pemphigus, in Europe, has been ranging between 0.5 and 
8 per million (Alpsoy et al., 2015), knowing that the higher incidence refers to the 
Mediterranean Basin (Meyer and Misery, 2010) whereas BP has a incidence ranging 
between 0.1 and 42.8/million per year in European countries (review in, Alpsoy et al., 
2015), as its possible to see summarized in Table 7. 
 
Table 7 - Incidence of PV, PF and BP. 
Continent Country Cohort Pemphigus Sex 
Gender 
Mean age 
of onset 
(years old) 
Incidence 
PV, PF / BP 
(per million) 
Reference 
Africa Mali  25 PF / 4 
PF 
80% 
women 
46.7 2.9 Mahé et al. 
1996 
 Tunisia 23 
pemphigus 
20 PF Not 
specified 
 4 Morini et al. 
1993 
 Tunisia 174 ABD 53% 
pemphigus / 
24% BP 
Not 
specified 
50 for 
pemphigus / 
68.6 for BP 
8.62 for 
pemphigus 
and 3.84 for 
BP 
Zaraa et al. 
2011 
 Tunisia  61% PF  36.7 6.7 Bastuji-Garin 
et al. 1995 
Europe Turkey 148 
Pemphigus 
123 PV 
13 PF 
 43 2.4 Uzun et al., 
2006 
 Serbia 51 
Pemphigus 
72.55% PV 
and 11.76% 
PF 
 55.6 6.6 and 0.85 
/ 100 000 
over age of 
20 
Golusin et 
al., 2005 
 Greece 129 PV PV 41 men / 
88 women 
59.8 8 Michailidou 
et al., 2007 
 Italy (Liguria) 32 
pemphigus 
 13 men / 
19 women 
 10 Cozzani et 
al., 2001 
 France  73% PV  52 1.7 Bastuji-Garin 
et al. 1995 
 France 502 BP BP   21.7 Joley et al., 
2012 
 Switzerland 168 
pemphigus 
and BP 
 73 men / 
95 women 
P 62.3 / BP 
77.2 
0.6 for PV 
and PF / 
12.1 for BP 
Marazza et 
al., 2009 
 Germany Pemphigus / 
BP 
   94.8 for PV / 
10.0 for PF / 
259.3 for BP 
Künber et 
al., 2016 
 Germany 27 BP   62 0.5 Bertram et 
al., 2009 
 UK 869 BP 
138 PV 
BP and PV 61% 
women in 
BP and 
91% 
women in 
PV 
71 6.8 for PV / 
42.8 for BP 
Langan et 
al., 2008 
 Scotland 83 BP   79.2 14 Gudi et al., 
2005 
 Denmark     60 
pemphigus / 
120 for 
pemphigoid 
Eaton et al., 
2010 
Asia Israel 180 159 PV and 66 men 54.7 7.2 (Jewish Kridin et al., 
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20 PF and 114 
women 
7.5; 3.6 
Arabs) 
2016 
 Israel 290 PV  49.7  Baum et al., 
2016 
 Iran 1209 PV  42 10 (16, 
Tehran) 
Chams-
Davatchi et 
al., 2005 
 Iran 
(Shiraz) 
221 87.7% PV 
and 9% PF 
 38 6.7 Salmanpour 
et al., 2006 
 Iran 
(Isfahan) 
188 PV PV 72 men 
116 women 
41.1 50 Asilian et al., 
2006 
 Iran 
(Yazd) 
89 
Pemphigus 
 44.9% men 
and 55.1% 
women 
44.9 9.8 Noorbala et 
al., 2012 
 Iran 122 BP  35.2% 
males and 
64.8% 
females 
65  Esmaili et 
al., 2012 
 India 41 
Pemphigus 
32 PV 
8 PF 
   Chowdhury 
et al., 2016 
 Thailand 58 BP  69.3  Kulthanan et 
al., 2011 
 Taiwan 853 
Pemphigus 
 42.9% men 
and 57.1% 
women 
52.5 4.7 Huang et al., 
2012 
America Brazil 20 12 PV and 8 
PF 
66.7% 
women in 
PV and 
75% men 
in PF 
  Pires et al., 
2014 
 Brazil 
(endemic 
Region) 
266 163 PV and 
103 PF 
 32.1 PV / 
41.5 PF 
 Gonçalves et 
al., 2011 
 Brazil 
(Amerindian) 
1351    40.5 Hans-Filho 
et al., 1996 
 Colombia 130 PF (FS) 95.4% men 50  Abrèu-Velez 
et al., 2003 
 USA 
(Connecticut) 
Pemphigus    4.2 (32, in 
Jews) 
Simon et al., 
1980 
 
10.1. Africa 
a. Mali 
A study made in Bamako, Mali, reported that pemphigus in this specific 
area have a distinctive pattern, with an annual incidence of 0.29 
cases per 100 000 inhabitants, more prevalent in women (80%) with 
a mean age of onset of 46.7 years; and a ethnic group named Fulani 
(33%). The cohort had 25 PF and 4 PV cases. In resemblance to 
what have been reported in Tunisia, pemphigus in Mali too differ from 
what happens in North America and Europe, and in Brazil (Mahé et al., 
1996). 
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b. Tunisia 
A cohort with 23 Tunisian pemphigus patients was assessed 
to perform a prospective study about PF occurrence in Tunisia. 
Of the 23 cases, 20 were PF mainly in young women. The 
incidence was estimated to be 4 new cases per million per 
year, higher than in European or North American, however, 
lower than most severely affected areas in Brazil. One of the 
characteristics that differentiate Tunisian pemphigus from 
PF observed in Europe, North America and Brazilian FS 
is the lack of familial cases and the major incidence in 
women (Morini et al., 1993). 
Zaraa et al. performed a retrospective study between 1997 and 2007, gathering a cohort 
with 174 patients with ABD, where pemphigus was the most common with a mean age of 
onset of 50 years old, where 53% represent only the pemphigus cases (61% PV and 36% 
PF (Tunisian pemphigus)). Also, BP was the second most frequent with 41 patients 
suffering with it, with a mean age of onset of 68.6 years old. It was reported that 
pemphigus has an incidence rate of 8.62 new cases per year and BP 3.84 new cases per 
year. It was also reported that PF has a higher prevalence than in Western Europe (Zaraa 
et al., 2011). 
Moreover, in previous studies, Bastuji-Garin et al. reported the high incidence of PF in 
Tunisia, when comparing with the incidence rates of pemphigus in a large area of France, 
which revealed an incidence rate of 1.7 cases per million, per year. PV represented 73% 
of all cases. Tunisia revealed an incidence of 6.7 cases per million per year. PF was more 
frequent, with 61% of the cases, and much more prevalent in young women aged 25 to 34 
years old, with an incidence rate of 15.5 cases per million per year. These data, once 
again, demonstrates the unusual pattern of pemphigus in Tunisia, and patients were not 
related (Bastuji-Garin et al., 1995). 
 
10.2. Europe 
a. Turkey 
In Mediterranean region of Turkey, Adana and Antalya, a prospective 
study was made, from 1998 to 2004, comprising a cohort with 148 
pemphigus patients. From all the patients, 123 were diagnosed with 
PV and 13 with PF. The incidence was estimated to be 0.24/100 000 
cases per year with a female predominance and a mean age of 
onset of 43 years. Also, in 82% of all PV patients the disease initiated 
as oral ulcers. This Mediterranean region has a relatively high 
incidence of pemphigus when compared with other countries (Uzun et al., 
2006). 
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b. Serbia  
A study conducted in South Baçka, Vojvodina, evaluated the 
incidence of pemphigus in this area. A 13 year period produced a 
total of 51 new pemphigus cases, with a peak in 1996, resulting 
an incidence of 0.66 cases per 100 000 inhabitants and 0.85 per 
100 000 inhabitants in those over age of 20 years. Of all cases, 
72.55% were PV and 11.76% were PF. The mean age on onset 
was estimated in 55.6 years, and a slight increase of women 
prevalence. Moreover, the autors did not found any significant seasonal influence (Golusin 
et al., 2005). 
 
c. Greece 
A study from 2007 reported an average incidence of eight new 
PV patients per year (0.8/100 000 inhabitants), in the northern 
Greece population, and a mortility rate was 2.3%. This study was 
made with 129 PV patients, 41 males and 88 females. It was 
possible to infer that the disease occurred most frequently in the 
sixth decade of patients’ life. Also, the mean age of onset in 
males ranged 30 to 88 years and in females ranged 34 to 80 
years (Michailidou et al., 2007). 
 
d. Italy 
A two-year study in Liguria intended to demonstrate the 
incidence of BP in this region. Liguria is a coastal region of north-
western Italy and has about 1.7 million inhabitants. The 32 cases 
collected (13 males and 19 females) over the period of the study 
corroborates an average incidence of 1/100 000 cases per year, 
as proven previously (Cozzani et al., 2001).  
 
e. Switzerland 
A major study was done in Switzerland in 2009, encompassing 
January 2001 to December 2002. A cohort with 168 patients, 73 
men and 95 women, with BP and pemphigus were collected. The 
results showed that BP had a mean incidence of 12.1 new cases 
per million per year and this incidence increases after the age of 
70 years old. When we standardize the incidence in Europe, the 
incidence seems to be lower, with 6.8 new cases per million per 
year. In the other hand, the incidence of PV and PF combined is lower, 0.6 new cases per 
million per year. This study covered the entire country, so it is possible to stablish two 
things: first, if compared with PV and PF, BP is the most frequent autoimmune bullous 
disease and, second, this incidence have nothing to do with ethnicities, since it is not 
specified, but have to do with the advanced age of Swiss population (Marazza et al., 
2009). 
 Epidemiology – what’s happening around the globe? 
 
170 
 
f. France 
A prospective study comprising three French regions with a total of 
3.858 million inhabitants investigated the BP incidence. From 2000 
to 2005, a cohort of 502 incident BP patients was identified. 
Overall, the incidence was estimated to be 21.7 cases per million 
per year, which is three times higher than the incidence in 1985. 
When they look close to population with 70 years or more, the 
incidence increases to 162 cases per million per year. In the first 
year, after diagnosis, the survival rate is estimated to be 62%. Moreover, the risk of death 
in BP patients is six times higher than in general population (Joly et al., 2012). 
 
g. Germany 
In 2014 it was performed a study to evaluate the incidence of 
autoimmune bullous diseases, using data from a major 
Germany health insurance company. They concluded that in 80 
925 million inhabitants in Germany, 40 400 suffer from 
pemphigus and pemphigoid diseases. Being BP the one with 
the major rate of incidence, with 259.3 patients per million. PV 
have an incidence of 94.8 patients per million and, PF have 10.0 
patients per million. So, in this study, BP was determined to be 
2.5 fold higher, when compared with PV and PF (Hübner et al., 2016). 
Another study from 2009 reported the incidence of BP in Lower Franconia (the Franconian 
lands belong to Bavaria, and are located in the centre of Germany) with 27 BP patients 
diagnosed make this disease, once again the most prevalent among the group of the 
ABD, with 13.4 new cases, per million, per year (Bertram et al., 2009). 
 
h. United Kingdom 
Langan et al., 2008, reported the incidence and mortality in the UK, with 
a an cohort with 869 BP patients and 138 PV patients, with a mean 
age of onset of 80 years in BP cases and for PV patients was 71 
years. Both BP and PV were more prevalent in women, 61% of all 
BP patients were females and 91% of PV was female.  
The incidence of BP was 4.3/100 000 and PV had a frequence of 
0.7/100 000 person years. It was also seen that the BP incidence has 
been increasing over time of an average of 17% a year, and so PV has been increasing 
too, abou 11% per year. BP patients also had twice probability of death than controls and 
PV patients had three times more probability of death, also compared with controls 
(Langan et al., 2008). 
The Grampian Region, northeast Scotlant, was investigated to assess causes of mortality 
of BP patients, with a cohort of 83 patients, collected between 1991 and 2001. The annual 
incidence was estimated to be 14 cases per million per year. It was also observed a rise in 
the incidence in the elderly, and 48% of patients died whithin 2 years of diagnosis, in the 
majority from respiratory disorders (Gudi et al., 2005). 
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i. Denmark 
A study from 2006 reported that the incidence of pemphigus and 
pemphigoid diseases were 60 patients per million and 120 
patients per million, respectively. This study took into account 
that the entire population of 5 506 574 persons in Denmark on 
October 31, 2006 (Eaton et al., 2010). 
 
10.3. Asia 
a. Israel 
A very recent retrospective study estimated the incidence of 
pemphigus in Israel. The main difference between this study and the 
others e that here the authors also investigated the differences 
between two major ethnic populations, in two Israeli regions: Haifa, 
with 875 000 inhabitants, and northern districts, with 691 000, 
according to 2008 census. During a 16 year period, a cohort of 180 
pemphigus patients was gathered, in which 159 were PV and 20 
were PF; and 66 were men and 114 were women. The mean age of 
diagnosis was 54.7 years. It is the origin of the patients that gives us a new insight of 
epidemiologic Israeli studies, 59.4% were Ashkenazi Jews, 22.2% were Sephardic Jews 
and 17.2% were Arabs. So, the overall incidence was determined to be 7.2 cases per 
million per year, from 2000 to 2015, in northern Israel. The incidence in the Jewish sub-
group decreased from 11 cases per million per year, in 2000 to 2005 to 9.3 cases per 
million per year in 2006 to 2010 and again decreased to 7.5 cases per million per year in 
2011 to 2015. The contrary happened among the Arab sub-group, where the incidence 
slightly increased from 3.1 in 2000 to 2005 to 3.6 in 2011 to 2015 (Kridin et al., 2016). 
Another retrospective study with data from a medical center in Israel, from 1980 to 2009, 
Jews, intended to investigate epidemiology in Jews, Ashkenazi and non-Ashkenazi. A 
cohort with 290 PV patients revealed that the mean age of onset was 49.7 years and, 
again, a female prevalence. The ratio of Ashkenazi and non-Ashkenazi, in Jews patients, 
was 1.23:1.00 (Baum et al., 2016). 
 
b. Iran 
A study reported that the most prevalent form of pemphigus is PV, with 
an incidence of 1.0/100 000 per year. The incidence increases 
slightly in Tehran with 1.6/100 000 per year. Also, it was reported 
that the disease is more prevalent in females and the age of onset 
was a bit lower than classically reported. About 6.2% eventually die 
of the disease (Chams-Davatchi et al., 2005). 
In Shiraz, south-western Iran the incidence of pemphigus was 
0.67/100 000 per year, with data collected from 1991 to 2000. The mean 
age of incidence was 38 years and, again, more prevalence in women. PV was the most 
frequent, 87.7% and, next, PF with 9%. It was verified that the first manifestation mostly 
occurred during winter, in about 30.8% of the patients (Salmanpour et al., 2006). A cohort 
from Isfahan was also evaluated, with 188 PV patients, 72 men and 116 women, from 
1994 to 2004. It was determined an annual incidence rate of 5/100 000 and an age of 
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onset of 41.1 years old. Also, in 74% of the patients the mucosal involvement was the 
initial presentation and in the remaining 26% the skin was firstly affected by disease. Once 
again, women hold the largest incidence. In the course of the study, 9 patients died due to 
pneumonia and septicaemia (Asilian et al., 2006). In central part of Iran, in Yazd province, 
a cohort with 89 pemphigus patients, comprising 44.9% male and 55.1% female, from 
1996 to 2006, and the incidence was determined to be 0.98/100 000 and the mean age of 
onset was 44.9 years. Once again, the most common form of pemphigus is PV with a 
probability 3.4 times higher than PF (Noorbala, et al., 2012). There is a higher incidence of 
PV in Iran, when compared to other regions of the world and, also, the mean age of onset 
is earlier (Asilian et al., 2006). 
A retrospective study with 122 BP patients, from 1987 to 2007, was made to determine 
clinical and demographic characteristics of BP in Iranian patients. The mean age of onset 
was 65 years old, and the cohort comprised 35.2% males and 64.8% females. About 
97.5% had cutaneous bullae, 27% had oral lesions and 30.3% had eosinophilia (Esmaili 
et al., 2012). Similar data about clinical phenotype in Iranian patients have already been 
reported (Daneshpazhooh et al., 2007). 
 
c. India 
A recent study gives us to know the reality of clinic histopathology 
patterns in eastern India, with a total 41 patients, over a period of a 
year. Of the 41 patients, 32 cases have PV (78%) and 8 cases with 
PF (19.51%). Most of the patients were between 41 and 60 years, 
and about 26.26% of the cases were above 60 years. Also, a female 
predominance was demonstrated in the PV cases, however, in PF 
cases, the sex ration was equal. In PV, initial lesions involve mucous 
membranes in 40.62% of the cases. Moreover, the eventual mucosal involvement was 
seen in (63.41%). It is possible to notice a change in PV disease development, which 
could represent a paradigm shift in this study population. In PF cases, 25% had both 
mucosal and skin involvement, and 75% of the cases had only skin manifestations. Again, 
when we are referring to PV, 20 cases (62.5%) demonstrated intra-epidermal suprabasal 
vesicles and about 5 cases (15.62%) demonstrated mid-epidermal vesicles. Twenty-nine 
cases showed acantholysis, which represent 90.62%. Cases with pure mucosal cases 
had no blister development. Twenty-three cases (53.5%) demonstrated inflammatory 
infiltrate in bulla cavity, and row of tombstone appearance was present in 17 cases 
(53.12%). Concerning the eight PF cases, seven cases (87.50%) showed acantholysis. 
Half of the cases had inflammatory infiltrate in bulla cavity. The DIF analysis revealed that 
19 of the 32 PV cases had intra-epidermal deposition of intercellular deposition of 
intercellular IgG and C3 and 13 of the 32 had IgG deposition. In the PV cases, 87, 5% 
revealed antibody deposition in epidermis and 9.7% in the lower epidermis. Also, 71.87% 
cases had moderate strength of deposit. In PF group, 75% the antibody deposition 
occurred in the upper epidermis and 87.5% had a higher strength of deposit. For instance, 
the DIF intensity had a weak correlation with disease severity/activity scores. In PF, DIF 
can be used to evaluate the extent of skin involvement (Chowdhury et al., 2016). 
 Epidemiology – what’s happening around the globe? 
 
173 
 
d. Thailand 
Between 1991 and 2009, a study comprised 58 BP patients to 
determine clinical characteristics in Thai patients. The cohort 
was obtained in Bangkok. The mean age of onset in these 
patients was 69.3 years with a higher prevalence in women. 
Mucosal involvement was seen in 15% of all patients and 38.9% 
had eosinophilia. It was also reported high inicidence of 
hypertension (41.4%), diabetes mellitus (19%) and cardiovascular 
disorders (24.1%) in these patients (Kulthanan et al., 2011). 
 
e. Taiwan 
The stimative of incidence of pemphigus and mortality rates in Taiwan 
revealed in cohort of 853 patients newly diagnosed from 2002 to 
2009, in which 42.9% were men and 57.1% were women. The 
incidence was 4.7 per million per year and 88 patients died during 
the follow up period of 3.8 years, maily due to pneumonia, 
septicemia, cardiovascular disease and peptic ulcer disease. Also, 
the mean age of onset was 52.5 years old. It was also possible to 
determine that the incidence was higher in women (Huang et al., 2012). 
 
10.4. America 
a. Brazil 
During a period of 2003 to 2010, records of hospitalized patients with PV 
and PF were collected from the Dermatology Service of Hospital 
Fundação Santa Casa de Mesericórdia do Pará, Belém, Northern 
Brazil. A total of 20 pemphigus cases were analysed, in which 8 were 
PF and 12 were PV. Male patients were predominant in PF, with 75%, 
whereas, females were predominant in PV cases, 66.7%. Three 
patients died (25%) (Pires et al., 2014). A study made in 2011 noticed that 
in the northeast region of the state of São Paulo, Brazil, where PF is endemic, the annual 
incidence is decreasing, whereas the incidence of PV in increasing. This study used a 
wide cohort with 163 cases of PF and 103 cases of PV, over 21 years, from 1988 to 2008. 
This incidence of PV had a mean age of 41.5 years old and the mean age of incidence of 
PF was 32.1 years old. Since 1998 that PV has been exceeding the incidence of PF 
(Gonçalves et al., 2011). 
Usually PF (FS) occurs in Brazilian states localized between 45º and 60 º west longitude 
and 5º to 25º south latitude, and an altitude between 500 and 800 m (Culton et al., 2008). 
Ameridian reservation of Limão Verde is located in Mato Grosso do Sul and is home of 
1351 members of the Terena tribe of Ameridians and is also an active FS focus with 3% 
of disease prevalence (Hans-Filho et al., 1996). 
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b. Colombia 
Between 1992 and 2001, it was found 130 patients with PV (FS) in El 
Bagre surroundings, Colombia. About 90% of the cases started in the 
municipality of El Bagre (90%) and the remaining 10% in the 
neighboring rural areas. The majority was men (95.4%) with a mean 
age of onset of 50 years; the remaining 4.6% were women in post 
menopause. Also, 98% were illiterate and poor and had outdoors 
activities like farming. It is also important to note that they live without sewage and water 
systems, but all have good personal and home hygiene (Abrèu-Velez et al., 2003). 
 
c. USA 
In Hartford County, Connecticut, a study provided data that estimated 
the incidence of pemphigus, overall, was 0.42 cases per 100 000. Also 
Jewish adult population was investigated, revealing an incidence rate 
of 3.2 cases per 100 000, confirming that Jewish inhabitants had a 
higher risk of pemphigus than the general population (Simon et al., 
1980). 
 
 
 
10.5. Concluding Remarks 
This final chapter helps understanding how these ABD spread around the globe. There is 
a pattern, where it is possible to see that in Africa, America and Asia, the incidence of PV 
and PF predominates. Whereas in Europe there a major incidence of BP and PV. These 
differences found in all continents are maybe due different cultures, populations’ quality of 
life, economic and hygiene factors. Or maybe it is possible to infer that the genetic factor 
is also crucial. And this conclusion again brings us back to the question that it is 
necessary further genetic and epidemiologic studies to try to bridge this gap. 
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Final Conclusion 
By the time I finished this dissertation I was sure about the inconsistencies that this issue 
entails. 
This review results from the research of about 8% of all PubMed data, available about the 
subject. And still it seems that urge further research. It is necessary to fully and truly 
understand the exact pathway that causes blistering in pemphigoid and pemphigus, 
although we are on the right path. There are many coherent and accurate explanations, 
however, I feel that a mechanism that integrates all theories and tells us with certain what 
happens in molecular terms, is missing.  
I could notice that, in the past few years, there has been a huge effort in order to find a 
better therapy for these patients, with fewer side effects and, preferably, one that doesn’t 
include corticosteroids. It urges the need to design a novel and more specific therapeutic 
strategies that could counteract the chronic morbidity and mortality. It is necessary to 
know more about these ABD. And it may be necessary to begin by deepening the 
interference of triggers in these diseases. 
Even when we talk about the diagnosis of these diseases we cannot say that accurating. 
Some patients are misdiagnosed, which delays the therapy.  
The associated diseases are also a very important topic since it could lead us to 
understand how ABD behaves and how it really interferes with our organism, besides the 
skin. There are many diseased that have been correlated with these ABD.  
It also could be interesting if the patients could be screened for genetic abnormalities, 
since it is very possible that these ABD have something to do with some somatic 
mutations. And this field may be transversal to all other areas of study. 
If we evaluate the epidemiologic data alone it may not show the real impact of these 
diseases worldwide but if, for example, we   do the math for the Swiss population, every 
year they have approximately 100 new BP cases. And in France an astonish number of 
about 1300 new BP cases per year.  
Essentially, the purpose of this review, through an exhaustive research, was to guide us in 
the sense of perceiving what remains to be done and what is lacking for the patients. It 
became extremely important to be aware of the condition of these patients. The three 
ABD addressed in this dissertation are serious and dangerous conditions that put the 
patients at risk. Also, and beside the physical part, the daily life and psychosocial well-
being are too affected. In the course of this exhaustive review, I only found one recent 
study about the quality of life of the patients, from Kouris et al., 2016. And only more 
recently there has been more research on more effective and less painful and deadly 
therapies for patients, for example. Only more recently there seems to be more 
awareness of what these diseases actually do to patients.  
Perhaps, if we look more at the prism of the patient and what has been done up to now 
and even the price to pay for therapy with corticosteroids, we will be able to see that so 
much work that has yet to be done. It is scary that many patients still die not because of 
the disease itself but due to the corticosteroid therapy.  
 
 
In the present year, Ahmed et al. (2016) published an article with the main concern for the 
future, suggesting more molecular pathways that still need to be worked, new theories 
and new possibilities.  
Also, in the end of each chapter I careful sublimate some interesting points that could help 
to clarify better what could happen in each field of these diseases.  
As I said in the beginning of this dissertation, this review was born not only of the desire to 
complete my master's degree but also of the desire to better understand how much is still 
lacking about these autoimmune blistering diseases and how can we help the patients 
who are suffering also from the main therapy. With this review it was also possible to see 
that there are great researchers, doctors, professors mainly dedicated to the theme, active 
in the study of these diseases. And for this same reason my bibliography is so extensive. 
And as it is perceived there is no focus on the mechanism, this involves many molecules 
and many alternative ways, so it is difficult to be targeted, which leads us to ramble on the 
subject, over all the chapters I have spoken. 
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